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ABSTRACT 
Nigel Leonard Kennea 
The potential of mesenchymal stem cells (MSC) to differentiate into neural 
lineages has raised the possibility of autologous cell transplantation as therapy 
for neurological diseases. There are, however, no studies reporting significant 
numbers of oligodendrocytes, the myelin-forming cells of the central nervous 
system, derived from MSC. We have recently identified a population of 
circulating human fetal MSC that are highly proliferative and readily differentiate 
into bone, cartilage, fat and muscle. I demonstrated for the first time that 
primary fetal MSC differentiate into cells resembling neural precursors and then 
oligodendrocytes both in vitro and in vivo. By exposing cells to a neuronal 
conditioned medium, rates of oligodendrocyte differentiation approaching 50% 
were observed, and cells appeared to mature appropriately in culture. 
Importantly, the differentiation of a clonal population into both mesodermal 
(bone) and ectodermal (oligodendrocyte) lineages was achieved. In the 
developing murine brain, cells integrated but oligodendrocyte differentiation of 
naive fetal MSC was very low. The proportion of oligodendrocyte differentiation 
was increased (from 0.2% to 4%) by pre-exposing the cells to differentiation 
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medium prior to transplantation. The process of in vivo differentiation occurred 
without cell fusion. Although the main focus of this thesis was oligodendrocyte 
differentiation, I also recapitulated controversial published work into neuronal 
differentiation of MSC. The exposure of cells to the reducing agent butylated 
hydroxyanisole induced rapid changes in cell morphology and expression of 
neuronal markers. These `differentiated' cells did not, however, appear 
functional with no upregulation of voltage-gated sodium channels or 
synaptophysin. 
Finally, while stem cells offer promise for correction of brain diseases, one 
major obstacle is the poor survival of grafted cells. Investigation of apoptotic 
signalling showed fetal MSC have functional apoptotic machinery in both the 
intrinsic (mitochondrial) and extrinsic (death receptor) pathways which could be 
manipulated to prolong stem cell survival by inhibition of death signalling. 
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1. Introduction 
In order to develop strategies for cell therapy for neurological disease, a 
detailed knowledge of the processes involved in brain development and the 
cues that govern fate choices of multipotent cells is essential. 
1.1. Neural cell differentiation in development 
The central nervous system is composed of three major types of neural cell; 
neurons, astrocytes and oligodendrocytes. The neurons are primarily involved 
in the transfer and coordination of information, and interact with the macroglial 
cells - the oligodendrocytes and astrocytes. Oligodendrocytes, which largely 
reside in the cerebral white matter, form myelin sheaths which surround axons 
and promote rapid and efficient nerve conduction (Bunge, 1968). Disruption of 
CNS myelin, through disease or injury, can lead to severe neurological deficits. 
The function of astrocytes is less clear but they have a role in the support of 
other neural cells and the regulation of the extracellular environment (Simard & 
Nedergaard, 2004) and may have a role in modulating synaptic connections 
(Ullian et al, 2001). 
All of these three cell types originate from multipotent neuroepithelial cells of the 
neural tube. Neural differentiation is an early event in mammalian 
embryogenesis that occurs soon after germ layer differentiation. The tissues of 
the CNS are derived from a clearly defined neuro-ectoderm, the neural plate, 
which lies along the dorsal midline of the embryo. It appears that the neural 
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plate arises by the local suppression or avoidance of signals that induce non- 
neural differentiation. Examples of such signals are from the bone morphogenic 
proteins (BMPs) (Varga & Wrana, 2005) that instruct epidermal differentiation 
around the start of gastrulation, and other transforming growth factor-ß (TGF-ß) 
superfamily molecules (Wilson & Edlund, 2001; Kintner, 2002). 
Neural fate of murine embryonic stem cells is suppressed by BMPs (Munoz- 
Sanjuan & Brivanlou, 2002) and BMPs have an important role in the 
maintenance of the undifferentiated state and suppression of differentiation 
(Ying et al, 2003). In vivo, several molecules that promote neural differentiation 
such as noggin, follistatin and chordin are BMP antagonists. Indeed BMPs have 
been shown to be important in the regulation of human ES differentiation, with 
noggin inducing a neural fate (Pera et al, 2004). While noggin antagonises 
BMP signalling, it is not essential for induction of early neurogenesis since 
knockout mice are normal at embryonic day 8.5 (although they die at birth). 
These data suggest that other BMP antagonists may compensate in the 
absence of noggin expression, and illustrate the concept of redundant signalling 
pathways during embryonic development (McMahon et al, 1998). There needs 
to be care in extrapolating murine BMP data to human ES cells as there are 
clearly differences. For example, in culture with Fibroblast Growth Factor (FGF), 
BMPs allow human ES cells to generate trophoblast (Xu et al, 2002) - this does 
not occur in murine ES cells. Also, in contrast to murine ES studies, when BMP 
signalling is blocked in human ES cells in the presence of FGF they are 
maintained in an undifferentiated state (Wang et al, 2005a; Xu et al, 2005). The 
actions of BMPs is further complicated by the fact that there are two BMP 
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receptors, the ubiquitously expressed BMPR-1A and BMPR-1 B, which does not 
appear until embryonic day nine. Expression of BMPR-1A induces BMPR-1B 
expression; a process that is inhibited by sonic hedgehog (Shh) (Panchision et 
al, 2001). 
1.1.1. Regional and temporal patterning 
The further development of the neural plate into the cells of the mature CNS is 
clearly and precisely regulated with both spatial and temporal patterns of 
differentiation. Growth and proliferation of the cells in the early neural plate 
eventually results in the closure of the developing neural groove to form the 
hollow neural tube. The cavity of the neural tube later gives rise to the 
ventricular system, while the epithelial layer contains the stem cells that will give 
rise to the neuronal and glial cells of the CNS. One of the central questions in 
developmental neurobiology has been the mechanism by which the simple 
neuro-epithelium that is only a single cell thick can give rise to the diverse cell 
types that make up the mammalian CNS. There is now a wealth of research 
identifying both the intrinsic factors and extrinsic soluble signals that affect this 
regional patterning and specific neural differentiation. One example of this in 
vertebrate neurogenesis is the opposing soluble signals that impart dorsal and 
ventral patterning in the spinal cord (Figure 1.01. ): Shh and the BMP 
antagonists, chordin and noggin, are secreted from the floor plate (Briscoe & 
Ericson, 2001) while other signals (eg TGF-ß, wnt) originate from the roof plate 
to form gradients of signal concentration. The precise concentration and ratio of 
each signal within the neural tube is central to the development of specific 
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neuronal phenotypes at different points along the gradients. For example, there 
is a concentration-dependent induction of patterning genes within progenitor 
cells that encode homeodomain transcription factors. Differences in such 
expression patterns create groups of neurons with different patterns of division 
and differentiation (and ultimately distinct phenotypes) along the dorso-ventral 
1. 
1. ectoderm 
2. roof plate 
3. neural tube 
4. floor plate 
5. notochord 
a 
C 
&-_JO 
3. 
3 
2. 
4. 
Adapted from www. embryology. ch 
Figure 1.01. Regional patterning within the developing spinal cord. Soluble 
signals affect regional and temporal patterning of neural cell differentiation. 
Opposing soluble signals impart dorsal and ventral patterning: Sonic Hedgehog 
(Shh) is secreted from the floor plate and other signals (eg TGF-ß, wnt) 
originate from the roof plate to form gradients of signal concentration across the 
developing neural tube (1-3). The concentration and ratio of each signal leads 
to concentration-dependent induction of patterning genes encoding transcription 
factors. Differences in such expression patterns create groups of neurons with 
different patterns of division and differentiation (and ultimately distinct 
phenotypes) along the dorso-ventral axis. 
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In the human, the neural tube is formed during the third and fourth weeks of 
gestation. Initially the neuro-epithelial lining consists of morphologically similar 
neural stem cells (NSC) in a single layer. These cells then divide symmetrically 
to enrich the NSC pool, or asymmetrically to generate more differentiated 
progeny from which mature cells of neuronal and glial lineages develop. The 
signals that determine symmetrical or asymmetrical division are not fully 
understood (Jan & Jan, 1998) although presumably the BMP family of 
molecules is again involved. Retroviral labelling studies have been used to 
identify dividing cells in the ventricular zone. Cai et al. demonstrated about 48% 
of labelled cells remained in colonies within the ventricular zone suggesting 
self-renewal at this site (Cai et al, 1997). It is likely that in humans and other 
mammals this active proliferation of progenitors will be balanced by apoptosis in 
order to maintain a steady population, but the exact mechanisms are yet to be 
determined (Raoul et al, 2000; Gilmore et al, 2000). 
As development continues, neurons migrate away, guided in part by radially- 
oriented glial processes, and the ventricular zone diminishes in size. NSC 
remain attached to the basal lamina. It has been demonstrated that these cells 
may divide asymmetrically and more differentiated progeny migrate away from 
the ventricular zone towards the overlying cortex. Such cells can further divide 
and can be distinguished from NSC by the acquisition of specific phenotypic 
markers (Rao, 1999). Oligodendrocyte precursors, for example, can be 
identified through the expression of platelet-derived growth factor receptor a 
(PDGFra) (Pringle et al, 1992; Pringle & Richardson, 1993), mRNAs for myelin 
associated proteins including 2'3'-cyclic-nucleotide 3'-phosphodiesterase 
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(CNPase) and DM20, an isoform of the myelin proteolipid protein (PLP) (Timsit 
et al, 1995) and the identification of the transcription factors Olig1 (Lu et al, 
2000; Lu et al, 2002) and OIig2 (Zhou et al, 2000; Zhou & Anderson, 2002). 
1.1.2. Neurons appear before oligodendrocytes 
During CNS development, temporal patterning results in the generation of 
neuronal cell types prior to oligodendrocytes (Abney et al, 1981; Frederiksen & 
McKay, 1988). In the spinal cord it seems that these two cell populations can 
arise from common precursors, and the final fate decision depends on extrinsic 
signals, and specific patterns of transcriptional activation (Jessell, 2000; Tanabe 
& Jessell, 1996). 
1.1.2.1. Patterns of transcriptional activation determine cell fate 
There are two main classes of transcription factor that can determine neuronal 
or glial fate. These are the homeodomain factors, an example of which is 
NKx2.2 (Vetter, 2001) and the basic helix loop helix family of transcription 
factors that include Olig1 and Olig2 (Zhou et al, 2001; Sun et al, 2001). The 
expression of the Olig transcription factors is regulated by extrinsic signals like 
Shh and their expression has been shown to clearly define cells that become 
oligodendrocytes. However, in the mouse, Oligl and OIig2 are expressed from 
E9; well before the presence of oligodendrocytes precursors. At this early stage 
OIig2 is known to be central to neuronal development in a specific region of the 
ventral spinal cord (Takebayashi et al, 2000) and localises to cells that can be 
tracked to motor neuron fate. The importance of Olig2 in neurodevelopment has 
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been demonstrated in gain of function experiments (Mizuguchi et al, 2001; 
Novitch et al, 2001; Kim, 2004) and in vitro experiments where OIig2 over- 
expression induces mature oligodendrocyte differentiation from NSC in culture 
(Copray et al, 2006). As development proceeds, Oligl and Olig2 expression 
persists and begins to overlap with the homeodomain transcription factor 
NKx2.2. These double positive progenitor cells migrate away from the ventral 
midline and mature into oligodendrocytes. 
Recently Anderson and co-workers developed Oligl and Olig2 double mutant 
mice (Zhou & Anderson, 2002). These animals lack oligodendrocytes and also 
display a considerable loss of motoneurons. In Oligl/Olig2 double mutants the 
progeny of stem cells in the pMN region of the developing cord, which normally 
develop into motoneurons and then oligodendrocytes, instead form V2 
interneurons and subsequently astrocytes. These results suggest that the 
expression of combinations of transcription factors determines the fate of pools 
of multipotent cells in the developing embryo. This does not however preclude 
the existence of more restricted dividing cell populations. Indeed, recent data 
using a cell ablation techniques to kill Olig-expressing cells support the model 
where motoneurons are generated ahead of oligodendrocytes from neural stem 
cells but suggest they may not share a common lineage-restricted precursor 
(Wu et al, 2006). In these experiments differentiated motoneurons and 
oligodendrocytes were eliminated; there was a continuous generation and then 
death of precursors; but a normal number of oligodendrocyte precursors were 
formed on day 12 after all motoneuron precursors had been killed. 
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The expression of pro-gliogenic transcription factors may be regulated through 
cell surface receptors such as notch (Frisen & Lendahl, 2001). It has been 
shown that jagged-1 (a notch ligand) signalling by neurons suppresses the 
oligodendrocyte phenotype (Rogister et al, 1999). Presumably when the 
neuronal numbers are sufficient jagged-1 is down-regulated and pro- 
oligodendrocyte signals (one of which may be an increase in electrical activity) 
trigger myelination (Wang et al, 1998). Once a neural precursor has made a 
fate commitment to the oligodendrocyte lineage, precursors undergo extensive 
proliferation. The final step to the formation of a myelin forming cell requires the 
presence of the transcription factor Sox 10. Indeed, NSC lacking this 
transcription factor fail to myelinate retinal ganglion axons following 
transplantation (Stolt et al, 2002). At this point neurotrophic signals such as 
FGF, thyroid hormones and platelet derived growth factor (PDGF) are important 
factors in the promotion of oligodendrocyte formation (Kondo & Raff, 2000). 
1.1.2.2. Other factors determining cell fate 
Several other trophic factors and their receptors are also involved in fate choice 
both in vivo and in vitro. As outlined earlier, members of the TGF-ß superfamily 
are central (Shah et al, 1996) and play specialised roles in the maturation of 
specific cell types. Thus, BMP2 induces the basic helix-loop-helix transcription 
factor Mash-1 and is involved in neurogenesis, while BMP-4 and BMP-7 
enhance adrenergic sympathetic neurons in neural crest cell cultures. Other 
growth factors such as glial derived neurotrophic factor (GDNF) are also 
involved. GDNF-deficient mice have deficits in dorsal root ganglia and 
sympathetic neurons, as well as lacking an enteric neural network (Moore et al, 
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1996; Pichel et al, 1996; Sanchez et al, 1996). A similar phenotype is observed 
in mice lacking the GDNF receptor (Cacalano et al, 1998) and other growth 
factor receptors including Ret and ErbB (Britsch et al, 1998). The importance of 
extrinsic signals in the decision process has been demonstrated by Temple and 
colleagues (Qian et al, 1997) who observed that FGF concentrations also 
increase during fetal development and this specifically promotes glial 
differentiation, possibly explaining the switch from neuronal to glial fate. 
Significantly their study showed that the intrinsic ability of neural precursors to 
generate neurons was not diminished with time, but rather that the environment 
became progressively more gliogenic. In fact it is now known that the 
generation of neural cells continues beyond the early developmental period and 
into adult life. This is discussed in the next section. 
1.2. Neurogenesis in the adult mammalian brain 
Ongoing neurogenesis in the adult was identified as early as 1962 by Altman, 
who demonstrated [3H]-thymidine incorporation in the adult rat brain (Altman, 
1962; Altman, 1966). Because of the very limited recovery of brain tissue from 
CNS injury, it seemed unlikely that an endogenous pool of precursor cells could 
exact functional regeneration. Nevertheless, populations of dividing cells with 
the potential to self-renew and differentiate into mature neural phenotypes have 
been isolated from two main areas of the adult brain (Kaplan & Hinds, 1977; 
Lois & Alvarez-Buylla, 1993). Dividing cells continue to be seen in the 
subventricular zone (SVZ), a remnant of the embryonic ventricular zones, and 
persist throughout life. In vivo, these progenitors give rise to migrating cells that 
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eventually differentiate into interneurons within the olfactory bulb (Lois & 
Alvarez-Buylla, 1994). A similar population of progenitor cells has also been 
identified in the subgranular zone of the hippocampus that contributes to 
ongoing neurogenesis in the dentate gyrus (Bayer et al, 1982; Kaplan & Hinds, 
1977; Lois & Alvarez-Buylla, 1993). There are also reports of discrete areas of 
neurogenesis elsewhere in the adult mammalian brain, including the subcortical 
white matter (Takemura, 2005) but this is controversial, and work is at an early 
stage. 
1.2.1. Areas of neurogenesis in the adult brain 
1.2.1.1. Neurogenesis in the adult subventricular zone 
The SVZ lies along the lateral walls of the lateral ventricles and contains 
actively proliferating cells throughout adult life (Kuhn et al, 1996). As outlined 
earlier, antagonism of BMP signals favour neurogenesis in the embryo; a 
similar function has been identified in the adult SVZ where noggin, expressed 
by ependymal cells, can also block BMP signalling. In the absence of noggin, 
BMP favours gliogenesis over the production of neurons. In this way, a specific 
gliogenic niche is created in the SVZ (Lim et al, 2000). Proliferation of SVZ stem 
cells has been demonstrated by [3H] thymidine and bromodeoxyuridine (BrdU) 
incorporation into dividing cells. In these labelling experiments, the progeny 
have been demonstrated to migrate forward along the rostral migratory tract 
into the olfactory bulb where they develop into inter-neurons (Altman, 1969; 
Lois & Alvarez-Buylla, 1994; Kornack & Rakic, 1999; Pencea et al, 2001; 
Peretto et al, 1999). In the rodent, it takes only 2-6 days for the cells to cover 
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this distance of up to 8 mm. These migrating neuronal precursor cells, also 
known as Type A cells, form long chains and migrate without the guidance of 
axons or radial glia. These chains are ensheathed by layers of specialised glial 
fibrillary acidic protein (GFAP) positive astrocytes (type B cells), of which there 
are at least two forms, based on whether they contact the ependyma (type 131) 
or not (type B2) (Doetsch et al, 1997). 
Chain migration has been demonstrated using explant cultures and has been 
shown to be several fold faster than the equivalent migration along radial glia. 
Type A cells express nestin (a neural precursor marker), TuJ1 (a neuron- 
specific tubulin) and polysialylated NCAM (PSA-NCAM). This polysialylated 
form of NCAM is thought to be very important in chain migration since NCAM 
null mice (Cremer et al, 1994; Tomasiewicz et al, 1993) and those in which the 
PSA form is degraded (Ono et al, 1994) show impaired cell migration and 
smaller olfactory bulbs. There are at least two other cell types in the SVZ: type 
C cells, initially thought to be rapidly-proliferating immature precursors that form 
clumps adjacent to migrating type A cells (Garcia-Verdugo et al, 1998), and the 
ependymal cells (type E cells) that line the ventricular cavity. A diagram of the 
cellular organisation of the SVC is shown in Figure 1.02. 
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B. 
Figure 1.02. Summary diagram of the organisation of the adult SVZ. 
Schematic cross section through a chain of migrating neuroblasts (red) 
ensheathed by two types of glial cells (B1, B2, blue) that separate the migrating 
cells from the striatum (left) and ependymal cells (grey). Type C cells (green, 
putative precursor) are not ensheathed by glia and are associated closely with 
the chains of migrating neuroblasts (A). (B) is a schematic en face view of the 
SVZ viewed from the striatum. The red channels represent the chains of 
migrating neuroblasts (Type A cells) with tangentially elongated nuclei (light 
red). The blue blocks represent the ensheathing glial cells (Type B1 and B2). 
These cells form tunnel-like structures through which the Type A cells migrate. 
Putative precursors (Type C cells, green) are closely associated with, and 
speckled in small clusters along, chains of migrating neuroblasts. The 
underlying ependymal cells (grey) form a sheet lining the ventricular surface. 
From Doetsch et al, 1997 (Doetsch et al, 1997). 
1.2.1.1.1. Which cell type are the SVC multipotent `stem cells' 
There has been considerable debate as to which cells in the SVZ are the 
multipotent `stem cells' that give rise to the migrating neuronal type A cells. 
Experiments measuring [3H] thymidine and BrdU incorporation have been 
unhelpful, since considerable uptake has been observed in many of the SVZ 
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cell types. Johansson et al (Johansson et al, 1999) have suggested that the 
ependymal cells are the SVZ stem cells. They demonstrated that Dil (a 
fluorescent dye)-labelled ependymal (E) cells could divide in vivo, and over time 
labelled cells were seen to appear as neurons in the olfactory bulb. Co-culture 
experiments with labelled and unlabelled cells showed that the dye was unlikely 
to be transferred between cell types. Dil labelled cells increased after 
experimental injury and many cells became GFAP-positive astrocytes. The 
assumption that E cells are the stem cells that generate type A cells has been 
challenged by observations such as their very slow rate of division and the 
possibility of Dil labelling occurring in small proportions of other cell types in the 
SVZ. Indeed, the work of Alva rez-Buylla's group suggested that type A cells do 
not self-renew (Lim & Alvarez-Buylla, 1999), but can be generated from cultures 
enriched for type B and C cells. In later studies by the same group following the 
specific ablation of type A and type C cells it was found that type B cells, the 
astrocytes, gave rise to new type C cells which in-turn differentiated into the 
migrating neural cells (Doetsch et al, 1999). This was confirmed by specifically 
labelling type B cells with retroviral vectors and tracking their migration to the 
olfactory bulb. Finally, purified SVZ derived astrocytes cultured in the presence 
of FGF and Epidermal Growth Factor (EGF) are able to form expanding 
neurospheres (Laywell et al, 2000) and differentiate into neuronal phenotypes 
(Doetsch et al, 1999). 
This result clearly challenges the traditional dogma that neural stem cells (NSC) 
give rise to neurons first then glia. Indeed, it suggests that glial cells might 
generate neurons! Further evidence for this intriguing possibility comes from 
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studies of the hippocampus, where it was shown astrocytes are capable of 
regulating neurogenesis by instructing stem cells to adopt a neuronal fate and 
may even themselves be the hippocampal stem cells (Song et al, 2002a). 
1.2.1.2. Neurogenesis in the adult hippocampus 
In addition to the SVZ, active neural cell proliferation has been discovered in the 
dentate gyrus in rodents. The dividing cells arise in the subgranular zone and 
then migrate into the granule cell layer, where they differentiate to acquire 
neuronal morphology and phenotype. Gage and colleagues have demonstrated 
a similar population of dividing cells in a group of brain tumour patients who 
received BrdU infusions for diagnostic purposes, and later died (Eriksson et al, 
1998). In all treated patients, BrdU labelled cells were present in the granule 
layer and co-expressed neuronal markers. 
Very recently, it has been claimed that while neurogenesis occurs in both the 
dentate gyrus and in the subependymal zone, NSC only reside in the latter 
region. Seaberg and Van der Kooy elegantly micro-dissected and cultured cells 
from both brain regions and observed that only committed neuronal and glial 
progenitors were present in the dentate gyrus while true NSC were present in 
the subependymal zone. One caveat of this study is that cells were studied in 
culture and so it cannot be excluded that an important factor necessary for 
plasticity of dentate gyrus NSC is absent in vitro (Seaberg & van der, 2002). On 
the other hand, using retroviral green fluorescent protein (GFP) labelling of 
clonally-derived NSC from the adult (rat) hippocampus, Gage and colleagues 
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showed that these cells could develop into neurons or astrocytes (Song et al, 
2002b). Post-mitotic GFP-labelled neurons displayed action potentials and 
functional synaptic inputs (van Praag et al, 2002). Since it was not shown that a 
single NSC could give rise to both astrocytes and neurons in culture, the 
possibility remains that committed neural progenitors for each lineage may have 
been present in the starting material. 
1.2.2. The role of neurogenesis in healthy adults 
Since it is now evident that new neurons are constantly being generated in the 
adult why does the mature brain display only a very limited capacity to repair? 
Perhaps this is a reflection not of the cell population that reside in adult 
neurogenic regions, but rather that the environment is not conducive to promote 
stem cell proliferation and terminal differentiation. Does adult neurogenesis 
represent an endogenous attempt to replace lost or damaged cells or is it a 
reflection of ongoing physiological processes such as learning? In the avian 
brain, the song system (in particular the high vocal centre) in canaries and 
zebra finches, has been well studied (Nottebohm, 2002). It seems that neurons 
are produced during adulthood to replace others (Alvarez-Buylla et al, 1992). 
Although the total number of neurons in this brain region remains constant, 
singing has been shown to increase the levels of brain derived neurotrophic 
factor (BDNF). Both BDNF expression and the survival of newborn neurons are 
proportional to the number of songs in a given unit of time (Rasika et al, 
1999). 
In this system, neurogenesis seems necessary for the learning of new song 
patterns and neuronal cell death is likely to be as important as new nerve 
formation (Scharff et al, 2000). 
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1.2.2.1. External influences on adult neurogenesis 
There has been much interest in external influences on neurogenesis in the 
adult hippocampus, particularly since it is of primary importance in the long term 
potentiation of memory. In adult mice, neurogenesis in the hippocampus has 
been shown to be regulated by physical exercise, with subjects exposed to 
enhanced environments displaying improved performance in learning tasks 
such as the Morris water maze (van Praag et al, 1999). Similarly, Kempermann 
et al. have demonstrated an increase in neuronal number in the dentate gyrus 
and in the size of the granule layer in adult mice housed in an enriched 
environment compared to litter-mate controls (Kempermann et al, 1997), while 
van Praag et al. reported increased neurogenesis in the dentate gyrus in mice 
given access to a running wheel (van Praag et al, 1999). These observations 
suggest that in healthy animals, ongoing neurogenesis in the adult 
hippocampus may contribute to behaviour, learning and memory. 
The role of other external factors has also been studied. Gould has recently 
reviewed the effects of glucocorticoids and stress on hippocampal 
neurogenesis (Gould & Tanapat, 1999). Adrenal glucocorticoids appear to have 
an inhibitory effect on dentate cell proliferation in the rat that is most evident 
following adrenalectomy (Cameron & Gould, 1994), or shortly after birth (the so- 
called stress hyporesponsive time) when endogenous steroids decline to low 
levels and granule cell neurogenesis is rapid. Experimental increases in 
glucocorticoids at this time markedly reduce cell proliferation. Similarly, it has 
been shown that exposure to stressful environments during this critical period 
also results in reduced cell division in the dentate gyrus, while repeated stress 
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leads to a profound and prolonged suppression. Other external factors, such as 
antidepressants that increase serotonin (5HT) action, increase neurogenesis 
(Malberg et al, 2000) and indeed if adult neurogenesis is blocked by irradiation, 
the behavioural effects of fluoxetine (a 5HT re-uptake inhibitor) are abolished 
(Santarelli et al, 2003). Some investigators are thus studying the interesting, 
and as yet unproven, hypothesis that insufficient hippocampal neurogenesis 
actually underlies depression (Jacobs et al, 2000; D'Sa & Duman, 2002). 
1.2.3. Neurogenesis and brain injury 
The identification of dividing cells in the mature CNS has led to research into 
neurogenesis in degenerative diseases and following cerebral injury. This 
research both investigates the potential for endogenous repair, and also aims to 
learn more about the permissive and restrictive cues in the damaged brain that 
will be crucially important if cell replacement therapy is considered in the future. 
It is now clear that injury to the CNS does indeed result in the proliferation of 
neural precursors. 
A number of studies have used BrdU labelling, in conjunction with neuron- 
specific markers, to demonstrate the proliferation and differentiation of 
endogenous neural precursors following experimental stroke (Abe, 2000). 
For 
example, using a gerbil model of cerebral ischaemia, proliferation, migration 
and differentiation of NSC was investigated using BrdU along with PSA-NCAM 
and NeuN (neuron-specific nuclear protein) to label NSC and neurons 
respectively. BrdU-Iabelled NSC were first detected in the subgranular zone of 
the dentate gyrus 20 days after injury, with NeuN positive neurons increasing 
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up to 60 days following injury (Iwai et al, 2002). Similarly, neurogenesis was 
found to increase ten-fold in the subgranular zone of the dentate gyrus after 
global ischaemia in the gerbil (Liu et al, 1998). Endogenous repair in response 
to stroke can also involve the proliferation of neural progenitor cells in the SVZ. 
Following middle cerebral artery occlusion, injection of BrdU labelled cells in the 
ependymal and subependymal layers. Interestingly the cells were identified as 
astrocytes immediately after stroke but later acquired the characteristic 
antigenic markers of neurons after injury (Li et al, 2002), lending further support 
to Alvarez-Buylla's hypothesis that the SVZ stem cells are astrocytes (Doetsch 
et al, 1999). In other studies, neurogenesis has been demonstrated in models 
of newborn hypoxic ischaemic brain injury (Ong et al, 2005), and similarly active 
neurogenesis has been demonstrated in aged and young rats following stroke 
(Darsalia et al, 2005). SVC cell proliferation is enhanced further in rats housed 
in an enriched environment following stroke (Komitova et al, 2005). In a 
separate model employing chemically induced seizures in the rodent, a 
pronounced increase in the generation of neuronal precursors in the SVZ and 
their subsequent migration and integration towards the olfactory bulb was 
reported (Parent et al, 2002). Proliferation was demonstrated using BrdU 
labelling and migration confirmed by retroviral tracing. While it was proposed 
that ischaemia-induced neurogenesis might contribute to the specific recovery 
of memory function lost following injury, a high proportion of the dividing cells 
were lost over the weeks following injury. It remains to be demonstrated 
whether such neurogenic responses are specific or represent a generic global 
response that occurs in areas that already have ongoing adult neurogenesis. 
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While the demonstration that neural cell proliferation and differentiation can be 
further stimulated by injury is encouraging, neural cells have only a limited 
capacity to regenerate, and the small population of endogenous neural stem 
cells seems unable to reconstitute fully and restore function after damage. This 
has led several groups to examine the potential of stem cell replacement 
therapy after cerebral injury (Olanow et al, 1996; Bjorklund & Lindvall, 2000). 
These studies leave little doubt that under appropriate conditions cellular grafts 
can integrate and function in the brain. 
1.3. Repairing brain injury by cell transplantation 
1.3.1. Sources of cells for replacement therapy 
The potential for exogenous cell replacement to repair the injured nervous 
system has led to active research in this area. Three main sources of cells for 
replacement therapy have been explored in animal models of brain injury: 
neural tissue from fetuses, immortalised cell lines and stem cells. 
1.3.1.1. Fetal neural tissue 
Fetal neural cell transplantation has been used with some success in several 
adult brain injury models. Fetal cortical grafts survive in the infarct area 
following focal forebrain injury in adult rats and appear to receive connections 
from the surrounding brain resulting in an improvement in motor function 
(Sorensen et al, 1996). Fetal hippocampal tissue transplanted into adult rat 
hippocampus damaged by global ischaemia improves spatial learning and 
memory (Hodges et al, 1996). Experience already exists of fetal neural cell 
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transfer in humans suffering neurodegenerative disorders. Over 300 patients 
with Parkinson's disease (PD) have now received fetal mesencephalic 
precursors grafted into the striatum. These grafts are spontaneously active and 
can restore dopamine release to near-normal levels with symptomatic 
improvement (Olanow et al, 1996; Hauser et al, 1999). However, there are 
some difficulties: graft survival is poor with transplanted cells dying by 
apoptosis, and thus clinical improvement is not sustained; also, in a recent 
clinical trial in the USA, 15% of grafted patients developed unacceptable 
dyskinesias (Freed et al, 2001). A further problem is the limited supply of 
appropriate fetal neural tissue. Using stem cells could overcome this problem 
by in vitro expansion and encouragingly, embryonic day 12 NSC propagated in 
culture retain the capacity to differentiate into dopaminergic neurons and to 
improve outcome in a rat model of PD (Studer et al, 1998). 
1.3.1.2. Immortalised cell lines 
As an alternative to fetal tissue, immortalised cell lines have been used in 
animal models of brain injury. Neurons grafted from a human teratocarcinoma 
cell line into rats with focal ischaemia resulted in histological integration and 
functional improvement (Borlongan et al, 1998), as did grafting a hippocampal 
neuro-epithelial cell line into damaged hippocampus in the mouse (Sinden et al, 
1997). A number of studies have also demonstrated the successful 
transplantation of oligodendrocyte progenitor cell lines for demyelinating 
diseases including experimental autoimmune encephalomyelitis (Tourbah et al, 
1997) and ethidium bromide-induced demyelinating lesions in the spinal cord 
(Franklin et al, 1996). In these studies, transplanted cells migrated away from 
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the injection site to repopulate and repair areas of demyelination and did not 
affect or penetrate uninjured white matter. In these experiments, the close 
association of the transplanted progenitors with reactive astrocytes suggests 
that, contrary to the current dogma, inflammatory signals within the injured CNS 
may actually promote integration. Indeed there is now evidence that 
inflammation enhances myelination by transplanted oligodendrocyte precursors 
in retinal ganglion cell axons (Setzu et al, 2006). There are, however, 
considerable fears that immortalised cell lines are prone to tumourogenesis and 
that they are unable to reconstitute the full spectrum of cell types lost in cerebral 
injury. This makes them of only limited use in clinical applications. Stem cells 
provide the most promising alternative source of cells for therapeutic transfer. 
They are multipotent, can be propagated in vitro, and can be tagged with 
markers or therapeutic genes. 
1.3.1.3. Stem cells 
Stem cells can be broadly defined as cells that have the capacity to self-renew, 
and can generate differentiated progeny (Morrison et al, 1997); such cells are 
found abundantly during embryogenesis. In later development and adulthood, 
populations of stem cells have now been identified in most tissues including 
bone marrow (Pittenger et al, 1999), brain (Gage, 2000), liver (Alison & Sarraf, 
1998), skin (Watt, 1998) and gut (Poften, 1998). In vitro, stem cells that are 
derived from a specific tissue generally continue to produce cell types specific 
to the tissue of isolation suggesting that they have become lineage-restricted 
through development. In the past few years there have, however, been 
demonstrations of previously unrecognised plasticity of tissue-derived stem 
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cells (Ferrari et al, 1998; Gussoni et al, 1999; Bjornson et al, 1999; Odic et al, 
2001). Indeed, some studies have suggested tissue stem cells may differentiate 
into unrelated cell types even beyond their germ layer boundaries - so called 
transdifferentiation. For example, ectoderm-derived neural stem cells can 
support haematopoiesis (Bjornson et al, 1999) and mesodermal bone marrow 
stem cells can be differentiated into many tissues including neuro-ectodermal 
cells (Brazelton et al, 2000; Kopen et al, 1999; Mezey et al, 2000). The concept 
of stem cell transdifferentiation is not universally accepted (Anderson et al, 
2001) and is discussed in more detail later. 
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1.3.2. The choice of stem cell for neural replacement 
Three principle sources of stem cell are being evaluated for capacity to 
generate neural cells for therapy - embryonic stem cells, more committed 
neural stem cells and tissue-derived non-neural stem cells (Figure 1.03. ). 
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Figure 1.03. Sources of stem cell for neural cell replacement. Neural 
progenitor cells can be derived from ES cells and neurogenic regions of the 
fetal and adult mammalian brain. They can be expanded in vitro and can 
differentiate into the three major neural cell types. Recent studies suggest non- 
neural cells may have the ability to differentiate into neural subtypes. 
1.3.2.1. Embryonic stem (ES) cells 
ES cells from the inner cell mass of the blastocyst are truly totipotent and give 
rise to all tissues including those of the nervous system. They can be 
maintained in long-term culture as floating aggregates, known as embryoid 
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bodies, and retain their ability to differentiate into cell types of all three 
embryonic germ layers, as well as extra-embryonic trophoblast (Xu et al, 2002). 
The first demonstration that mouse ES cells can be induced to express multiple 
neural phenotypes in culture was reported by Bain and colleagues, who used 
retinoic acid (RA) as a trigger for differentiation (Bain et al, 1995). The newly- 
formed neurons were capable of generating action potentials and expressed 
numerous ion channels. Several groups have now proposed culture conditions 
that enrich neural progenitors from murine ES cells (Okabe et al, 1996; Mujtaba 
et al, 1999; Brustle et al, 1997). Okabe et al. developed elaborate sequential 
culture conditions that differentiated ES cells towards a nestin-positive neural 
phenotype. Initial differentiation was observed in medium supplemented with 
insulin, transferrin, selenium and fibronectin and then more committed 
progenitors were maintained with the mitogen, basic FGF (Okabe et al, 1996). 
Finally, growth factor withdrawal then triggered differentiation into neuronal and 
glial phenotypes. Other groups have successfully purified NSC from ES cultures 
by selecting cells expressing the surface markers A2B5 or PSA-NCAM 
(Mujtaba et al, 1999) or the transcription factors Sox 1 and Sox 2 (Li et al, 
1998). In embryogenesis, Sox 1 is confined to the neuro-epithelium of the 
neural plate, whereas Sox 2 is also found in the early neural crest. This 
approach allows enrichment of cells expressing the neurogenic basic helix loop 
helix transcription factors Mash 1 and Mash 4A as well as Pax 3 and Pax 6, 
which are known to be important in dorso-ventral neural tube patterning. 
This 
knowledge, if exploited carefully, may facilitate the isolation of different 
populations of ES-derived neural precursors. Each clone could then be 
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analysed for both neurogenic potential and survival following engraftment in 
order to select the best cell type for therapeutic use. 
More recently, with the increased availability of human ES cells (Thomson et al, 
1998), groups have shown that such cells can be propagated in a similar way to 
murine ES cells, and can differentiate into neural lineages. Carpenter et al. 
have demonstrated such differentiation using combinations of growth factors 
and RA (Carpenter et al, 2001). As in murine ES cell studies, they 
demonstrated that more committed neural progenitors could be enriched with 
antibody selection for A2B5 and PSA-NCAM using immunopanning or magnetic 
bead sorting. Other groups have confirmed these findings and have shown that 
enriched neural precursors from ES cells can incorporate and differentiate in 
vivo (Reubinoff et al, 2001). Su-Chan Zhang transplanted enriched neural 
precursors into the lateral ventricles of newborn mice, and observed migration 
to multiple brain regions, followed by differentiation into cells with mature 
neuronal and astrocytic phenotypes. Interestingly no mature oligodendrocytes 
were identified (Zhang et al, 2001). Other studies have confirmed that 
transplanted ES cells have the potential to populate the normal brain (Flax et al, 
1998; Svendsen et al, 1999). Such in vivo studies are important in two respects: 
first, they suggest that transplanted cells do have the potential to populate the 
brain and, second, they highlight the fact that more manipulation may be 
necessary before the required neural cell types are efficiently generated (Flax et 
al, 1998; Svendsen et al, 1999). Nevertheless, early success in neural 
differentiation of cell grafts in vivo has led to further work in injury models to see 
whether transplanted cells can integrate and functionally improve outcome 
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following defined CNS insults where multiple cell types are lost (Svendsen et al, 
1996; McDonald et al, 1999). Although some success has been reported, it is 
clear that there is still a significant gap in our knowledge of how to direct 
appropriate differentiation of ES cells in vivo. In addition, there are however 
considerable ethical issues in using human embryonic stem cells, and concern 
that their rapid proliferation may lead to tumourogenesis. 
1.3.2.2. Neural stem cells (NSC) 
NSC can be defined as lineage-committed cells found within the central 
nervous system (CNS). These cells have the ability to self-renew and can be 
maintained in culture with mitogens such as EGF and FGF. They can be 
propagated in aggregates (Svendsen et al, 1998; Vescovi & Snyder, 1999; 
Reynolds & Weiss, 1992) or as cell monolayers (Sabate et al, 1995). NSC are 
more restricted in their differentiation capacity than ES cells, giving rise 
predominantly to the three major cell types of the CNS: neurons, astrocytes and 
oligodendrocytes (Figure 1.04. ). 
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Figure 1.04. Progressive restriction of cell fate through development of 
NSC. NSC clearly differ in their potential according to the developmental stage 
at which they were isolated and the specific brain region from which are isolated 
(Rao, 1999; Ostenfeld et al, 2002a) suggesting that more restricted progenitors 
arise through the developmental program. 
Although their discovery and isolation is promising for the understanding of both 
brain development and repair, the basic biology of NSC is still not well 
understood. Indeed, the unequivocal identification of true NSC remains difficult 
as there are no specific markers for this cell type. Nestin, for example, is a 
widely used marker and is highly expressed in the developing neuro-epithelium 
and NSC (Tohyama et al, 1992; Lendahl et al, 1990), but is also found on other 
cell types such as endothelial cells, developing myoblasts and reactive 
astrocytes (Lin et al, 1995). Other markers used to define NSC include CD133, 
Musashi and notch-1 (Okano et al, 2002; Sakakibara et al, 2002; Okano et al, 
2005; Hall et al, 2006) but none of these is absolutely specific. NSC are thus 
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defined largely on their culture properties, their proliferation and their 
differentiation capacity both in vitro and in vivo. For the purposes of this thesis, 
NSC have been defined as neural cells with the potential to self-renew and to 
generate all the different cell types of the nervous system following 
differentiation. 
NSC have been identified in many areas of the developing mammalian brain 
and also in specific regions of the adult CNS (Johansson et al, 1999; Palmer et 
a/, 1995). These cells can be cultured in aggregates and driven to differentiate 
into neurons, oligodendrocytes and astrocytes (Gage et al, 1995; Gage, 2000). 
Such cells have been shown by clonal analysis (Reynolds & Weiss, 1996; 
Kalyani et al, 1997), labelling (Levison & Goldman, 1997) or transplantation 
experiments to have the potential for differentiation into all three neural cell 
types but cells from different sites are not identical, displaying different growth 
characteristics, growth factor requirements and restricted patterns of 
differentiation (Rao, 1999; Mayer-Proschel et al, 1997; Morrison, 2001). In 
addition, these multipotent progenitors clearly differ in their potential according 
to the developmental stage at which they were isolated and the specific brain 
region from which they were isolated (Rao, 1999; Ostenfeld et al, 2002a). This 
suggests that more restricted progenitors arise through the developmental 
program. 
Although the bulk of experimental data has been obtained using rodent NSC, 
similar multipotent cells have been identified in the human (Carpenter et al, 
1999; Piper et al, 2001). There are clearly similarities between the in vivo, and 
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culture properties of NSC from rodents and from man, but there are notable 
differences too. These differences are discussed at length in Ginis and Rao's 
recent review (Ginis & Rao, 2003). One of the most evident is that 
differentiation of rat neurospheres generates large quantities of 
oligodendrocytes, whereas similar experiments in human cells generate 
relatively few. The reason for this is not clear and more work is needed to 
determine what signals influence the cell phenotype and, indeed, what the 
specific cues are for terminal differentiation. 
Uchida et al. have described the isolation of NSC, and subsequent neurosphere 
cultures, from fresh human fetal tissue. The cells were obtained from 
dissociated brain and spinal cord, and enriched by fluorescence activated cell 
sorting. It was demonstrated that single CD133+, CD34-, CD45-, CD24-110,5E12+ 
cells could generate neurospheres, self-renew and differentiate into neurons 
and glia. When these cells were injected into the lateral ventricles of 
immunodeficient NOD/SCID new-born mice they showed engraftment, 
migration and region-specific neuronal differentiation on examination up to 
seven months later (Uchida et al, 2000). 
Although ethically controversial, human fetal CNS tissue represents a potential 
source of human NSC for future research and therapy. An attractive property of 
fetal NSC is their proliferative capacity. In one study, human neural progenitors 
isolated from embryonic forebrain were expanded for up to a year in culture 
using EGF, FGF and leukaemia inhibitory factor (LIF). Prolonged culture did not 
profoundly affect the potential of these cells, and indeed injection of these cell 
Neural Differentiation of Fetal Mesenchymal Stem Cells Chapter 1 
54 
lines into the developing rat brain showed extensive migration and integration 
(Englund et al, 2002). Although these results are encouraging, it is clear that 
challenges remain in determining the best source and developmental age to 
isolate NSC from fetal tissue, and to define the optimal ex vivo propagation 
conditions for each therapeutic application. 
Another potential source of human NSC is from the adult brain and indeed, 
such cells have now been cultured from human cadavers up to five days after 
death (Palmer et al, 2001; Schwartz et al, 2003). At present, NSC derived from 
adults are difficult to isolate, found in small numbers, have a more limited 
proliferative capacity and seem to have a more restricted differentiation 
potential than their fetal counterparts. In the light of current knowledge, it would 
appear that fetal NSC will be more useful for cell therapy. However, the highly 
controversial nature of this source of neural tissue has provided an impetus for 
understanding adult NSC in more detail. 
1.3.2.2.1. Fetal vs adult NSC 
Comparisons of fetal NSC with those derived from defined developmental 
niches in the mature brain seem to indicate that NSC plasticity decreases with 
developmental age. Although the precise mechanisms are not fully understood, 
there is evidence that many of the fate decisions may be cell intrinsic (Morrison, 
2000). For example, EGF receptor expression increases in cortical stem cells 
with increased passage number and this may result in an increased 
responsiveness to this ligand (Burrows et al, 1997). NSC differ according to the 
developmental stage at which they were isolated and also the site from where 
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they were obtained (Rao, 1999). There is also good evidence that more 
committed glial and neuronal precursors exist. Studies of NSC clones have 
demonstrated that there are single cells that can only give rise to cells of 
neuronal phenotype, and even cells whose progeny are single specific neuronal 
subtypes. Many investigators have now maintained pools of cells, from a variety 
of brain regions that are committed neuronal progenitors but many experiments 
used mixed populations of cells. Much more recently, isolation of neuronal 
precursors has been successfully achieved by cell sorting of cells, transfected 
with GFP under the early neuronal promoter of al tubulin, from the embryonic 
forebrain (Roy et al, 2000). Interestingly, these cells did not give rise to glial 
populations. Similarly, glial precursors have been isolated from E13 in mice, 
and E14.5 in rats (Spassky et al, 1998). Such cells can be identified by A2B5 
immunoreactivity, and purified by immunopanning using this antibody. These 
cells also express NKx2.2 and PLP-DM20, while other markers of more 
differentiated cells such as PDGFra are absent (Rao et al, 1998). Rao and 
colleagues have termed these cells glial-restricted precursors and 
demonstrated their differentiation into oligodendrocytes and astrocytes both in 
vivo and in vitro suggesting a common precursor. Other groups have isolated 
more restricted glial precursors. Raff and colleagues isolated and characterised 
the oligodendrocyte type-2 astrocyte precursor cell (02A). This more committed 
cell type was initially discovered in the rat optic nerve (Raff et al, 1983), but 
has 
subsequently been isolated from other brain areas, and does not appear 
to 
differentiate into type 1 astrocytes in vivo. It has been recognised that the type 
2 
astrocyte cell may be an artefact of cell preparation and culture, and may not 
have an identical in vivo counterpart; none the less, the differentiation of 02A 
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cells into mature oligodendrocytes has been extensively studied, and the stages 
of oligodendrocyte development defined by combinations of phenotypic 
markers. This differentiation pattern appears to match closely what occurs in 
the developing CNS and is represented in Figure 1.05. It is likely that many of 
the same aspects of oligodendrocyte progenitor differentiation that occur during 
normal development will be recapitulated in repair. If used for cell therapy, the 
optimal stages of the lineage at which cells would be most useful for repair are 
likely to be those during early development when the cells are highly mitotic, 
migratory and can give rise to myelinating progeny. 
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Figure 1.05. Stages of oligodendrocyte development. Oligodendrocytes 
begin as simple cells and, as they develop, go through a bipolar progenitor 
stage before becoming more elaborate with complex processes. Each stage 
can be defined by a series of phenotypic markers. Representative staining and 
morphology through the lineage is demonstrated in the fluorescence 
micrographs of primary rat oligodendrocytes through development. 
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In separate studies, astrocyte-specific precursors have also been identified (Mi 
& Barres, 1999) that give rise to type 1 astrocytes, but not oligodendrocytes. 
These cells can be isolated from the rat optic nerve up to postnatal day 1, are 
A2B5+ and upregulate GFAP upon differentiation. 
Whether fetal or adult NSC are used in cerebral transplants, little is known 
about the cell-intrinsic and external factors that influence proliferative capacity 
and fate choice. By careful examination of the effects of defined neurotrophic 
factors and accurate definition of the factors in the transplant microenvironment, 
it may well be possible to improve the potential of NSC therapy in the future. 
1.3.2.3. Tissue-derived, non-neural stem cells 
1.3.2.3.1. Bone marrow transplantation studies 
A growing number of studies suggest that non-neural cell types can be 
propagated and transdifferentiated into neural lineages. Much of this work is 
controversial, but if useful autologous neural cells could be obtained from other 
tissues, it would circumvent the ethical problems of using embryonic stem cells 
and fetal tissue, and the practical issues of deriving cells from post-mortem 
brains. Early in vivo experimental data were based on bone marrow 
transplantation (BMT) studies in lethally-irradiated mice. The transplanted cells 
were followed by genetic differences (e. g. mouse strain, sex, expression of 
green fluorescent protein) between the injected cells and the host. In one study 
of female mice rescued by male BMT, up to 2.4% of neuronal cells were found 
to be male as defined by localisation of the Y chromosome (Mezey et al, 2000). 
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Similar studies have demonstrated the presence of donor markers in neurons of 
the olfactory bulb (Brazelton et al, 2000). 
1.3.2.3.2. Transdifferentiation or cell fusion 
Similar work has also been undertaken in humans. Post-mortem studies of 
females who received BMT from male donors revealed a small proportion 
(0.1%) of Purkinje cells that carried the Y chromosome and were presumed to 
be of donor origin (Weimann et al, 2003a). It has been claimed, however, that 
the small number of neuronal cells do not represent differentiation 
('transdifferentiation') of donor cells, but are the result of cell fusion between 
endogenous Purkinje cells and donor cells forming stable heterokaryons 
(Weimann et al, 2003b) that express markers of both recipient and donor tissue 
(Figure 1.06. ). 
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Figure 1.06. Different mechanisms by which `transdifferentiation' could 
occur. The three models shown represent mechanisms of differentiation from 
bone marrow derived cells (MSC) into neural phenotype. A. More multipotent 
cells, which are not yet committed to the MSC lineage, exist at low frequency, 
and maintain the ability to differentiate into multiple diverse cells types including 
MSC and neural lineages (like MAPC). B. The generation of neural cells from 
MSC may be explained by the reprogramming (trans- or de- differentiation) of 
an already committed blood progenitor. MSC may be able to directly change its 
gene expression pattern into an alternate cell type. C. Fusion could occur 
between a MSC and neural cell leading to the conclusion that the MSC has 
acquired neural markers. 
Recently, two elaborate studies have confirmed cell fusion in stem cell systems 
in vitro. In the first, by co-culturing GFP labelled neurons with hygromycin- 
resistant ES cells, undifferentiated hybrid cells with molecular characteristics of 
both neurons and ES cells were obtained (Ying et al, 2002). In the second 
study, co-culture of bone marrow cells (labelled with GFP) with ES cells 
resulted in fused cells that were GFP-positive and expressed a number of ES 
cell genes. Significantly, the hybrid cells were predominantly tetraploid 
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demonstrating that bone marrow cells can fuse spontaneously with other cell 
types, adopting their phenotype (Terada et al, 2002). 
Fusion of donor cells with host brain cells may explain the apparent 
transdifferentiation of blood to brain in vivo, but cannot explain all of the in vitro 
data. There are now a variety of published protocols for directing bone marrow 
stromal cells (BMSC) to neural lineages. Such cells have been stimulated in 
vivo and in vitro to differentiate predominantly into neurons (Mezey et al, 2000; 
Kopen et al, 1999; Priller et al, 2001) and astrocytes (Zhao et al, 2002; 
Sanchez-Ramos et al, 2000; Kopen et al, 1999; Sanchez-Ramos et al, 2001; 
Nakano et al, 2001). Oligodendrocytes have been identified at very low 
frequency in some experiments on the basis of a single phenotypic markers, 
and without the demonstration of cell maturation from simple precursors to 
more elaborate mature cells (Zhao et al, 2002; Nakano et al, 2001). 
1.3.2.3.3. In vitro neural differentiation of non-neural stem cells 
Sanchez-Ramos et al (Sanchez-Ramos et al, 2000) demonstrated the 
acquisition of neuronal markers NeuN, 8111 tubulin, and the astrocyte marker 
GFAP in a small proportion of bone marrow stromal cells exposed to RA alone 
or in combination with growth factors in both human and murine cells (Sanchez- 
Ramos et al, 2000). Others have even demonstrated the synaptic transmission 
based on immunostaining for synaptophysin and electrophysiological studies in 
vitro following exposure to RA (Cho et al, 2005). Combinations of growth and 
trophic factors, known to be important in brain development, have also been 
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used to stimulate neural development from mesenchymal stem cells (MSC) by 
several investigators leading to cells with mature neural markers (Kang et al, 
2004; Long et al, 2005). The problem with the majority of these studies is that 
the starting population of cells is heterogeneous, and there remains the 
possibility that small numbers of contaminating neural cells, or more multipotent 
cells could account for the result. Indeed, several recent studies have 
demonstrated MSC populations may have a predisposition to neural 
differentiation and that some cells express 'neural genes' in their 
undifferentiated state (Blondheim et al, 2006). Investigators have now reported 
that undifferentiated MSC express mesenchymal and neural markers both at 
RNA level and the protein level (Minguell et al, 2005). In Minguell's study, 
expression of nestin, NeuN, NSE and CNPase were demonstrated by western 
blot, with nestin expression confirmed in 84.5% and CNPase in 66.5% of naive 
MSC by flow cytometry. Importantly these data were obtained in mixed, non- 
clonal, populations. 
Another popular method by which both rat and human BMSC have been 
induced towards a neuronal phenotype is by the application of potent anti- 
oxidants (eg ß-mercaptoethanol, butylated hydroxyanisole) (Woodbury et al, 
2000; Black & Woodbury, 2001). With these compounds there is a rapid change 
in cell morphology over hours and neuron-specific markers such as 
neurofilament-M are upregulated, although no oligodendrocytes are identified 
using this approach (Woodbury et al, 2000). Although this protocol has been 
widely used in MSC from several species and tissues, it remains controversial 
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and some believe it is an artifact of culturing cells in toxic environments 
(Neuhuber et al, 2004; Lu et al, 2004; Croft & Przyborski, 2006). Neuhuber et 
al. rightly suggest caution in interpreting such rapid morphological and 
phenotypic change as true neuronal differentiation in these potent culture 
conditions. They demonstrate similar results in dermal fibroblasts as with MSC, 
and demonstrate that the morphological changes were a result of rapid 
disruption of the actin cytoskeleton, and the apparent neurites a result of 
cytoplasmic shrinkage rather than active extension of processes (Neuhuber et 
al, 2004). Croft et al. confirmed these findings in rat MSC, and importantly 
showed that targeted reorganisation of the cytoskeleton led to activation of 
several kinase pathways eventually resulting in gene transcription. In these 
experiments, disruption of the actin cytoskeleton with serum withdrawal or 
cytochalasin-B resulted in neural-like morphology, and resulted in upregulated 
expression of nestin and NeuroD1. These changes were reversible, and also 
attenuated by inhibitors of protein kinase C (PKB), suggesting PKB has a role in 
mediation of morphological changes and the expression of neural proteins. This 
led the authors to conclude that the expression of neural proteins was a cell 
stress response to cytoskeletal disruption (Croft & Przyborski, 2006). 
Kohyama et al have described two further approaches with murine BMSC 
(Kohyama et al, 2001). They used 5-azacytidine, a demethylating agent, in 
combination with growth factors in some experiments and in others used the 
neural inducer noggin (a bone morphogenic protein antagonist). Both these 
protocols lead to multi-processed cells that expressed a range of neuronal 
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markers, and responded to depolarising stimuli. One further approach that has 
been used in vitro for neural differentiation is the use of agents that increase 
intracellular cAMP levels. Compounds such as forskolin have augmented neural 
differentiation determined by morphology and the rather non-specific neuronal 
markers (NSE and vimentin) (Deng et al, 2001). 
Although controversial, much of the transdifferentiation data is tantalising and is 
not easily explained by cell fusion. In these experiments, the generation of 
neural cells from blood could be either due to the presence of a minute 
subpopulation of highly multipotent cells in the marrow, or may be explained by 
reprogramming (trans- or de- differentiation) of an already committed blood 
progenitor. Indeed, Verfaillie's group has described the `multipotent adult 
progenitor cell' (MAPC) as a bone marrow-derived cell that has multi-tissue 
potential (Jiang et al, 2002a), including neural lineages. When transplanted, 
these cells have been shown to ameliorate neurological deficits in a rat model 
of cerebral ischaemia (Zhao et al, 2002). 
Blood or bone marrow would be an ethically-acceptable and easily-accessible 
source of cells for neural replacement, although research is at an early stage 
and the findings controversial. 
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1.4. Mesenchymal Stem Cells (MSC) 
MSC, also known as marrow stromal cells (Prockop, 1997) or mesenchymal 
progenitors (Conget & Minguell, 1999) were first described in the stromal 
compartment of the adult bone marrow by Friedenstein in 1966 who isolated 
bone-forming progenitors from rat bone marrow (Friedenstein et al, 1966). MSC 
represent a very small proportion of the nucleated cells (0.001-0.01%) in adult 
bone marrow and can be readily isolated and expanded before differentiation 
into multiple cell types (Pittenger et al, 1999). MSC have now been successfully 
isolated and characterised in a wide variety of vertebrate species (Pittenger et 
al, 1999; Meirelles & Nardi, 2003; Ringe et al, 2002; Kadiyala et al, 1997; 
Worster et al, 2000; Niku et al, 2004; Lee et al, 2006), and cells with similar 
phenotype and biological properties to those from bone marrow have now been 
identified in many other tissues including human adult (Kuznetsov et al, 2001), 
umbilical (Lee et al, 2004), and fetal blood (Campagnoli et al, 2001), placental 
tissue (In 't Anker et al, 2004), trebecular bone (Noth et al, 2002), synovial 
membranes (De Bari et al, 2003), adipose tissue (Gronthos et al, 2001), 
skeletal muscle (Jankowski et al, 2002), scalp (Shih et al, 2005), lung (Noort et 
al, 2002) and even deciduous teeth (Miura et al, 2003). MSC have great 
therapeutic potential in tissue repair because of their ability to self renew and to 
readily differentiate into mesodermal lineages including fat, cartilage and bone. 
As discussed above, it has been recently suggested that MSC may have even 
more plasticity with the potential to be guided towards neural lineages. 
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1.4.1. Isolation and culture of MSC from bone marrow 
There are several methods for isolating MSC from bone marrow. Human MSC 
are typically isolated from the mononuclear layer of bone marrow after 
separation by density gradient centrifugation (Friedenstein et al, 1974; Pereira 
et al, 1995; Colter et al, 2000; Sekiya et al, 2002). MSC can be isolated from 
mononuclear cells by their selective adherence to plastic (Mendelow et al, 
1980; Gordon et al, 1983; Meirelles & Nardi, 2003). Over time in culture non- 
adherent haemopoietic stem cells are washed away resulting in a population of 
MSC. Standard conditions for their growth include the presence of serum, 
usually fetal bovine serum, although human MSC have now been successfully 
expanded in autologous human serum (Stute et al, 2004). MSC grow vigorously 
in culture making them an abundant cell source for study and therapy. MSC 
obtained from a2 ml bone marrow aspirate can be expanded 500-fold over 
about 3 weeks and could result in a theoretical yield of 12.5 - 35.5 billion cells 
(Spees et al, 2004). 
1.4.2. Morphology and phenotype of MSC 
MSC are fusiform and fibroblast-like in morphology. While at present there is no 
specific marker that can identify MSC alone, they express several antigens 
including CD29, CD44, CD49, CD54, CD90, CD102, CD105, CD106, 
CD121 a, b, CD123, CD124 and are negative for markers of endothelial cells 
(CD31), monocyte/macrophages (CD14), lymphocytes (CD11 a/LFA-1), 
leukocytes (CD45), red blood cells (glycophorin A) and other haemopoietic cells 
(CD3, CD14, CD19, CD34, CD38 and CD66b) (Haynesworth et al, 1992; 
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Majumdar et al, 1998; Pittenger et al, 1999; Jiang et al, 2002a; Roufosse et al, 
2004). MSC have been frequently identified using the antibodies SH-2, SH-3 
and SH-4 and others have also used the antibodies STRO-1 (Simmons & 
Torok-Storb, 1991; Gronthos et al, 1994), SB-10 (Bruder et al, 1997; Bruder et 
al, 1998) and antibodies to the low affinity nerve growth factor receptor 
p75LNGF (Quirici et al, 2002). The SH-2 antibody (Haynesworth et al, 1992), 
initially raised against human MSC binds CD105, the transforming growth 
factor-beta (TGF-ß) receptor, endoglin (Barry et al, 1999). This antibody has 
been used for enrichment and selection of MSC, but was subsequently found 
not to be specific since it also reacts with endothelial cells, macrophages and 
connective tissue stromal cells (Cheifetz et al, 1992; Barry et al, 1999). SH-3 
and SH-4 antibodies bind separate epitopes of the membrane bound ecto-5'- 
nucleotidase, CD73, which is an antigen involved in B cell activation (Barry et 
a/, 2001). SB-10, an antibody which binds CD166, identifies undifferentiated 
MSC with its reactivity declining upon osteogenic differentiation, and STRO-1 
antibody has been used to purify MSC populations as have antibodies to the 
nerve growth factor receptor, p75LNGF. None of these markers is specific for 
MSC. 
Further phenotypic information has been obtained from studies of the 
interaction between MSC and haemopoietic stem cells. This research has 
characterised adhesion molecules on the surface of MSC and identified 
molecules whose ligands are present on mature haemopoietic cells. Flow 
cytometric analysis identified the high expression of integrins al, a5, and P1, 
and low expression of a2, a3, a6, av, ß3, and ß4, with no expression of a4, aL 
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and 02. The surface adhesion molecules ICAM-1, ICAM-2, VCAM-1, CD72, 
and LFA-3 were present (Majumdar et al, 2003). 
Most investigators now accept that no single set of phenotypic markers is 
capable of identifying a cell as an MSC (Bianco & Cossu, 1999; Devine, 2002; 
Jorgensen et a/, 2003; Vogel et al, 2003; Phinney, 2002; Smith et al, 2004). 
Surface antigens may differ with different cell isolation, plating density and 
culture duration (Devine, 2002) and cultures of MSC only become 
homogeneous morphologically and phenotypically after several passages in 
culture (Bianco et al, 2001; Devine, 2002). Only recently has the culture and 
differentiation of MSC been demonstrated at the single cell level (Smith et al, 
2004) and indeed the true test of successful MSC transfer for tissue repair still 
awaits the demonstration of differentiation with appropriate cell function 
(Javazon et al, 2004). 
1.4.3. Immunological properties of MSC 
MSC express low levels of HLA Class II and there is variation in the level of 
HLA Class I. Some investigators demonstrate no expression of HLA Class I in 
undifferentiated MSC cultured in low serum (Reyes et al, 2001) whereas others 
find MSC to consistently express this antigen (Deans & Moseley, 2000; Liechty 
et al, 2000). Adult MSC are not immunogenic; they do not elicit a proliferative 
response in allogeneic lymphocytes in vitro (Le Blanc et al, 2003), and inhibit 
the responses of naive and memory antigen-specific T cells to cognate peptide 
(Krampera et al, 2003). The modulation of the immune response has been 
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demonstrated in experiments where intravenous administration of donor MSC 
was well tolerated and prolonged allogeneic skin graft survival in baboons 
(Bartholomew et al, 2002). Little is known at present about the host response to 
transplanted MSC (Javazon et al, 2004). 
1.4.4. Ageing and adult MSC 
The effects of aging on stem cells are not well understood, although it is 
believed that stem cells from younger individuals have greater potential (Fehrer 
& Lepperdinger, 2005). Older stem cells have a reduced proliferative capacity, 
less developmental potency and give rise to fewer progeny particularly when 
exposed to cell stress (Wynn et al, 1999). Similar effects of aging have been 
noted in MSC (Mareschi et al, 2006) with proliferative capacity being inversely 
related to the in vivo age of the donor (Bruce et al, 1986). In addition, human 
adult MSC cease proliferation earlier in vitro (40-50 population doublings) than 
murine MSC with cell senescence paralleled by a loss of multi potentiality 
(Stenderup et al, 2003; Meirelles & Nardi, 2003). Molecular changes such as a 
reduction in telomere length have been linked to MSC ageing. Human adult 
MSC do not appear to have telomerase activity (Zimmermann et al, 2003), 
although this is controversial, and there is a correlation between proliferative 
capacity of human MSC and telomere length, both in culture and with donor age 
(Sharpless & DePinho, 2004). The above data lead many investigators to 
suggest that fetal stem cells might have advantages over adult stem cells for 
therapy but clearly further work needs to be done in this area. 
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1.5. Fetal MSC 
Cells with similar properties to adult bone marrow derived MSC have now been 
isolated from first trimester human fetal blood, fetal liver and fetal bone marrow 
(Campagnoli et al, 2001). Like other MSC, they can self-renew and have the 
potential to develop into tissues derived from mesoderm; their ability to 
differentiate into endodermal or ectodermal tissues is still being investigated 
and this thesis forms part of such research. The differentiation potential of fetal 
blood cells has been recognised for some time. Over 30 years ago Macek et al, 
during studies of the differentiation abilities of fetal blood cells from 16-25 
weeks gestation, demonstrated an adherent fibroblast-like cell population and 
speculated that they originated from a common mesenchymal precursor (Macek 
et al, 1973; Macek & Hurych, 2002). The presence of fetal stromal cells was 
also observed by Hann et al (Hann et al, 1983), who cultured adherent cells 
from bone marrow at 12 weeks gestation, and hypothesised that stem cells 
could be derived from the stromal elements. Van den Heuval et al described the 
stromal cell system in mice and observed that it was formed prior to the onset of 
haematopoiesis in the murine fetus (Van den Heuvel et al, 1987). 
1.5.1. Sources of fetal MSC 
Recently, Campagnoli et al isolated and characterised human fetal MSC from 
fetal blood, bone marrow and liver - these cells have a prolific capacity to self- 
renew and demonstrate multilineage potential (Campagnoli et al, 2001). Human 
fetal MSC are present in the fetal circulation by 7 weeks gestation, when they 
represent about 0.4% of fetal nucleated cells, and persist throughout the first 
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trimester. Their frequency declines to very low levels by 14 weeks (Campagnoli 
et al, 2001; Yu et al, 2004). Their phenotype is non-haemopoietic (CD14-, 
CD45-), non-endothelial (CD31-, CD34-) and myo-fibroblastic. The cells can be 
expanded in medium containing 10% fetal bovine serum and can be maintained 
in culture for over 6 months without phenotypic change. Multilineage potential 
has been demonstrated in defined culture conditions by differentiation into 
osteocytes, chondrocytes, adipocytes and muscle cells (Campagnoli et al, 
2001; Chan et al, 2006). This is shown in Figure 1.07. 
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Figure 1.07. Multilineage potential of fetal MSC. 
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1.5.2. Fetal blood MSC in relation to the development of 
the fetal bone marrow microenvironment 
There are three main cellular systems in the bone marrow: haemopoietic, 
endothelial and stromal. The stromal cells are non-haemopoietic cells of 
mesenchymal origin and provide a scaffold along with haemopoietic cells and 
extracellular matrix for the establishment and development of haemopoiesis 
during fetal life (Majumdar et al, 1998). The stromal cell compartment is formed 
before active haemopoiesis (Charbord et al, 2002) and indeed, the time of 
isolation of fetal MSC in the fetal liver, spleen and bone marrow is related to the 
developing haemopoietic activity in these tissues. Fetal MSC migrate from one 
anatomical site to the another in the early fetal circulation before establishing in 
the bone marrow (Hann et al, 1983; Van den Heuvel et al, 1987; Campagnoli et 
al, 2001) and the observation that circulating fetal MSC are present from early 
gestation and then decline in frequency during the first trimester suggest an 
important role during first trimester haemopoiesis (Campagnoli et al, 2001). 
Their presence in the blood prior to the initiation of medullary haemopoiesis, 
and their decline in the circulation as haemopoiesis is established is consistent 
with the notion that they are homing to the marrow microenvironment, where 
they adhere, in preparation for haemopoiesis (de la Fuente et al, 2002). 
1.5.3. Immunophenotype and properties of fetal MSC 
Fetal MSC have fibroblastic morphology and form adherent colonies in culture. 
Standard conditions for their growth, similar to adult-derived MSC, include the 
presence of serum, usually fetal bovine serum, and cell density is a critical 
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factor affecting their proliferation (Zhou et al, 2003). With few exceptions, fetal 
MSC have a similar phenotype whether obtained from bone marrow, liver or 
blood. They do not express markers associated with haemopoietic or 
endothelial differentiation. They do not express CD45, CD34, CD14, CD31 and 
are vWF negative. Like adult-derived MSC, they express a large number of 
adhesion molecules including CD44, VCAM-1 and CD29 and in their 
undifferentiated state are positive for markers such as fibronectin, laminin, 
vimentin and for mesenchymal markers such as SH-2. SH-3 and SH-4 
(Campagnoli et al, 2001; Gotherstrom et al, 2004; In 't Anker et al, 2003a). This 
is summarised in Table 1.01. 
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Antigen Blood Bone 
Marrow' 
Liver Lung Kidney Pancreas 
CD45 - - - - - - CD14 - - - - ND ND 
CD68 - - - ND ND ND 
CD34 - - - + - - 
CD31 - - - - - ND 
CD29 + + + + + + 
C D44 + + + + + + 
CD106 + + + - - + 
CD105 ± ± ± + - ND 
SH-3 + + + + ND ND 
SH-4 + + + + ND ND 
HLA-DR - - - - ND - 
Vimentin + + + ND + + 
Laminin + + + ND + ND 
Fibronectin + + + ND ND ND 
Type I - - - ND + + Collagen 
Table 1.01. Immunophenotype of human fetal mesenchymal stem cells by 
source. Positive (+), negative (-), 10-20% cells positive (±), Not determined (ND). 
I Campagnoli, C., Roberts, I. A., Kumar, S., Bennett, P. R., Bellantuono, I. and Fisk, N. M. 
(2001) Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, 
liver, and bone marrow. Blood, 98,2396-402 
2 In 't Anker, P. S., Noort, W. A., Scherjon, S. A., Kleijburg-Van Der Keur, C., Kruisselbrink, A. 
B., Van Bezooijen, R. L., Beekhuizen, W., Willemze, R., Kanhai, H. and Fibbe, W. E. (2003) 
Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen 
exhibit a similar immunophenotype but a heterogeneous multi-lineage differentiation potential. 
Haematologica, 88,845-52 
3 Almeida-Porada, G., El Shabrawy, D., Porada, C. and Zanjani, E. D. (2002) Differentiative 
potential of human metanephric mesenchymal cells. Exp Hematol, 30,1454-62 
4 Hu, Y., Liao, L., Wang, Q., Ma, L., Ma, G., Jiang, X. and Zhao, R. C. (2003) Isolation and 
identification of mesenchymal stem cells from human fetal pancreas. J Lab Clin Med, 141,342-9. 
Fetal MSC are highly proliferative in vitro with population doublings about every 
30 hours, compared to the 48-72 hours of adult-derived MSC, and display no 
apparent change in phenotype after 20 passages (Campagnoli et al, 2001). 
Using protocols derived from work with adult MSC, they can give rise to bone, 
cartilage, adipose tissue and myelo-supportive stroma, although their 
differentiation potential may vary depending on the tissue source of the cells 
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(Reyes et al, 2001; Fibbe, 2002; In 't Anker et al, 2003a). This thesis describes 
the first work exploring the neural potential of fetal MSC. 
1.6. Stem cell therapy in brain disease & injury 
While the therapeutic replacement of entire tissues with stem cells is some way 
off, bone marrow transplants are routinely used to treat immune deficient 
patients, and tentative steps are being taken to manage degenerative and acute 
brain disease with neural cell grafts. It is important to emphasise that treatment 
of localised diseases and global or disseminated diseases may require different 
approaches. The latter do not preclude the use of cell therapy since stem cells 
are able to migrate extensively within the mature brain and even home to sites 
of injury and degeneration. Furthermore, since it has been estimated in 
Parkinson's disease, that more than 80% of striatal neurons and more than 
50% of nigral neurons have died by the time the first observable symptoms of 
neurodegeneration appear (Fearnley & Lees, 1991; Kish et al, 1988), a 
relatively small degree of repair or trophic compensation may lead to a dramatic 
clinical improvement. Stem cell therapies for neurodegeneration and acute 
injury are discussed below. 
1.6.1. Parkinson's Disease (PD) 
PD is characterised by the progressive loss of dopamine producing neurons in 
the substantia nigra that project to the striatum. PD is typified by motor 
symptoms including tremor, rigidity and bradykinesia (slowness of gait and 
movement). Experience already exists of fetal neural cell grafting in humans 
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suffering neurodegenerative disorders. Over 300 patients with PD have now 
received grafts of fetal mesencephalic cells into the striatum. These grafts are 
spontaneously active and can restore dopamine release to near-normal levels 
with symptomatic improvement. There is a downside however; in a clinical trial 
from Denver and New York, 15% of grafted patients developed unacceptable 
dyskinesias (Freed et al, 2001). Furthermore, the supply of fetal neural tissue is 
limited and there is a need to use multiple donors. The limitation of poor tissue 
supply might be overcome by generating dopaminergic neurons from stem 
cells. Using murine ES cells, two recent studies have led to promising results. 
Bjorkland et al. showed that undifferentiated ES cells transplanted into the 
striatum of a rat model of PD spontaneously differentiated into dopaminergic 
neurons with an improvement in motor asymmetry (Bjorklund et al, 2002). The 
results were tempered however by a lack of graft survival in 24% of recipients, 
and teratoma formation in others. The risk of tumour formation from ES cells 
may be reduced by directed differentiation into dopaminergic neurons prior to 
transplantation. This has been achieved with transfection of nuclear receptor 
related-1 (Nurrl), a transcription factor that has a role in the differentiation of 
midbrain precursors into dopamine neurons (Zetterstrom et al, 1997; Saucedo- 
Cardenas et al, 1998), followed by a multi-step culture protocol involving 
exogenous growth factors (Kim et al, 2002b). These differentiated neurons 
released dopamine, integrated into the striatum of 6-hydroxydopamine (6- 
OHDA)-lesioned rats and exhibited electrophysiological properties of 
mesencephalic neurons leading to an improvement in motor function. 
Cell 
transplantation studies have also been carried out using NSC rather than ES 
cells. Rodent NSC can be propagated in culture whilst retaining the capacity to 
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differentiate into dopaminergic neurons and to improve outcome in a rat model 
of PD (Studer et al, 1998). Studer et al demonstrated NSC populations could be 
expanded in vitro and efficiently differentiate into dopaminergic neurons, survive 
intrastriatal transplantation and induce functional recovery in hemi-parkinsonian 
rats (Studer et al, 1998). Human fetal neural stem cells have also been 
expanded in vitro and transplanted into the injured rodent brain; they 
demonstrate long-term survival in a rat model of PD. In this study, EGF and 
FGF-2 expanded human neural precursors repopulated the dopamine-depleted 
striatum, with some observable differentiation into TH-positive cells (Svendsen 
et al, 1997). NSC from adult human mesencephalon, labelled with a nestin-GFP 
transgene, have also been shown to have the potential to generate 
dopaminergic neurons - the implanted cells were able to restore dopaminergic 
function in the host striatum, and lead to functional recovery in behavioural tests 
(amphetamine-induced rotation) (Sawamoto et al, 2001). 
In studying the therapeutic effects of stem cell transplantation, it has been 
proposed that, in addition to neuronal replacement, stem cell grafts may offer 
trophic support, neuroprotection to endogenous cells and even stimulate 
endogenous neurogenesis. Such a protective effect has been seen with 
unilateral grafting of the immortalised cerebellar neural precursor line C17.2 into 
a bilateral lesion model of PD. C17.2 cell express GDNF. Although the 
transplanted cells largely remained undifferentiated, there was an increase in 
TH expression bilaterally, and functional improvement. Careful analysis 
demonstrated that the TH positive cells were host, and not donor-derived, and it 
is likely that the GDNF rescued degenerating host populations (Ourednik et al, 
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2002). These results are consistent with a previous study where GDNF- 
secreting C17.2 cell exhibited neuroprotective effects in a different model of PD 
(Akerud et al, 2001). GDNF has now been over-expressed by lentiviral 
transduction in neural precursors (Ostenfeld et al, 2002b) with a resultant 
increase the survival of transplanted dopamine neurons. Recently, in the first 
study to infuse growth factors into the human brain, direct GDNF administration 
into the putamen lead to direct clinical improvement in five patients with PD with 
minimal side effects (Gill et al, 2003). In addition to the encouraging data with 
GDNF, there are exciting data emerging that with infusions of PDGF-BB and 
BDNF striatal neurogenesis can be induced in adult rats with 6- 
hydroxydopamine lesions (Mohapel et al, 2005). Taken together stem cell 
replacement, perhaps in conjunction with growth factor treatment, has the 
greatest potential in the future treatment of PD. 
1.6.2. Huntington's Disease (HD) 
HD is an autosomal dominant neurodegenerative disorder which results in 
neuronal degeneration, predominantly in the striatum and neocortex resulting in 
progressive motor, cognitive and psychiatric impairments. The genetic basis for 
this disease has been identified as a mutation in the huntingtin (htt) gene 
(1993). This leads to aberrant protein expression and accumulation of mutant 
protein within affected cells (DiFiglia et al, 1997). The precise mechanism 
behind the cell death and the localisation of injury remains unclear. There is 
currently no effective therapy for HD. The development of cell-based therapies 
for HD has relied on experimental models and until recently the widely studied 
models involved excitotoxic injury using kainic acid, ibotenic acid or quinolinic 
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acid (Coyle & Schwarcz, 1976; Schwarcz et a!, 1979; Schwarcz et a!, 1983), or 
metabolic toxins like 3-nitropropionic acid (Borlongan et al, 1997). These toxins 
target striatal neurons inducing progressive motor and cognitive impairment. 
With the identification of the genetic basis of this disease, several groups have 
now generated transgenic mice expressing forms of the mutant gene (Menalled 
& Chesselet, 2002) that have progressive neurological deterioration. These 
provide good models to assess cell replacement strategies, but as in other CNS 
conditions it may well be that cell replacement may improve outcome in other 
ways but differentiation and integration. A clue to this may be in the mouse 
strain HD-94, that expresses the N-terminal fragment of the htt gene with CAG 
repeats under the Tet-Off conditional expression system (Yamamoto et al, 
2000). This mouse develops progressive symptoms from 4-8 weeks and 
develops intracellular inclusions and ultimately cell death. If the expression of 
the htt gene is switched off by administration of tetracycline after onset of the 
disease, the progression of the disease is blocked, cellular inclusions resolve 
and normal behaviour is restored over months (Yamamoto et al, 2000). This 
suggests cellular dysfunction is a major force underlying this disease before cell 
death, and if this can be modulated by cell grafts the clinical progression may 
be attenuated. 
Embryonic striatal tissue has been transplanted into models of HD with some 
success, leading to functional improvement (Mayer et al, 1992). Indeed, striatal 
grafts develop rich afferent and efferent connections with the host brain 
(Dunnett, 1995). Such work has led to clinical trials of fetal human and porcine 
striatal cell implantation in patients with HD. The results of these studies are 
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mixed, with improvements seen in some patients (Bachoud-Levi et al, 2000; 
Hauser et al, 2002). One patient died from cardiovascular disease 18 months 
after such transplantation, although post-mortem histological analysis 
encouragingly demonstrated surviving transplanted cells with typical 
morphology of the developing striatum (Freeman et al, 2000). 
Currently there are considerable efforts in research towards stem cell therapies 
for HD. Indeed, intracerebral human neural precursor grafts show signs of 
striatal differentiation (Armstrong et al, 2000), and it has been recently 
demonstrated that intravenously-injected human NSC can migrate into striatal 
lesions, attenuate striatal atrophy, and induce long-term functional improvement 
in an excitotoxic striatal degeneration model (Lee et al, 2005). These studies 
are at an early stage, and it may be that the clinical improvements are due to 
trophic effects rather than integration. Certainly in one study of autologous 
BMSC grafts in a model of HD, the transplants significantly reduced working 
memory deficits. Histology revealed that most of the transplanted cells 
appeared quite primitive and very few cells expressed neural phenotypes - this 
led the authors to suggest that release of growth factors may underlie the 
clinical improvement (Lescaudron et al, 2003). 
1.6.3. Alzheimer's Disease (AD) 
AD is a progressive degenerative brain disease and is the commonest form of 
dementia. The characteristic histopathological features of the condition are 
senile plaques and neurofibrillary tangles associated with a neurochemical 
abnormality resulting in a cholinergic deficit. Although there is no cure, some of 
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the symptoms such as cognitive decline can be partially relieved with anti- 
cholinesterases. Current pharmacological approaches are unable to halt or 
delay the progression of the disease. A promising development was made 
recently when murine NSC were differentiated into high proportions of 
cholinergic neurons, which could potentially be used for neuronal replacement 
in AD and indeed cholinergic NSC from murine ES cells have been recently 
been reported to improve outcome in a murine model of AD (Wang et al, 
2005b). Despite these encouraging results, stem cell therapy for AD is in its 
infancy and more research is needed. 
1.6.4. Multiple Sclerosis (MS) 
MS is a chronic autoimmune inflammatory demyelinating condition which leads 
to multi-focal loss of myelin, oligodendrocytes and axonal degeneration. With a 
lifetime risk of one in 400, it is one of the major causes of neurological disability 
in young adults (Compston & Coles, 2002). There appears to be an attempt at 
endogenous remyelination that can partially restore axonal conduction and 
motor function, but this is limited to acute inflammatory lesions within which 
oligodendrocyte progenitors are found (Scolding et al, 1998; Wolswijk, 1998; 
Chang et al, 2002). Cell restoration for MS is still at an early experimental 
stage, but already there are encouraging data demonstrating stem cell 
migration extensively through the adult brain towards lesion sites, graft survival, 
proliferation and then remyelination of bare axons. Rodent ES cell-derived 
oligodendrocytes transplanted into an adult rat model of MS have shown 
efficient re-myelination (Brustle et al, 1999). Pluchino et al demonstrated that 
adult murine NSC injected into the cerebral ventricles, or intravenously, in the 
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experimental autoimmune encephalomyelitis (EAE) model of MS, enter the 
brain parenchyma, migrate extensively and home almost exclusively to areas of 
injury resulting in functional improvement (Pluchino et al, 2003). This impressive 
stem cell migration has been shown in other dysmyelination models; the 
implantation of NSC into newborn shiverer (shi) mice brains leads to the 
widespread replacement of dysfunctional oligodendrocytes and myelination. In 
this study, clonal neural stem cells were transplanted in the cerebral ventricles 
at birth resulting in widespread engraftment throughout the shi brain with 
repletion of MBP (Yandava et al, 1999). Rodent NSC appear to generate large 
numbers of oligodendrocytes at all passages, which can remyelinate 
experimental MS-like spinal cord lesions (Hammang et al, 1997). In some 
experiments, NSC have been directed towards the oligodendrocyte lineage 
prior to grafting. Oligodendrocyte progenitors can be derived from NSC from 
several species by supplementing the culture medium with conditioned medium 
from B104 neuroblastoma cells (Avellana-Adalid et al, 1996; Zhang et al, 
1998a; Zhang et al, 1998b; Smith & Blakemore, 2000; Fu et al, 2005). This 
conditioned medium has been used for some years for the maintenance of 
primary rat oligodendrocyte precursors (Bottenstein et al, 1988). Indeed, 
neonatal rat NSC exposed in vitro to EGF and B104 conditioned medium, to 
induce their differentiation into oligodendrocytes, have been shown to produce 
myelin when transplanted into the myelin-deficient rat (Zhang et al, 1998b). An 
important aspect of cell therapy is the developmental stage at which cells are 
transplanted. More committed oligodendrocyte progenitor cells (OPC) from 21- 
23 week human fetal brains have been isolated, purified and cultured. These 
cells were xenografted into shi brains and developed into oligodendrocytes that 
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myelinated host axons (Windrem et al, 2004). Interestingly, in this study, OPC 
from adults generated oligodendrocytes more efficiently than fetal OPC. 
Although this indicates that both NSC and more committed progenitors can 
replace a single cell type, other studies in different models are less 
encouraging. Twitcher mice are a model of Krabbe disease, where there is an 
absence of galactocerebroside (GaIC) resulting in the accumulation of the toxic 
lipid, psychosine. NSC transplantation into this model resulted in no 
improvement in disease signs or survival in spite of extensive oligodendrocyte 
differentiation and myelination (Park et al, 2002). It is possible that the 
transplanted cells could not sufficiently overcome the toxic environment of the 
endogenous tissue. There is little published work on non-neural stem cells as a 
source of oligodendrocytes for study or therapy. In one study, CD117+ 
haematopoietic stem cells (HSC) from adult bone marrow have been shown to 
differentiate into oligodendrocytes after intracerebral transplantation into 
experimental mice (Bonilla et al, 2002). This represents an important 
development in the search for more effective cell types for cell replacement in 
MS. However, further analyses are required in order to confirm the neurogenic 
potential of this abundant source of stem cells and to establish the safety of the 
procedure. There are exciting preliminary reports of MSC therapy in 
experimental models of CNS demyelination. For example, MSC implanted into 
X-ray or ethidium bromide-mediated lesions of the adult rat spinal cord seem to 
extensively remyelinate damaged axons (Bizen et al, 2003) and bone marrow 
stromal cells seem to attenuate reduction in NGF expression and axonal loss in 
EAE mice (Zhang et al, 2006). In addition intravenous injection of MSC seems 
to profoundly modulate the immune system with the induction of T cell 
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unresponsiveness. This dramatically ameliorates EAE, with a marked reduction 
in CNS inflammation and demyelination (Zappia et al, 2005). 
1.6.5. Traumatic brain and spinal cord injury 
Traumatic brain injury, or spinal cord injury, are results of variable insults and 
have heterogeneous pathologies. After the primary insult from direct impact, a 
delayed injury ensues. Studies performed to evaluate the temporal pattern of 
cell death following regional traumatic injury have demonstrated acute neuronal 
degeneration within minutes followed by longer lasting loss over prolonged 
periods up to a year. Such loss has been demonstrated in areas including the 
neocortex, thalamus, and hippocampus (Raghupathi et al, 2000; Royo et al, 
2003). Although the nature of immediate cell death is necrotic (Dietrich et al, 
1994), apoptotic cell death has been observed acutely following injury (Rink et 
a/, 1995), and is the predominant mode of progressive cell death in the longer 
term (Conti et al, 1998; Yakovlev et al, 1997; Newcomb et al, 1999). Several 
cell transplantation studies have yielded promising results (Longhi et al, 2005) 
although it is still not clear how much of this effect is caused by generating new 
neural cells and how much is due to the nourishing effects of a graft in 
diminishing endogenous injury and promoting angiogenesis (Miya et al, 1997). 
Fetal CNS tissue has been grafted into various models of traumatic injury and, 
in some cases, short term integration has been seen in the spinal cord 
(Jakeman & Reier, 1991) as well as improvements in motor function (Refer et 
al, 1992). Importantly, these effects were related to survival of the cell grafts 
(Anderson et al, 1995). Stem cell transplantation has been considered in 
models of traumatic brain and spinal cord injury. Murine ES cells grafted into a 
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model of spinal cord contusion survived long term, differentiated into the three 
major neural lineages, and improved motor function (McDonald et al, 1999). 
Also, ES cells induced towards the oligodendrocyte lineage have been shown 
to myelinate axons in vitro and following transplantation into the injured spinal 
cord (Liu et al, 2000). Injection of more committed neural progenitors has 
yielded similar encouraging results. Embryonic spinal cord-derived NSC 
differentiate and extend processes into host tissue following spinal cord 
contusion leading to functional improvement (Ogawa et al, 2002). Recently 
human NSC have been transplanted into a weight-drop model of traumatic 
brain injury and demonstrated to proliferate and migrate widely over weeks with 
differentiation into neurons and astrocytes (no oligodendrocytes were seen) 
(Wennersten et al, 2004). Bone marrow-derived stem cells (BMSC) have also 
been grafted into models of traumatic injury. Following weight-drop injury in 
mature rats, BMSC transplanted into the site led to a significant improvement in 
motor function, and histology 5 weeks after spinal cord injury revealed that 
BMSC were tightly associated with longitudinally arranged immature astrocytes 
and formed bundles bridging the epicentre of the injury; however no apparent 
neural differentiation was observed (Hofstetter et al, 2002). Interestingly the 
cells survived better if transplanted a week after injury, rather than acutely, 
indicating a window when the environment was less permissive for graft 
survival. In a controlled cortical impact model in adult rats, BMSC administered 
by intra-arterial or intravenous injection on the day after injury were later found 
in multiple organs, including the brain. In these studies, improvement of 
neurological outcome and cellular expression of both the neuronal marker 
NeuN and the astrocytic marker GFAP in the engrafted cells (Lu et al, 2001; 
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Mahmood et al, 2001a). Intraparenchymal transplantation of whole bone 
marrow into the pericontusional tissue after controlled cortical impact brain 
injury in rats also resulted in improved functional outcome and differentiation of 
transplanted cells into populations expressing neuronal and glial markers 
(Mahmood et al, 2001 b). Most recently, labelled bone marrow cells injected 
intravenously 3 days after traumatic brain injury were demonstrated to migrate 
to the injured cerebral cortex, become immunopositive for antigens including 
MAP2, CNPase, GFAP and the microglial marker OX-42 and led to a functional 
improvement in motor function compared to controls (Lu et al, 2006). 
1.6.6. Stroke 
Cell therapy for stroke has been considered to replace those cell lost, and to re- 
establish neural circuits. In addition it is clear that, rather like following traumatic 
injury, there is a continuing process of cell death for some weeks after injury 
and cell grafting may exert neuroprotective effects by trophic support as well. 
Indeed, fetal neural cell transplantation has been successfully applied to several 
experimental models of stroke. Fetal cortical grafts survive in the infarct area 
following focal forebrain ischaemic injury in adult rats and appear to receive 
connections from the surrounding brain with a resulting improvement in motor 
function (Sorensen et al, 1996), spatial learning and memory (Hodges et al, 1996). 
Neural progenitors transplanted into rat brains after experimental ischaemic 
stroke can survive, release neurotransmitters, establish connections with the 
host brain and even restore lost function (Johansson & Grabowski, 1994; 
Bjorklund & Lindvall, 2000; Kondziolka et al, 2002; Savitz et al, 2002; Uchida et 
al, 2003). There have also been studies using ES cells (pre-treated with retinoic 
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acid) for the treatment of experimental stroke leading to functional 
improvement. Again, the transplanted cells demonstrated differentiation to all 
three major neural cell types. Interestingly, the survival of the graft could be 
prolonged by over-expressing anti-apoptotic Bcl-2 (Wei et al, 2005). Non-neural 
progenitor cells from bone marrow (Hess et al, 2002; Li et al, 2000; Li et al, 
2001) or umbilical cord blood (Chen et al, 2001c) have been used following 
cerebral ischaemia and improve outcome (Chen et al, 2001 b; Zhao et al, 2002) 
and there are data supporting improvement after intracerebral grafting or 
injection into the bloodstream (Chen et al, 2001 a; Chen et al, 2001 b). More 
recently, it has been demonstrated that intravenous administration of human 
MSC protects against cerebral ischaemia in adult rats (Honma et al, 2006), and 
that therapy with MSC expressing BDNF or GDNF transgenically had reduced 
infarct size and showed enhanced functional recovery following transient middle 
cerebral artery occlusion (Kurozumi et al, 2005). A therapeutic benefit of bone 
marrow stromal cell transplantation has even been demonstrated when cells 
are administered 1 month after injury (Shen et al, 2006). 
1.6.7. Brain Tumours 
Gliomas are a highly invasive form of CNS neoplasms with a very low patient 
survival rate. Due to the highly motile phenotype of glioma cells, tumour 
margins tend to be diffuse and complete resection is almost impossible. NSC 
are highly motile and can migrate through the brain parenchyma towards area 
of pathology before integrating into the host cytoarchitecture. They exhibit a 
striking degree of tropism for glioma cells and seem capable of tracking 
disseminated disease (Aboody et al, 2000). Additionally, neural progenitor cells 
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have been engineered to produce therapeutic molecules which can be 
delivered to the tumour by this cell tropism. Genetically modified NSC 
expressing molecules toxic to gliomas (eg interleukin-4, interleukin-12, TRAIL) 
have been successfully used in animal tumour models leading to the survival of 
most tumour-bearing mice (Benedetti et al, 2000; Ehtesham et al, 2002b; 
Ehtesham et al, 2002a). The relative ease with which NSC can be genetically 
manipulated makes them an attractive option for the treatment of otherwise 
intractable malignancies (Yandava et al, 1999). A recent study found that MSC 
(transfected to express interleukin-2) have a similar effect on glioma cells after 
transplantation into experimental tumours (Nakamura et al, 2004). 
1.6.8. Perinatal brain diseases 
Research into the perinatal uses of stem cell transplantation is at a very early 
stage and such therapies is likely to be limited to a few disorders. Until recently, 
the application of cell therapies was only considered for focal brain diseases or 
insults. This was based on the fact that it would not be practicable to deliver 
cells (with multiple injections) to multiple sites in the brain. However the majority 
of neurological diseases that manifest in childhood are global and affect 
widespread areas of the CNS, and multiple cell types. These include genetic 
causes such as inborn errors of metabolism, lysosomal storage diseases and 
leukodystrophies, as well as the widespread abnormalities that can follow acute 
brain injury after asphyxia, or the more subtle white matter abnormality that 
occurs in the majority of extremely-preterm infants. The global nature of these 
diseases may not preclude the use of perinatal cellular therapy for two reasons: 
first NSC have been shown to migrate extensively in the developing brain (and 
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more readily than the mature brain); and second in other injury models stem 
cells seem to migrate and even home to widespread sites of injury. 
One of the major obstacles to using human NSC perinatal therapy is that at 
present, for the majority of brain diseases, the pathogenesis is not well 
understood at the molecular or cellular level. It is likely that a detailed 
knowledge of the timing of pathological events and the associated 
environmental signals would aid successful treatment design. It is intuitive that 
cell replacement may be more successful in cases where a specific population 
of cells are lost in an environment where other cells are competent; however, 
this is rarely the case. There is frequently more global and ongoing cell loss 
with a distorted and abnormal microenvironment and cytoarchitecture. 
Although undifferentiated NSC offer the potential to replace numerous cell 
types, this is unlikely to occur effectively in the absence of appropriate signals. 
Since NSC can undoubtedly respond appropriately to developmental cues this 
makes the developing brain a particularly attractive environment for 
transplantation. Clearly, more work needs to be done to examine the transplant 
environment and how it can be manipulated in disease and injury. A further 
problem when considering many of the neurodegenerative conditions of 
childhood (eg inborn errors of metabolism), is that the process is ongoing and 
the environment inherently toxic. Unless the transplanted cells, or the local 
environment, are manipulated the graft would itself be vulnerable and ultimately 
lost. Indeed, even when the disease process is not ongoing, graft loss by 
apoptosis is a problem and hampers long-term success - this will be discussed 
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later. Although perinatal NSC therapy in humans is some way off, examples of 
potential therapeutic targets (metabolic brain disease, white matter disease, 
and hypoxia ischaemia) are discussed below. 
1.6.8.1. Metabolic brain diseases 
One of the major advantages of considering perinatal cell therapy for inborn 
errors of metabolism is that, if the diagnosis is known, treatment could be 
commenced early to prevent or minimise ongoing brain damage or 
deterioration. It is important to recognise, however, that the majority of infants 
with metabolic disease (frequently autosomal recessive) do not have affected 
parents and so treatment before the onset of symptoms or manifestations, 
especially in utero, would not generally be possible. There are other important 
issues to take into account. First, it could be argued that metabolic diseases are 
multi-organ diseases and should therefore be treated with global cell therapy 
such as bone marrow transplantation (BMT), although this approach may have 
little impact on neurological deterioration. One example of this is the treatment 
of metachromatic leukodystrophy (arylsulfatase deficiency) with BMT, where it 
was found that only in the kidney and liver of transplanted animals was lipid 
storage improved, while in the brain, neuronal damage was as severe as in the 
untreated animals (Gieselmann, 2003). Second, in a given metabolic disorder 
where the majority of cells are likely to be affected, it would be unlikely that a 
cell replacement strategy would be curative. Cell replacement therapy may 
attenuate the clinical course of the disease and this has been demonstrated 
with oligodendrocyte progenitor cell therapy in metachromatic leukodystrophy 
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(Givogri et al, 2006). In addition, stem cells could be used as vehicles to deliver 
a missing or aberrant gene/protein, or to simply generate trophic support for 
endogenous cells to slow their degeneration. Third, cell therapy would have to 
be designed in such a way that grafted cells would escape the pathological 
processes affecting host cells. Already several researchers have examined 
NSC therapy in models with inborn errors of metabolism with mixed results. 
Meng et al. investigated the possibility of using NSC in the treatment of 
metabolic brain disease in a murine model of mucopolysaccharidosis type VII 
(Meng et al, 2003). This condition arises from a defect in the ß-glucuronidase 
gene and results in lysosomal accumulation of glycosaminoglycans in the brain, 
with subsequent neurodegeneration. In this study NSC were modified to over- 
express the missing enzyme (ß-glucuronidase) and transplanted into the 
cerebral ventricles of newborn affected mice. These NSC migrated widely, 
produced large quantities of ß-glucuronidase and resulted in a dramatic 
clearance of the lysosomal accumulation in host cells to near normal levels. 
Such experiments prove the principle that NSC can be used as gene delivery 
vehicles in genetic deficiency disorders. One downside to this experiment was 
that graft survival was limited by apoptotic cell death and so the benefits would 
not be long lasting - improving graft survival is an important concept that will be 
discussed later. 
1.6.8.2. Newborn white matter disease 
Although in the majority of CNS diseases a number of different cell types are 
affected, cell replacement therapy has been most successfully used in models 
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where damage to a single cell type is predominant. One example of this is white 
matter disease and indeed there are already several rodent models with 
specific abnormalities in oligodendrocytes - the myelin forming cells of the 
CNS. These models, as well as demonstrating proof of principle, will provide 
useful prototypes for perinatal therapy. There is accumulating evidence that, 
although periventricular leukomalacia is becoming rare, brain injury or 
abnormality found in the majority of survivors of extremely preterm birth remains 
predominantly in white matter and involves oligodendrocyte precursor loss. 
Magnetic resonance imaging studies have confirmed involvement of the white 
matter (Maalouf et al, 1999; Counsell et al, 2003) (Figure 1.08. ) and in vitro 
data also suggest that oligodendrocyte precursors, abundant in the preterm 
brain, are very much more vulnerable to a variety of stressors compared to 
mature oligodendrocytes (Ness et al, 2001). Oligodendrocyte death or 
maldevelopment may be a primary event in preterm brain injury. 
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Figure 1.08. White matter abnormality in extremely preterm infants. T2 
weighted transverse MR images. (a) An image of a preterm infant at term- 
corrected age demonstrating patchy high signal intensity in the white matter 
(arrows). Overt white matter cystic change (periventricular leukomalacia) is now 
very rare but more subtle white matter signal change on MR imaging occurs in 
the majority of infants at 28 weeks. This pattern represents abnormality 
(Counsell et al, 2003) and is not present in normal term-born infants. (b). This 
MR feature probably represents loss or maldevelopment of oligodendrocytes 
and their precursors. 
Despite the distance between the theory and clinical practice of neural stem cell 
transplants, laboratory work examining oligodendrocyte replacement, as 
described in the previous section on multiple sclerosis, has provided some 
encouraging results. However there is no work reported to date using cell 
therapy for preterm brain injury. Also, if cell-based therapy is to be considered 
seriously for these infants, better tools will be needed to estimate long-term 
neurodevelopmental outcome in the perinatal period in order to optimise patient 
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selection, together with a better understanding of the pathogenesis of the 
condition. Neither of these obstacles is close to solution at present. 
1.6.8.3. Hypoxic ischaemic encephalopathy (HIE) 
Hypoxic ischaemic encephalopathy (or newborn encephalopathy) is another 
important cause of newborn brain injury. After such an insult there is immediate 
necrotic brain cell death, followed by delayed cell death by apoptosis (Edwards 
et al, 1997; Mehmet et al, 1998; Taylor et al, 1999). Indeed, there are currently 
a variety of neuroprotective strategies being evaluated in animal models 
attempting to reduce the apoptotic cell death and therefore improve 
neurodevelopmental outcome. There have been encouraging results using 
selective head cooling following HIE as a neuroprotective treatment (Gluckman 
et al, 2005) and following a successful pilot study (Azzopardi et al, 2000), there 
are large-scale human clinical trials are underway of whole body hypothermia. 
Anti-apoptotic therapies may help minimise later cell death, but will not impact 
on immediate necrotic cell death and so cell replacement may need to be 
considered in the future. In HIE the pattern of brain injury depends on the type 
and severity of insult, but in severe cases involves both grey and white matter 
(Figure 1.09. ). 
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Figure 1.09. Severe hypoxic ischaemic encephalopathy. Severe hypoxic 
ischaemic encephalopathy in newborn infants leads to grey and white matter 
loss with subsequent neurodisability. T1 transverse MR images of two infants 
with severe brain injury following hypoxic ischaemic encephalopathy. (a) A 
transverse image acquired in an infant at 18 days age demonstrating large 
areas of low signal intensity in the white matter (arrows), which later atrophy. (b) 
An image at the level of the basal ganglia of an infant at 20 days age showing 
loss of grey and white matter with cystic change in the basal ganglia (arrow). 
NSC transplantation in animal models of ischaemic brain injury are encouraging 
in that NSC survive, migrate into the infarct areas and differentiate into what 
seems appropriate neuronal and glial sub-types. However, there are 
considerable problems extending successful animal studies to humans. Animal 
models use a clearly-defined injury often with carotid artery ligation with 
hypoxia. By contrast, in the clinical arena HIE is the endpoint of a variety of 
pathways, and usually not an isolated and clearly-defined acute insult. This 
makes evaluation and study difficult. Indeed, even with advanced imaging 
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methods, it remains a challenge to give an early estimate of long-term 
prognosis in moderately-affected infants, and thus difficult to define a population 
for study to be confident of outcome differences. 
1.7. Factors affecting transplant success in cell 
based therapies 
A number of factors can influence the success of cell based therapies. 
Environmental factors, the tissue source of stem cells, their developmental 
stage, stem cell death (by apoptosis) and the receptiveness of the host 
environment will all contribute to the ultimate survival of grafted cells. For 
example, it appears that neural precursors cultured from different areas of the 
brain have distinct neural potentials. In a recent study, Svendsen and co- 
workers found that cells isolated from the developing rat brain, propagated as 
neurospheres, displayed different growth properties and give rise to cells with 
distinct phenotypes depending on their site of origin (Ostenfeld et al, 2002a). 
The stage of differentiation of the transplanted cells may also be a factor. For 
demyelinating diseases, the use of multipotent neural precursors rather than 
more restricted oligodendrocyte precursors seems be more useful (Zhang et al, 
1999; Yandava et al, 1999; Smith & Blakemore, 2000). While cells committed to 
a defined lineage may generate a larger proportion of a given cell type after 
injection, they have reduced proliferative potential and certainly less plasticity in 
environments where several cell types are lost. The developmental age of the 
cells for transplantation may also be a significant factor in determining the 
successful outcome. In conclusion, there are a variety of factors influencing the 
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success of stem cell grafts. Research is only beginning to understand such 
factors and there is a clear need for further study in this area. 
1.7.1. Cell Environment 
Cell-cell interactions may also be important in determining the correct terminal 
differentiation of NSC. While the culture of either embryonic striatal precursors 
or adult subependymal cells in the presence of FGF yielded only small numbers 
of neurons producing TH, the inclusion of soluble factors (conditioned medium) 
from glial cell cultures increased the yield of TH-positive neurons by more than 
17-fold. Embryonic striatal precursors were significantly more responsive to the 
differentiation environment, further indicating that stem cells from earlier 
developmental sources may be provide more successful transplants (Daadi & 
Weiss, 1999). The importance of the host environment has been demonstrated 
by transplantation into the cerebral ventricles of embryonic hosts in utero. Not 
only do the donor cells differentiate into neurons, but they also acquire the 
phenotype of the surrounding cells. McKay and co-workers found that cells 
incorporated into the host hippocampus assumed morphologies resembling 
granule and pyramidal neurons, while those that integrated into the inferior 
colliculus resembled tectal neurons that reside in this region (Brustle, 1999). 
Although there are encouraging data suggesting that multipotent cells can 
respond appropriately to developmental cues from the brain, little is known 
about the extrinsic signals and molecular events that direct this process. 
The precise site of injection can also influence the fate of transplanted stem 
cells. By marking transplanted cells with GFP, human NSC have been shown to 
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differentiate into post mitotic neurons throughout the brain, while differentiation 
into glial cell types occurred predominantly at the sight of injection (Englund et 
al, 2002). Such outcomes may be overridden by employing genetically-modified 
donor cells that offer the advantage of combining cell replacement with gene 
therapy (Ourednik et al, 1999). For instance, transplants into a refractory 
environment (e. g. where activated microglia are present) would have an 
increased chance of success if the cells transferred contained a gene to 
counteract this hostile environment. For example, it has been suggested that 
ectopic expression of the neural cell adhesion molecule, L1, in astrocytes can 
increase the speed and efficiency of innervation of branching axons, thus 
improving the transplant success of grafted NSC (Ourednik et al, 2001). 
Stem cell therapy has been successfully employed for CNS lesions where there 
is significant cell loss, for example to repair focal infarctions resulting from 
stroke. However, even small numbers of neurons undergoing apoptosis can be 
replaced by human fetal neural precursors. It therefore seems that the brain can 
detect and respond to small changes in cell number or subtle perturbations in 
normal function by providing the appropriate cues for available stem cells to 
differentiate and repair the damage (Snyder et al, 1997). At the other extreme, 
what would be the outcome of grafts in a situation where cell loss was so 
extensive that tissue structure was significantly disrupted? In an important new 
development, transplantation of a polymer scaffold seeded with NSC may offer 
a significant improvement in motor function in a severe traumatic spinal cord 
injury model in rats (Teng et al, 2002). 
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1.7.2. Survival of grafts - death by apoptosis 
Areas of adult neurogenesis have been shown to contain high numbers of 
apoptotic cells (Biebl et al, 2000). During normal adult neurogenesis 
programmed cell death plays an important regulatory function by eliminating 
excess cells from neurogenic regions similar to that observed in the embryo (de 
la Rosa & de Pablo, 2000). Apoptosis of transplanted NSC may also be a major 
factor in determining the successful outcome of cell therapy. Inhibition of 
caspases can significantly increase the survival of nigral transplants in a model 
of PD (Schierle et al, 1999a). Survival of dopaminergic grafts into the striatum of 
Parkinsonian rats is also significantly increased if the transplants are spiked 
with a small population of fibroblasts expressing FGF. This growth factor acts 
both as a survival signal and enhances neuronal differentiation (Takayama et 
a/, 1995). Similarly stem cell factor (SCF) is important in the survival of defined 
stem cell populations although it is not clear whether this is true for NSC 
(Morrison et al, 1997). In the generation of dopaminergic neurons derived from 
cultures of pluripotent mouse ES cells, increased numbers of TH+ and 
dopamine-producing neurons were obtained in the presence of neurotrophins in 
combination with defined survival promoting factors, including IL-1P and GDNF 
(Rolletschek et al, 2001). Apoptosis of grafts used in neural cell therapies is 
discussed in more detail in the following section. 
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1.8. Apoptosis 
The term apoptosis, coined by Currie et al in 1972 (Kerr et al, 1972) refers to a 
controlled energy-dependent mechanism of cell death. It is the major form of 
programmed cell death by which metazoan organisms remove unwanted cells. 
It plays an essential role in development, tissue homeostasis and in a wide 
variety of diseases. The morphological hallmarks of this process are distinct 
from those observed in necrotic death (Figure 1.10. ). 
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Figure 1.10. Morphological features of apoptosis and necrosis. A normal 
cell (top) undergoing necrosis swells; the organelles become disrupted (A). It 
eventually bursts, releasing the cytosolic content into the extracellular space 
(B). During apoptosis the cell shrinks, the membrane blebs and the chromatin 
condenses; mitochondria and other organelles are intact (C). Apoptotic bodies 
that are small membrane-bound vesicles containing fragments of DNA and 
organelles bud off (D) and are phagocytosed by neighbouring cells (E) without 
causing inflammation. If an apoptotic cell becomes ATP-depleted or the 
mitochondria are damaged, secondary apoptosis may ensue. (adapted from 
http: //www. imm. ki. se/sft/text/enews4. htm) 
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1.8.1. Morphological features of apoptosis 
Apoptotic death follows the activation of an intrinsic cell suicide programme and 
is an active, ATP-dependent process. Its morphological hallmarks include cell 
shrinkage, nuclear compaction, membrane blebbing, chromatin condensation 
and DNA fragmentation, as well as formation of apoptotic bodies (Saraste & 
Pulkki, 2000). The integrity of the membrane and cytosolic organelles is 
maintained until late in this process. Nuclear chromatin undergoes marked 
condensation and margination, and the DNA is degraded in a regimented, 
characteristic fashion into 180-200 base pair fragments. Plasma membrane 
extensions bud off to form apoptotic bodies, usually containing condensed 
chromatin and organelles, which are rapidly engulfed and digested by 
neighbouring cells (Saraste & Pulkki, 2000; Fadok et al, 2000) without 
inflammation. This is in marked contrast to necrotic cells which swell and 
rupture leading to the release of intracellular contents eliciting a local 
inflammatory response. 
1.8.2. Molecular Basis of Apoptosis 
The basis and mechanism of apoptosis was first studied in the nematode worm 
Caenorhabditis elegans (C. elegans). This organism has a rigid fixed 
programme of cell division and differentiation that has been extensively studied. 
During its development to an adult hermaphrodite worm, 131 of 1090 somatic 
cells die by apoptosis. In a series of elegant experiments that started during the 
1970s Horvitz, continuing Brenner's and Sulston's work on the genetics and cell 
lineage of C. elegans (Brenner, 1974; Sulston & Brenner, 1974), investigated 
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whether there was a genetic program controlling cell death. In 1986, he 
identified the first two bona fide "death genes", ced ("cell death abnormal")-3 
and ced-4 (Ellis & Horvitz, 1986). Ellis and Horvitz showed that functional ced-3 
and ced-4 genes were a prerequisite for cell death to be executed while a third 
gene, ced-9, protected against cell death by interaction with ced-4 (Hengartner 
et al, 1992). Later, another gene egl-1 ("egg laying defective") (Conradt & 
Horvitz, 1998) was also shown to be involved. Loss of function mutants of egl-1, 
ced-3 or ced-4 result in survival of the 131 cells and in contrast, animals lacking 
functional ced-9 die early because of extensive apoptotic cell death. Gain of 
function experiments with ced-9 lead to survival of all 131 cells confirming ced-9 
as a suppressor of cell death. The apoptotic system in C. elegans is shown in 
Figure 1.11. 
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Figure 1.11. The apoptotic system in C. elegans. Apoptotic signalling in C. 
elegans is regulated by several genes with egl-1, ced-3 and ced-4 involved in 
promoting cell death whereas ced-9 blocks death (A). Vertebrate apoptosis is 
regulated by the Bcl-2 family of proteins, with the adapter molecule Apaf-1 and 
the caspases effecting death. Bcl-2, Apaf-1 and caspase 9 have homology 
(structural and functional) with c. elegans ced-9, ced-4 and ced-3 respectively 
(B). 
The death machinery is highly conserved through evolution and can be found in 
humans down to worms, insects and even the simple metazoan, hydra (Cikala 
et al, 1999). Structural and functional homologues of ced-3 comprise a family of 
cysteine aspartate proteases known as caspases. One of the apoptosis 
protease-activating factors (Apaf-1) is homologous to ced-4, while ced-9 
corresponds to the Bcl-2 protein family, which may be either pro- or anti- 
apoptotic. 
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1.8.2.1. Caspases 
Many of the morphological changes seen in apoptosis are driven by a series of 
proteases activated specifically in cells undergoing apoptosis. These proteases 
have an active-site cysteine, and cleave substrates after aspartate residues 
thus their name caspases. Caspases are present in the cell as inactive 
zymogens consisting of three domains: an N-terminal prodomain, a large 
subunit (p20) containing the active site, a C-terminal small subunit (p10) and an 
inter-domain containing one or two aspartate residues (Figure 1.12. ). 
Caspases are activated by cleavage between the p20 and p10 domain and at 
the aspartic acid residue between the prodomain and p20. The active enzyme 
is a heterotetramer derived from two procaspase molecules containing the p20 
and p10 subunits and 2 active sites (Thornberry & Lazebnik, 1998; Cohen, 
1997). 
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Figure 1.12. Caspase activation requires the cleavage of inactive 
zymogens. Caspase molecules are synthesised as inactive zymogens which 
require proteolytic cleavage for activation. The zymogens have an N-terminal 
prodomain, p20 and p10 domains. Following cleavage, the mature enzyme is a 
heterotetramer containing two p20/p1 O heterodimers and two active sites. 
1.8.2.2. Caspase Activation 
Caspases are involved in various stages of the apoptotic process. Some act as 
initiators in response to an apoptotic stimulus, while others function downstream 
operating as effector caspases. Initiator caspases, such as caspase 8 and 
caspase 9, are recruited and become activated by linker molecules between the 
caspase and the death receptor, in the case of caspase 8, or by cofactors such 
as Apaf-1 in the case of caspase 9. They integrate the apoptotic signals they 
receive and pass them on to a "common execution phase" by activating a large 
number of downstream effector caspases (e. g. caspases 3,6, and 7) thereby 
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amplifying the initial apoptotic signal (Denault & Salvesen, 2002). Furthermore, 
they act as a point of control before committing the cell to death (Denault & 
Salvesen, 2002). 
Activated downstream caspases cleave a number of target proteins necessary 
for the ordered dismantling of the cell. One example of a substrate is the 
nuclease, caspase activated DNase (CAD) responsible for the ordered cutting 
of genomic DNA between nucleosomes. CAD exists in an inactive complex with 
an inhibitory subunit, ICAD. Activation occurs by cleavage of the inactive 
subunit by caspase 3 (Liu et al, 1997; Sakahira et al, 1998; Enari et al, 1998). 
Caspase-mediated cleavage of other cell substrates explains the morphological 
changes seen in apoptosis. For example, caspase cleavage of nuclear lamins is 
required for typical nuclear morphology (Buendia et al, 1999), with loss of cell 
shape and cytoplasmic retraction being mediated by caspase degradation of 
cytoskeletal proteins (Kothakota et al, 1997). 
1.8.3. Two pathways to apoptosis 
There exist two distinct molecular pathways that lead to apoptosis: the 
mitochondrial pathway and the death receptor pathway (Figure 1.13. ). Both 
these pathways result in the initiation of caspase activation leading to cleavage 
and activation of caspase 3, a major effector caspase of apoptosis (Hengartner, 
2000). 
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Figure 1.13. The two major pathways to apoptosis. Apoptosis can be 
triggered by extrinsic activation of death receptors or by the intrinsic pathway 
through mitochondria (in this figure represented by DNA damage). Adapted 
from Hengartner (Hengartner, 2000). 
1.8.3.1. The mitochondrial pathway (intrinsic pathway) 
Mitochondria are essential organelles in the production of energy for cell 
function. Paradoxically mitochondria also play a active role in controlling the 
pathways that lead to cell death. The mitochondrial pathway leads to apoptosis 
following intrinsic cell death stimuli such as DNA damage, heat shock, hypoxia, 
trophic factor withdrawal and cytotoxic drugs (van Loo et al, 2002). The steps of 
this pathway, described below, include cytochrome c release, formation of the 
apoptosome and cleavage and activation of caspases 9 and 3. 
Neural Differentiation of Fetal Mesenchymal Stem Cells Chapter 1 
107 
1.8.3.1.1. Cytochrome c release 
Upon the reception of an intrinsic death stimulus, the mitochondrion releases 
cytochrome c, with other proteins, into the cytosol (Goldstein et al, 2000). The 
translocation of cytochrome c is believed to be the result of the opening of the 
permeability transition pore (PTP) which leads to the disruption of the 
mitochondrial trans-membrane potential (Arm). The mitochondrial matrix swells 
and the outer mitochondrial membrane ruptures releasing cytochrome c with 
other proteins including apoptosis-inducing factor (AlF) and Smac/DIABLO from 
the inter-membrane space into the cytosol (Goldstein et al, 2000; Hengartner, 
2000; van Loo et al, 2002). 
1.8.3.1.2. The apoptosome 
Cytochrome c, once in the cytoplasm, associates to form a complex with Apaf- 
1, dATP, and pro-caspase 9 (Zou et al, 1999). Initially, cytochrome c binds to 
Apaf-1 increasing its affinity for dATP. Apaf-1 contains a caspase recruitment 
domain (CARD) through which procaspase 9 molecules are recruited to the 
complex (Wang, 2001). The importance of Apaf-1 has been illustrated by the 
generation of Apaf-1 knockout mouse embryos by two separate groups, both of 
which observed craniofacial defects, an excessive number of neuronal cells in 
the brain, as well as a marked delay in the elimination of interdigital webs, due 
to a defect in apoptosis (Cecconi et al, 1998; Yoshida et al, 1998). Furthermore 
Apaf-1 null ES cells and thymocytes were protected against mitochondrial 
pathway-induced apoptosis (Yoshida et al, 1998). 
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Within this complex, referred to as the "apoptosome", pro-caspase 9 is 
processed (Zou et al, 1999). Once in its active form, caspase 9 is released 
ready to cleave its substrates including pro-caspase 3, a downstream effector 
caspase, as well as other pro-caspase 9 molecules that are recruited and 
processed in a new complex (Zou et al, 1999). It appears that cleaved caspase 
9 is critical for cytochrome c-induced activation of the caspase cascade. In the 
event of depletion of caspase 9, all other caspases fail to respond to 
cytochrome c release (Slee et al, 1999). 
1.8.3.1.3. Other mitochondrial apoptotic signals 
In addition to cytochrome c, other pro-apoptotic proteins are released from the 
mitochondria upon the presence of an apoptotic stimulus including 
Smac/DIABLO (Du et al, 2000), AIF (apoptosis inducing factor') and 
endonuclease G (Wang, 2001). Smac/DIABLO, a 25 kD protein, is also 
released by the mitochondria together with cytochrome c into the cytosol and 
functions as an inducer of apoptosis, by inhibiting IAPs ('inhibitors of apoptosis' 
- XIAP, c-IAP-1, c-IAP-2) (Du et al, 2000) proteins known to bind and prevent 
the activation of pro-caspase 9 or to bind directly and inhibit already active 
caspases (Deveraux et al, 1998). Through the release of Smac /DIABLO the 
cell ensures that even in the presence of high levels of IAPs apoptosis can 
proceed (Wang, 2001). AI F is a 57 kD flavoprotein that is localised in the 
mitochondrial inter-membrane region in healthy cells. Upon induction of 
apoptosis, AIF is released by mitochondria and translocates to the nucleus 
whereby it triggers chromatin compaction and DNA fragmentation (Susin et al, 
1999), although the precise mechanisms remain unclear. It is possible that AIF 
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acts indirectly by cooperating with DNases, as it has not been shown to have 
such an activity itself (Susin et al, 1999). Endonuclease G, a 30 kD nuclease, is 
also released by mitochondria upon induction of apoptosis. Although its function 
within the mitochondria of healthy cells remains controversial, it has been 
established that following its release from the mitochondria of apoptotic cells it 
may cause nuclear DNA fragmentation (Wang, 2001). Both AI F and 
endonuclease G function independently of caspase cleavage suggesting that 
apoptosis can be carried out via the mitochondrion in the absence of caspase 
activation. 
1.8.3.2. Death receptor pathway (extrinsic pathway) 
The death receptor pathway involves the activation of death receptors on the 
plasma membrane by specific death ligands and the subsequent activation of 
downstream caspases. The most well studied death receptors include the 
tumour necrosis factor a (TNFa) and Fas (also known as CD95) receptors. In 
the case of Fas, the receptor is activated by the binding of the Fas ligand (FasL) 
causing its trimerisation (Krammer, 1999). Upon ligand binding, Fas (CD95) 
death receptors aggregate and form membrane-bound death inducing signalling 
complexes (DISCs). The resulting clusters of Fas receptors employ intracellular 
death effector domains, through the Fas-associated death domain (FADD), to 
recruit and couple the receptors to procaspase-8 molecules. These are 
activated through mutual cleavage as mentioned above and result in the 
execution of apoptosis either by triggering the activation of effector caspases, or 
by cleaving and activating the mitochondrial pathway through Bid, a member of 
the pro-apoptotic BcI-2 Proteins (Hengartner, 2000; Leist & Jaattela, 2001). 
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Truncated Bid (t-Bid) translocates from the cytosol to the mitochondria inducing 
a mitochondrial response via the release of cytochrome c (Wang, 2001). 
1.8.4. Regulation of apoptosis by the Bcl-2 family 
The Bcl-2 family of proteins control mitochondrial events and key regulators of 
apoptosis (Kluck et al, 1997; Adams & Cory, 2001). They are a large 
homologous gene family encoding proteins which can inhibit (Bcl-2, Bcl-xL) or 
promote (Bax, Bak, Bad) apoptosis. Pro- and anti-apoptotic members form 
heterodimers which are thought to mutually neutralise the bound proteins. 
Thus, the relative balance of different proteins may be responsible for 
sensitising or protecting cells from apoptotic stimuli. The actual mechanism by 
which the Bcl-2 family members control apoptosis is thought to be by regulating 
the release of pro-apoptotic factors, especially cytochrome c, from the 
mitochondria into the cytosol. Indeed, BcI-2, a human oncogene over- 
expressed in follicular lymphoma, is an integral membrane protein, primarily 
localised in the outer mitochondrial membrane. Various hypotheses speculate 
that they may facilitate protein transport across the mitochondrial membrane by 
forming pores, although it is not clear if they would be big enough. Another 
possibility may be that they interact with other molecules to form these pores. 
Alternatively, Bcl-2 proteins may, directly or indirectly, alter mitochondrial 
homeostasis to result in rupture and release of pro-apoptotic molecules from 
the inter-membrane space. BcI-2 proteins may hold they key to understanding 
the critical regulatory mechanisms of apoptosis. They might be of use in 
treating diseases caused by dysregulation of apoptosis as well as ensuring graft 
survival in tissue and organs transplants. 
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1.8.5. Apoptosis in the nervous system 
1.8.5.1. Apoptosis during brain development 
It is now clear that physiological cell death is a central part of normal 
development (Jacobson et al, 1997). There is an over-production of cells 
followed by apoptosis to control cell populations to establish and remodel tissue 
architecture to enable specific function. The importance of apoptosis in brain 
development is highlighted by mice deficient in their apoptotic machinery (Apaf- 
1, caspase 9 or caspase 3 deficient) that have a lethal phenotype with 
pathology largely affecting the brain (Kuan et al, 2000). During brain 
development, at least half of the cells die by apoptosis. This process is thought 
to: 1. optimise synaptic connections; 2. removal of unnecessary neurons and 3. 
contribute to pattern formation. Like all cells, neural cells require trophic 
support. It seems that neurons are initially overproduced and compete for a 
limited amount of target-derived trophic factors, such as nerve growth factor 
(NGF), in order to survive. Only neurons successful in making appropriate 
connections would obtain the trophic support needed for survival. Initially, the 
cell death was believed to be passive and due to `starvation', but this idea was 
radically changed after it was demonstrated that inhibition of RNA and protein 
synthesis blocked the cell death of cultured neurons driven by NGF deprivation 
(Martin et al, 1988). This suggested neurotrophic factors maintain neuronal 
survival by suppressing an endogenous, active death program. The discovery 
of death gene ced-3, -4 and -9 in C. elegans and their vertebrate homologues 
(Metzstein et al, 1998) (reviewed by Meier et al (Meier et al, 2000)) allowed 
study of neuronal programmed cell death at a molecular level and there was 
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soon evidence that trophic factor withdrawal initiated a cellular suicide 
programme which involved the activation of caspases (Gagliardini et al, 1994). 
As discussed previously, mammalian apoptosis is regulated by the Bcl-2 family 
of proteins, with the adapter molecule Apaf-1 and the caspases important in 
transducing the signal. These molecules have homology with C. elegans ced-9, 
ced-4 and ced-3 respectively. 
1.8.5.2. The Bcl-2 family regulates neuronal apoptosis 
The BcI family of proteins have a crucial role in modulating apoptotic signal 
transduction in the brain (Merry & Korsmeyer, 1997). The gene family contains 
both pro- and anti-apoptotic members that are grouped by the presence of one 
or more Bcl-homology (BH) domains. The pro-apoptotic members include Bid, 
Bax, Bad and Bak. The two major anti-apoptotic members are BcI-2 and BCI-XL. 
The importance of the Bcl-2 family in modulating neural cell death is 
demonstrated by over expression, and knockout studies. The over expression 
of Bcl-2 prevents apoptosis of sympathetic neurons following NGF withdrawal 
(Garcia et al, 1992) and transgenic mice over-expressing BcI-2 in the nervous 
system are protected from neuronal cell death both during development and 
following experimental injury (Martinou et al, 1994; Dubois-Dauphin et al, 1994). 
In contrast BcI-2 knockout mice, after having relatively normal in utero brain 
development, have progressive death of sensory, motor and autonomic 
neurons after birth indicating BcI-2 is necessary for the maintenance of 
neuronal survival (Michaelidis et al, 1996). Bcl-XL knockout mice are embryonic 
lethal with massive CNS apoptosis; this cell death was high in post-mitotic 
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immature neurons (Motoyama et al, 1995) suggesting a role for BcI-XL in the 
survival of immature neurons compared with Bcl-2 that has a greater role later 
in development. The exact mechanism of the pro- and anti-apoptotic effects of 
Bcl-2 family is still not fully understood although Bcl-2 and BCI-XL function in part 
by neutralising pro-apoptotic members through heterodimerisation (Merry & 
Korsmeyer, 1997; Oltvai et al, 1993). 
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Figure 1.14. Bcl-2 family members - the balance of life and death. A major 
checkpoint in the common portion of this pathway is the ratio of pro-apoptotic 
(BAX) to anti-apoptotic (Bcl-2) members. Downstream of this checkpoint are 
execution programs mediated by mitochondria and the caspase pathways. 
Mitochondrial dysfunction results in cytochrome c release from the inter- 
membrane space protein which in turn (with Apaf-1) activates a downstream 
caspase program. Activated caspases can also affect the function of 
mitochondria. Caspases could be activated through Apaf-1/cytochrome c or 
directly by activation of cell surface death receptors. The activated caspase, 
composed of two large and two small subunits, cleaves death substrates which 
ultimately lead to cell death. Adapted from Gross et al. (Gross et al, 1999). 
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Indeed, the balance between the pro- and anti-apoptotic members determines, 
in part, the susceptibility of cells to a death signal (Oltvai et al, 1993) (Figure 
1.14. ). Pro-apoptotic members of the BcI-2 family of proteins are involved in 
sensing cell damage or stress stimuli (Gross et al, 1999) and triggering the 
release of cytochrome c with other apoptotic proteins such as Smac/DIABLO 
from mitochondria. In particular, sub-micromolar amounts of Bax have been 
shown to directly induce cytochrome c release from isolated mitochondria 
(Jurgensmeier et al, 1998). In these studies, neither mitochondria nor Bax 
individually induced proteolytic processing and activation of caspases, but in 
combination they triggered release of cytochrome c from mitochondria and 
induced caspase activation in isolated cytosols (Jurgensmeier et al, 1998; 
Desagher et al, 1999). Bax is widely expressed in the nervous system and is 
necessary for neuronal death in development, and by trophic factor deprivation 
(Deckwerth et al, 1996). Bax-deficient mice possess increased numbers of 
neurons superior cervical ganglia and facial nuclei and neonatal sympathetic 
neurons and facial motor neurons from Bax-deficient mice survive nerve growth 
factor deprivation and disconnection from their targets by axotomy (Deckwerth 
et al, 1996). 
However, the exact mechanism by which this is achieved is still unclear. It has 
been suggested that the pro-apoptotic members participate in the formation of 
pores in the mitochondrial membrane to create larger channels that will allow 
the efflux of larger molecules from the mitochondria into the cytosol. In contrast 
to the pro-apoptotic Bcl-2 family proteins appear to function by stabilising 
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cytochrome c within the mitochondria until the cell receives a death signal. 
However the exact mechanism by which this is achieved also remains unclear. 
1.8.5.3. Apaf-1 and caspases in neuronal cell death 
Apaf-1, the mammalian homologue of c. elegans CED-4 (Figure 1.11. ) 
complexes with cytochrome c and caspase-9 in order to activate caspase-9 
which in turn activates caspase-3. Apaf-1-null mice die in embryonic 
development and have decreased neural cell apoptosis and very marked 
enlargement of the periventricular zone (Cecconi et al, 1998) indicating it's role 
in apoptosis of neural progenitor cells. A similar phenotype is seen in capase-9 
and caspase-3 null mice with marked enlargement of the periventricular zone, 
with ectopic cells also evident in the cortex, hippocampus and striatum (Kuida 
et al, 1996; Kuida et a/, 1998). The prominent defect in neural apoptosis in 
Apaf-1, caspase-9 and caspase-3 deficient mice suggest this pathway is central 
to regulating neural cell number in the developing brain. In addition, the ability 
of caspase inhibition to attenuate cell death following trophic factor withdrawal 
or injury further highlights their crucial role, and is a possible mode of 
therapeutic neural cell rescue following injury. 
1.8.6. Survival signalling 
In the same way that different factors instruct a cell to die, there also exist 
signalling pathways that promote cell survival. It is thought that the major 
regulators of survival pathways are trophic factors and that their absence leads 
to the inactivation of the survival signalling cascade. 
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1.8.6.1. Trophic factor withdrawal 
There exists the view that apoptosis is a process that is programmed to occur 
by default and that only upon the presence of appropriate signalling molecules 
is the cell instructed to survive (Raff, 1992). These so-called trophic or survival 
factors are supplied by adjacent cells. Although an extreme view at the time, 
evidence from a number of studies now supports the idea that only upon the 
continuous presence of such factors can cells survive. For example, isolated 
oligodendrocytes and oligodendrocyte precursors cultured in the absence of 
other cell types or in survival factor-free media die by programmed cell death. 
Addition of growth factors and cytokines or other survival factor molecules may 
rescue these cells from apoptosis (Raff et al, 1993). These survival signals 
seem to act by suppressing an intrinsic cell suicide program, the protein 
components of which are expressed constitutively in most cell types- this 
suggests cell death may be the default pathway. Studies in cell types other than 
neural cells such as haemopoietic progenitors, T-lymphocytes and endothelial 
cells, confirm their dependence on trophic factors as well (Raff, 1992; Raff et al, 
1993). Furthermore, supporting evidence comes from a study where culture 
medium obtained from cells cultured at high density improved the survival of 
low density cell cultures presumably due an increase in secreted trophic factors 
in the higher density cultures (Raff et al, 1993). Since the establishment of the 
central role of survival factors in cell survival, a number of such molecules have 
been identified, including PDGF and insulin-like growth factor (IGF). But how do 
these factors signal to cells to stimulate them to survive and which intrinsic 
signalling pathway is activated to carry out the effects of these molecules? 
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1.8.6.2. Survival signalling: the P13K/Akt pathway 
In recent years it has been determined that one of the major cell survival 
signalling pathways utilised by growth factors is the PI3K/Akt pathway (Kennedy 
et al, 1997). Akt, also known as protein kinase B (PKB) is a multimeric 60kDa 
serine-threonine protein kinase composed of a pleckstrin-homology (PH) 
domain in its N-terminal (amino acids 1-147), a kinase domain spanning 
residues 148-411 and a tail region (amino acids 412-480) in the C-terminus of 
the protein (Marte & Downward, 1997). Akt is activated upon growth factor 
stimuli by the lipid kinase phosphatidylinositol 3-kinase (P13K) and mediates the 
response of these trophic factors by targeting, through phosphorylation, of its 
downstream substrates. Upon binding of the ligand to the growth factor 
receptor, the receptor auto-phosphorylates tyrosine residues thereby activating 
the p110 catalytic subunit of P13K through its interaction with the receptor- 
bound p85 subunit (Marte & Downward, 1997; Coffer et al, 1998). The 
activation of P13K results in the generation of P13-kinase phosphatidylinositol 
(3,4,5)-triphosphate (Ptdlns (3,4,5)P3) and P13-kinase phosphatidylinositol 
(3,4)-biphosphate (Ptdlns(3,4)P2) which become phosphorylated at the 3' 
position of their inositol ring. These two molecules bind the PH domain of Akt 
and recruit it close to the membrane together with the two Ptdlns(3,4,5)P3- 
dependent kinases (PDK1 and PDK2). In addition, Ptdlns(3,4)P2 induces the 
kinase activity of Akt, which becomes fully activated only upon phosphorylation 
of its Thr308 and Ser473 residues by PDK1 and PDK2 respectively (Marte & 
Downward, 1997; Coffer et al, 1998). 
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1.8.6.2.1. Akt substrates 
The characterisation of the consensus peptide sequence RXRXXS preferred by 
Akt for phosphorylation of its target molecules has aided in the identification of 
many of its substrates (Brunet et al, 2001). Numerous studies have identified 
different substrates for Akt phosphorylation in the control of cell survival. Among 
those are the pro-apoptotic members of the Bcl-2 family of proteins, Bad and 
Bax, 14-3-3, caspase 9, and FKHRLI, a member of the family of Forkhead 
transcription factors (Datta et al, 1997; Cardone et al, 1998; Brunet et al, 1999; 
Powell et al, 2002). FKHRL1 in particular is discussed in more detail below 
(Figure 1.15. ). 
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Figure 1.15. Survival signalling through the P13K/Akt Pathway. P13K 
becomes activated via its p85 subunit following the phosphorylation of a trophic 
factor receptor upon binding of its ligand. Activation of P13K brings about the 
phosphorylation of Akt. Active Akt has been demonstrated to phosphorylate and 
suppress Bad, a pro-apoptotic member of the Bcl-2 family of proteins. In 
addition Akt inhibits the release of cytochrome c from mitochondria, possibly 
through the indirect inhibition of Bax. Phosphorylation and inactivation of 
caspase 9 has also been demonstrated by Akt. At the transcriptional level Akt 
has been shown to phosphorylate a Forkhead transcription factor, which in its 
dephosphorylated form transcribes cell death genes, such as FasL. Adapted 
from: Kennedy et al., 1999 (Kennedy et al, 1999) and Marte and Downward, 
1997 (Marte & Downward, 1997). 
1.8.6.2.2. Forkhead-like 1 (FKHRLI) 
The induction of cell death upon trophic factor deprivation very often involves 
the transcription of new cell death genes that will execute the process of 
apoptosis suggesting that the control of cell survival is very often a 
transcription-dependent event. This is best illustrated by the findings of Brunet 
et al. (1999) who demonstrate that Akt is also capable of phosphorylating 
Neural Differentiation of Fetal Mesenchymal Stem Cells Chapter 1 
Thr308 
Kinase 
120 
transcription factors such as FKHRLI (Brunet et al, 1999). The observation that 
following treatment of cells with survival factors, Akt translocates to the nucleus, 
together with the fact that DAF16, a C. elegans member of the Forkhead family, 
contains three consensus Akt sites, prompted Brunet et al. (1999) to look at the 
effect of Akt on the phosphorylation status of another member of the human 
Forkhead family of transcription factors (i. e. FKHRL1). In the presence of 
survival factors, such as IGF-1, FKHRL1 is phosphorylated by Akt at Thr32 and 
Ser253, while the addition of a P13K inhibitor (LY294002) abolishes FKHRL1 
phosphorylation. Immunocytochemical studies indicated the retention of 
FKHRL1 in the cytoplasm upon the addition of survival factors in contrast to the 
situation in which cells have been serum deprived or treated with a P13K 
inhibitor, where FKHRL1 translocates to the nucleus. Moreover, co-expression 
of constitutively active Akt in serum starved cells results in the translocation of 
FKHRL1 from the nucleus to the cytoplasm. Taken together, these findings 
suggest that phosphorylation of FKHRL1 by Akt, results in retention in the 
cytoplasm and hence FKHRL1-dependent transcription is reduced (Brunet et al, 
1999). Immunoprecipitation experiments showed that FKHRLI binds to the 
chaperone protein 14-3-3, while a Thr32 mutant of FKHRLI was unable to 
associate with 14-3-3. Given that 14-3-3 is itself a direct substrate of Akt 
(Powell et al, 2002), it is probable that in survival factor-stimulated cells, Akt 
promotes the interaction of FKHRLI with 14-3-3, by phosphorylating both the 
transcription factor and its chaperone protein. Since Akt phosphorylation 
promotes cell survival, it is likely that the target genes of FKHRL1 are genes 
promoting apoptosis. Indeed, Brunet and co-workers searched for gene 
promoter sequences that contain the consensus binding site sequence for 
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Forkhead and identified the promoter of the FasL gene as a target of FKHRL1. 
It was further demonstrated that FKHRLI acts as a transcriptional activator in 
the absence of trophic factors (IGF-1). Finally, a mutant form of FKHRL1 (which 
cannot be phosphorylated) induced apoptosis even in cells treated with IGF-1. 
This suggests that FKHRL1, in its dephosphorylated form, induces apoptosis by 
promoting the transcriptional activation of cell death genes. When 
phosphorylated by Akt, in the presence of growth factors, FKHRL1 is retained in 
the cytoplasm and prevented from transcribing apoptosis-inducing genes. The 
observation that FasL is upregulated in serum deprived cells (Brunet et al, 
1999; Le Niculescu et al, 1999), further indicates a link between PI3K/Akt 
inactivation, FKHRL1 dephosphorylation and cell death. 
1.8.7. Apoptosis limits neural cell replacement 
Areas of adult neurogenesis have been shown to contain high numbers of 
apoptotic cells (Biebl et al, 2000). During normal adult neurogenesis 
programmed cell death plays an important regulatory function by eliminating 
excess cells from neurogenic regions similar to that observed in the embryo (de 
la Rosa & de Pablo, 2000). Apoptosis of transplanted cells in the nervous 
system may also be a major factor in determining the successful outcome of 
cell therapy. Inhibition of caspases can significantly increase the survival of 
nigral transplants in a model of PD (Schierle et al, 1999a). Survival of 
dopaminergic grafts into the striatum of Parkinsonian rats is also significantly 
increased if the transplants are spiked with a small population of fibroblasts 
expressing FGF. Presumably this growth factor acts both as a survival signal 
and enhances neuronal differentiation (Takayama et al, 1995). Stem cell factor 
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(SCF) is important in the survival of defined stem cell populations although it is 
not clear whether this is true for NSC (Morrison et al, 1997). In the generation of 
dopaminergic neurons derived from cultures of mouse ES cells, increased 
numbers of tyrosine hydroxylase (TH, the first and rate-limiting enzyme in 
dopamine synthesis) and dopamine-producing neurons were obtained in the 
presence of neurotrophins in combination with defined survival promoting 
factors, including IL-1ß and GDNF (Rolletschek et al, 2001). Modulating the 
levels of Bcl-2 family members has been used to prolong the life of stem cell 
grafts. However, the role of BcI-2 is not straightforward, since in other 
experiments, the anti-apoptotic gene BcI-2 only protects against apoptosis in 
culture, while NSC isolated from transgenic mice over-expressing Bcl-2 do not 
show increased survival on grafting; however, they do, rather intriguingly, 
display improved fibre outgrowth (Schierle et al, 1999b). 
One should also consider that engineering NSC to express pro-survival genes 
may have unexpected effects (Fernando et al, 2005), and also could increase 
the risk of tumours. Clearly, more work is needed to determine the role of 
apoptosis in the survival of stem cell transplants. 
1.8.8. Apoptosis in mesenchymal stem cell grafts 
There has been much interest in MSC as a potential stem cell type for cell 
therapy, but little work on apoptotic signalling. MSC differentiation into cardiac 
muscle has been reported following injection into the uninjured and ischaemic 
heart in mice (Toma et al, 2002; Orlic et al, 2001). However the effect is limited 
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as very few donor cells survived beyond 1 week (Toma et al, 2002). One major 
obstacle to successful tissue replacement or repair is the poor survival of grafts. 
Indeed, this is endorsed by transplantation experiments using rat MSC 
engineered to over-express anti-apoptotic Akt in a model of ischaemic 
myocardial damage which demonstrated that Akt protected against graft 
apoptosis; this resulted in considerable improvement in myocardial volume 
(Mangi et al, 2003). Although the benefit is clearly related to graft survival, this 
improvement may be due to paracrine cytoprotective factors from the grafts on 
host cardiomyocytes, rather than integration and function of the stem cells per 
se (Gnecchi et al, 2005; Gnecchi et al, 2006). Furthermore, experiments where 
engineered MSC over-express the mitogen and survival factor, FGF-2, there is 
enhanced graft survival in a model of ischaemic heart disease (Song et a/, 
2005). Recently bone marrow MSC transduced to express hepatocyte growth 
factor have been transplanted in a rat stroke model leading to an encouraging 
reduction in cell apoptosis and improved outcome (Zhao et al, 2006). 
Although it might be expected that highly proliferative mesenchymal stem cells 
have effective and efficient death machinery, there are very few studies of 
apoptotic signalling pathways in MSC or bone marrow-derived stromal cells, 
and no other studies using fetal MSC. Kim et al studied the effect of leptin on 
human bone marrow stromal cells and demonstrated that it caused cell death 
by apoptosis with release of cytochrome c, and activation of caspases 9 and 3, 
indicating the activity of the mitochondrial pathway in those cells (Kim et al, 
2003). Zhu et al have shown that MSC die by caspase-dependant apoptosis in 
response to hypoxia and serum withdrawal (Zhu et al, 2006). Another study of 
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human MSC responses to chemotherapeutic agents (high-dose cytarabine, 
dexamethasone, etoposide, paclitaxel and vincristine) showed death by 
apoptosis (defined by morphology and Annexin V labelling ± propidium iodide) 
but no signaling pathways were examined (Li et al, 2004). When considering 
the death receptor pathway, the expression of Fas has been demonstrated in 
mouse bone marrow stromal cells and cell lines derived from long-term BM 
cultures and functional death machinery by the induction of apoptosis with anti- 
Fas antibodies (Lepri et al, 1998). Such studies have not been published in 
human cells. 
Neural Differentiation of Fetal Mesenchymal Stem Cells Chapter 1 
125 
1.9 Aims 
Given data suggesting neural cells may be derived from bone marrow and other 
MSC, I investigated the neural differentiation of primary MSC derived from first 
trimester human fetal blood. These fetal MSC are easily isolated, and readily 
propagated and ultimately may represent a potential source of autologous cells 
for therapy. The ideal cell for neural cell replacement therapy is not known and 
it may be that fetal MSC have increased proliferative and differentiation 
potential compared to adult-derived cells. 
The main aim of this project was to determine whether fetal MSC could 
differentiate into neural lineages in vitro (differentiation defined using neural 
progenitor and lineage-specific markers both at mRNA and protein level), and in 
vivo in the developing murine brain. The in vitro work involved development of 
an oligodendrocyte differentiation medium as well as using protocols derived 
from published work on adult-derived MSC. The animal work explored neural 
differentiation by injecting fetal MSC into the embryonic brain and determining 
cell fate at later times. 
As a secondary area of research, knowing that the success of stem cell therapy 
in animal models has been limited by transplant death, I decided to focus on 
apoptotic pathways in fetal mesenchymal stem cells. The signalling pathways 
leading to stem cell death following engraftment are poorly understood. 
Knowledge of death pathways is necessary in order to prevent graft loss. Fetal 
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MSC were exposed to a variety of cell stresses including staurosporine, growth 
factor withdrawal and ligation of death receptors. 
1.10 Hypotheses 
Hypothesis 1 
Human fetal MSC can be differentiated into oligodendrocytes in vitro using 
medium containing conditioned medium from B104 neuroblastoma cells. 
Hypothesis 2 
Fetal MSC can be induced to neuronal lineages in vitro using extrinsic soluble 
factors similar to those described with adult-derived and rodent MSC. 
Hypothesis 3 
Fetal MSC differentiate into neural lineages in the developing murine brain, and this 
is not a result of cell fusion with host cells 
Hypothesis 4 
Fetal MSC, being highly proliferative multipotent cells, will have active and 
functional intrinsic and extrinsic apoptotic pathways that are influenced by extrinsic 
inhibitors. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1. Human samples 
2.1.1. Research ethics committee approval 
Fetal blood collection for research purposes was approved by the Research 
Ethics Committee of Hammersmith and Queen Charlotte's National Health 
Service (NHS) Trust (99/5575; 2001/6194; 2001/6234) [Consent Form - 
Appendix 1]. National guidelines (1988 Polkinghorne Guidelines on Fetal 
Tissues) were complied with in relation to the use of fetal tissues for research 
purposes. All pregnant women gave written informed consent for the surgical 
procedure, fetal tissue sampling and percutaneous needling for fetal blood 
sampling. 
2.1.2. First trimester fetal blood 
First trimester fetal blood samples (50-500NI) were obtained by ultrasound- 
guided cardiac aspiration between 7-14 weeks gestation (n=30, median 
gestation 10+5 weeks, range 7+6-13+5) before clinically-indicated surgical 
termination of pregnancy. Fetal blood collection was coordinated by the 
Experimental Fetal Medicine Group, Imperial College. Cardiocentesis was 
carried out under general anaesthesia using a disposable siliconised 20 gauge 
(G) 15 cm needle (Cook (UK) Ltd., Hertfordshire, UK) and a1 ml syringe. Both 
the syringe and the needle were heparinised before use by flushing them 
repeatedly with heparin sodium (1000 units/mI, CP Pharmaceuticals Ltd., 
Wrexham, UK). Fetal gestational age was determined by crown-rump length 
(CRL) by ultrasound measurement. 
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2.1.3. Other tissues 
Post-mortem adult human brain samples (paraffin embedded and fresh frozen) 
were kindly donated by the UK Multiple Sclerosis Tissue Bank, Charing Cross 
Hospital. The ethical approval to use these tissues was obtained by written 
application to Dr. Richard Reynolds, Scientific Director of the UK MS Tissue 
Bank. These samples were used as positive controls for staining of neural 
lineages, and to optimise immunostaining and fluorescence in situ hybridisation 
(FISH) on paraffin-embedded and frozen sections. Professor G. Moore also 
kindly donated cDNA from human fetal brain samples (10-18 weeks gestation) 
these were used as a positive control in reverse transcriptase polymerase chain 
reaction (RT-PCR) experiments exploring neural differentiation. 
2.2. Cell culture of undifferentiated fetal MSC 
2.2.1. Culture media for fetal MSC 
To culture first trimester fetal MSC, cells were maintained in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% filtered, heat- 
inactivated fetal calf serum (v/v), 2 mM L-glutamine, 1000/ml penicillin and 
100mg/ml streptomycin (Sigma-Aldrich, Poole, UK). This medium was used 
both at the isolation stage and for their subsequent culture and is referred to as 
`complete growth medium'. 
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2.2.2. Isolation of fetal MSC 
Fetal MSC were isolated as previously described (Campagnoli et a!, 2001). 
Nucleated cell concentrations were first calculated using a haemocytometer. 
Then, unselected nucleated cells from fetal blood were suspended at a density 
of 105 / ml in `complete growth medium' and plated into a well of a 6-well-plate 
and incubated at 37°C with 5% CO2 in air. Fetal MSC were selected by their 
adherence to plastic. At 72 hours, non-adherent cells were removed and the 
medium replaced. Fetal blood MSC lines were named by the Crown-Rump 
length of the original fetal blood sample and the sex (XX or XY, determined by 
FISH) of the cells, and stored with this code. 
2.2.3. Maintenance and expansion of fetal MSC 
Cells were cultured on uncoated 10cm plastic tissue culture dishes in 10ml of 
`complete growth medium' and the medium replaced every 3 days. Once cells 
reached -80% confluence, the medium was gently aspirated leaving the 
adherent monolayer behind. Cells were washed twice with HBSS (calcium and 
magnesium-free) and detached from the sub-stratum by incubating with 0.25% 
Trypsin-EDTA solution (Sigma-Aldrich) for 2 minutes at 37°C. After inspection 
under the light microscope to ensure cells had detached, the action of trypsin 
was neutralised by adding 2ml of complete medium with serum. Cells were 
collected, gently triturated through a pipette tip and the concentration of viable 
cells was deduced by counting unstained cells in trypan blue using a 
haemocytometer. The cells were then washed and divided into new dishes at a 
Neural Differentiation of Fetal Mesenchymal Stem Cells Chapter 2 
'31 
concentration of 6,250 cells/cm2 (250,000 viable cells per dish), clearly noting 
the passage number. 
2.2.4. Cryopreservation and thawing of fetal MSC 
Fetal MSC were stored in liquid nitrogen at 106 per ml in freezing medium, 
containing 30% FCS, 10% dimethylsulphoxide (DMSO) and 60% DMEM. Cells 
were then transferred into Nunc cryopreservation vials (1-2 x 106cells/vial, VWR 
International Ltd. ) and placed into a controlled freezing box (VWR International 
Ltd. ) at -70°C overnight. The following day, vials were transferred into liquid 
nitrogen for long-term storage. When stock fetal MSC were required, frozen 
MSC were thawed rapidly in a water bath at 37°C and then resuspended in 10 
ml of complete medium. Viable cell counts were performed and, after washing, 
cells were plated at 6,250 cells / cm2 in `complete growth medium' and 
subsequently expanded. For normal growth and expansion, fetal MSC were 
expanded on uncoated tissue culture plates, differentiation was, however, 
initiated on plates coated with fibronectin. 
2.2.5. Calculating growth kinetics of fetal MSC 
Growth population doubling times were determined at each passage by 
counting the number of adherent cells at the start and end of each passage, 
along with the time elapsed. For each passage cells were plated at 5x 105 / 
100mm dish; this was done in triplicate. Cells were trypsinised when sub- 
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confluent (after 48-96hr), counted in a haemocytometer and doubling times 
calculated via the equation outlined in Figure 2.01. 
A= A02" A= final cell number 
AO = Initial cell number 
n= number of cell divisions 
n= T/Tc T= time elapsed 
Tc = doubling time 
Therefore: 
A= A02T/Tc 
In (A/A%) = T/Tc In2 => 2.3log(AIAo) = T/Tc x 0.69 
TC = 0.3 T 
log (A/A0) 
Figure 2.01. The calculation of population doubling time for each passage. 
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2.3. Differentiation experiments 
2.3.1. Fibronectin coating of dishes for differentiation 
Fibronectin (1 mg/ml, Sigma-Aldrich) was dissolved for 30 minutes at room 
temperature, and coated on culture plates at 5mg/cm2. Plates were allowed to 
air-dry for an hour and excess fibronectin was removed by aspiration. 
2.3.2. Differentiation into mesodermal tissues 
2.3.2.1. Adipogenic differentiation 
Cells were plated at 1.5 x 104/ well in 8 well fibronectin-coated chamber slides 
(BDH Merck Eurolab Ltd., UK, Poole, UK) in DMEM with 10% FCS 
supplemented with 0.5 pM hydrocortisone, 0.5 pM isobutyl methylxanthine, and 
60 pM indomethacin (Sigma-Aldrich) for up to 31 days with change of medium 
every 3 days as previously described (Campagnoli et al, 2001). Fat cells stained 
with fresh Oil red 0 solution (Sigma-Aldrich). For Oil Red 0 staining, medium 
was aspirated from each well and cells fixed in 4% paraformaldehyde for 30 
minutes at room temperature. The fixative was then removed and the wells 
gently rinsed three times (5-10 minutes each) with 1x PBS and twice with 
water. Enough Oil Red 0 (0.6% solution) to cover the wells was added and 
incubated at room temperature for 50 minutes. The Oil Red 0 was then 
removed and the wells washed twice with water. The nuclei were 
counterstained with haematoxylin. Intra-cytoplasmic droplets of neutral lipids 
within adipocytes stained red, while the cell nucleus was stained black/blue 
from the haematoxylin. 
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2.3.2.2. Osteogenic differentiation 
To induce osteogenic differentiation, fetal MSC were plated at 2x 104/cm2 on 
fibronectin coated glass chamber slides and cultured in DMEM with 10% FCS 
supplemented with 10"8M dexamethasone, 0.2 mM ascorbic acid, and 10 mM ß- 
glycerophosphate (Sigma-Aldrich) for up to 3 weeks as previously described 
(Campagnoli et al, 2001). Bone formation was confirmed by Von Kossa 
staining. Von Kossa staining was performed using a standard protocol (Reyes 
et al, 2001). Briefly cells were fixed with methanol at -20°C for 2 minutes, 
treated with 2% silver nitrate (Sigma-Aldrich) in a clear glass Coplin jar and 
placed directly in front of a 60W lamp for 1 hour. Slides were then rinsed in 
distilled water, fixed with 2.5% sodium thiosulphate (Sigma-Aldrich) for 5 
minutes, and washed again in distilled water. Cells were counterstained with 1% 
neutral red (Sigma-Aldrich) for 1 minute and rinsed in tap water. Insoluble 
extracellular calcium hydroxyapitate crystals stain black in colour. 
2.3.3. Neural cell differentiation of fetal MSC 
2.3.3.1. Oligodendrocyte differentiation medium 
Fetal MSC were plated at 5x 104/cm2 on fibronectin coated plastic chamber 
slides or wells. Cells were allowed to adhere overnight in DMEM / 10% FCS. 
The following day medium was replaced with oligodendrocyte differentiation 
medium. Oligodendrocyte differentiation medium was based on conditioned 
medium from B104 rat neuroblastoma cells, and optimised to the following: 40% 
B104 conditioned medium (vol/vol) in DMEM supplemented with 5pg/ml insulin, 
5pg/mI human transferrin, 5ng/mI sodium selenite, l6pg/mi putrescine, 7.3ng/mi 
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progesterone (Sigma-Aldrich) in serum-free medium or with 0.5% FCS. This 
medium was changed every 2 days over the course of experiments. Preliminary 
differentiation experiments had demonstrated a dose-response with B104 
conditioned medium, beyond 40% there was increasing cell death and so this 
concentration was used in all subsequent experiments. Rat primary 
oligodendrocyte precursors and the oligodendrocyte cell line, CG4 were used 
as positive controls. The majority of experiments were undertaken with the 
24XY fetal MSC, and results confirmed with 4 other fetal MSC sources. 
2.3.3.1.1. B104 conditioned medium 
B104 rat neuroblastoma cells were cultured and expanded in DMEM / 10% 
FCS. Once confluent, cells were washed three times and medium exchanged 
for serum-free DMEM + N1 supplement (Sigma-Aldrich). 5 days later the 
medium was removed, centrifuged at 10,000g for 5 minutes and filtered 
(0.2pm). This conditioned medium was stored at -80°C until further use. 
Conditioned medium from SHSY-5Y (a human neuroblastoma cell line); and 
primary rat astrocytes was also used in similar experiments and the conditioned 
medium derived in the same way. 
2.3.3.2. Neuronal differentiation 
Neural differentiation of fetal MSC was investigated using two further 
approaches: the chemical induction of neuronal phenotype using the reducing 
agent butylated hydroxyanisole (BHA); the exposure to retinoic acid with and 
without the addition of growth factors; and the use of conditioned medium from 
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other neural cells. These two approaches were derived from those published on 
the differentiation of adult derived bone marrow MSC. 
2.3.3.2.1. Chemical induction with butylated hydroxyanisole 
A published protocol of neuronal differentiation from rat and human bone 
marrow stem cells (Woodbury et al, 2000) was modified to see whether similar 
results could be obtained in fetal MSC. To induce differentiation, growth 
medium was replaced with DMEM, 20% FCS ±10ng/ml bFGF overnight. The 
following day, medium was changed to DMEM with 200nM BHA, 5mM KCI, 2pM 
valproic acid, 10pM forskolin, 1pM hydrocortisone, and 5pg/ml insulin (Sigma- 
Aldrich). In initial experiments DMSO was used as a solvent for the BHA (final 
concentration 2%) as in the experiments of Woodbury et al. - this led to high 
levels of cell death and in subsequent experiments ethanol (0.5%) was used 
instead (Safford et al, 2002). Differentiation was determined at time points 
within the first day and up to 4 days by immunocytochemistry, RT-PCR and 
western blot analysis. The human cortical neuron cell line, HCN-2 and SH- 
SY5Y neuroblastoma cells (both obtained from American Type Culture 
Collection, Manassas, VA) were used as positive controls in these experiments. 
2.3.3.2.2. Exposure to retinoic acid ± growth factors 
Differentiation was attempted by replacing growth medium for DMEM for 
`neuronal growth medium' described by Sanchez-Ramos et al. (Sanchez- 
Ramos et a!, 2000). Sanchez-Ramos described the differentiation of bone 
marrow derived MSC (from rat and human) into neural cells expressing GFAP 
and neuron-specific nuclear protein, NeuN. Briefly, cells were replated in the 
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presence of a neuronal growth medium (N5) (Sanchez-Ramos et al, 2000) 
supplemented with 5% horse serum, 1% FBS, transferrin (100 mg/ml), 
putrescine (60mM), insulin (25 mg/ml), progesterone (0.02 mM), selenium (0.03 
mM), all-trans-retinoic acid (0.5 mM), and BDNF at a concentration of 10 ng/ml. 
After 7 to 14 days, differentiated cells were processed for 
immunocytochemistry, western blotting, and RT-PCR. This differentiation 
protocol was not successful in fetal MSC, and in later experiments the 
concentration of retinoic acid was increased as far as 10pM. Retinoic acid 
exposure in DMEM alone was also investigated as previously described (Cho et 
a/, 2005). 
2.3.4. Immun ocytoc hemi stry 
Fetal MSC were plated at 5x 104 /cm2 in 8 well chamber slides and exposed to 
differentiation medium for defined periods of time. Cell monolayers were then 
fixed in 4% paraformaldehyde for 10 minutes at room temperature, washed 
twice in PBS and stored at 4°C until use. Fixed cells were permeabilised with 
0.2% Triton X-100 (Sigma-Aldrich) for 10 min, and then non-specific protein 
interactions blocked by 1 hour in 5% normal goat serum / 5% bovine serum 
albumin (Sigma-Aldrich) followed by primary antibody incubation overnight at 
4°C. The primary antibodies used are described in Table 2.01. Antibodies used 
were against: human vimentin; the neural progenitor markers nestin; neuronal 
markers - neuron specific enolase (NSE), 
fl-Ill tubulin, MAP2; the astrocyte 
marker GFAP; early oligodendrocyte markers PDGFra, A2B5, NG2, 
CNPase; 
and later oligodendrocyte markers 04, myelin proteolipid protein 
(PLP), myelin 
Neural Differentiation of Fetal Mesenchymal Stem Cells Chapter 2 
138 
basic protein (MBP) and GaIC. Negative controls were cells exposed to the 
same concentration of isotype control antibody or no primary antibody. 
Antibody 
reactive to 
Host 
Species 
Specific for 
human 
Dilutions 
used 
Manufacturer 
Vimentin Mouse Yes 1: 50-1: 200 Dako 
Nestin Mouse Yes 1: 50-1: 200 Chemicon 
PDGFra Mouse No 1: 100 R&D systems 
NG2 Mouse No 1: 100 Bd Biosciences Pharmingen 
A2B5 Mouse No Neat-1: 10 Hybridoma (ATCC) 
CNPase Mouse No 1: 50-1: 200 Chemicon 
04 Mouse No Neat Hybridoma (ATCC) 
Gal. C Rabbit No 1: 100 Chemicon 
PLP / DM20 Mouse No 1: 100 Biogenesis 
MBP Mouse No 1: 100 Biogenesis 
pill Tubulin Mouse No 1: 100 Chemicon 
NSE Mouse No 1: 100 Chemicon 
NeuN Mouse No 1: 50 Chemicon 
MAP2 Mouse No 1: 50 
Bd Biosciences 
Pharmingen 
GFAP Rabbit No 1: 200 Sigma 
Table 2.01. Primary antibodies used to cietine ceii pnenotype. 
Control human brain tissues, neural cell lines (eg CG4, SHSY-5Y, HCN-2) and 
primary rat astrocytes / oligodendrocytes were used as positive controls. 
Primary antibodies were used at a 1: 100-200 dilutions in PBS / 0.5% BSA and 
hybridoma supernatants used diluted 1: 10. Following 3 washes in PBS, slides 
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were incubated for 1 hour at room temperature with an appropriate biotinylated 
secondary antibody diluted 1: 100 in 1% BSA (Vector Laboratories Ltd., 
Burlingame, CA). Detection of secondary antibodies was with diluted (1: 100) 
streptavidin-fluoresceine or streptavidin-TexasRed (Vector) or with ABC 
followed by 3,3' diaminobenzidine (DAB, Vector Laboratories Ltd. ). 
Immunostained cells were then washed three times in PBS and in fluorescence 
experiments, the nuclei counterstained with DAPI. Images were obtained using 
a Nikon, Eclipse E600 fluorescence microscope. 
2.3.5. Reverse transcriptase polymerase chain reaction 
(RT-PCR) 
2.3.5.1. RNA extraction and RT PCR 
Total RNA was isolated from cells with TRIzol Reagent (Invitrogen Ltd, Paisley, 
UK) using manufacturer's instructions, and quantified spectrophotometrically. 
20pg samples were reverse transcribed using oligo-(dT)12_18 primer and the 
SuperScript II Kit (Invitrogen Ltd). Parallel samples were generated with 
omission of reverse transcriptase in the reaction mix to rule out genomic DNA 
contamination. Amplification of the control RNA without reverse transcription did 
not generate any products in PCR reactions (data not shown). RT-PCR 
amplification was achieved using established primers or those designed 
from 
published cDNA sequences using Primer3 software (Copyright, Whitehead 
Institute). PCR cycle conditions were optimised for each primer pair. All RT-PCR 
products were resolved on 1-1.5% agarose gels. Primers are shown 
in Table 
2.01. Following amplification (25-35 cycles of 1 minute at 94°C, 1 minute at 
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59.4°C and 1 minute at 72°C) in a Techne Genius thermal cycler (Techne, 
Duxford, UK), the PCR products were resolved on 1-1.5% agarose gels and 
products photographed under UV light. Product size was defined using Bioline 
Hyperladder IV (Bioline, London, UK). GAPDH was a loading control, and 
embryonic human fetal brain cDNA was used as a positive control. 
Primer Sense primer Anti-sense primer Product 
size 
GAPDH ACC ACA GTC CAT GCC ATC TCC ACC ACC CTG TTG CTG 519 
Nestin TCC AGG AAC GGA AAA TCA AG TAG AGA CCT CCG TCG CTG TT 388 
Notchl TCA ATG AGT TCC AGT GCG AG AGG TGT AAG TGT TGG GTC CG 137 
Musashi GGT TTC CAA GCC ACA ACC TA GAG GAA TGG CTG TAA GCT CG 145 
Oll 2 TAA AAG GCA GTT GCT GTG GA GAC GCT ACA AAG CCC AGT TT 286 
Oligi GAG GTC ATC CTG CCC TAC TC CTG CCC AGC AGT AGG ATG TA 113 
NKx2.2 TTA CAG ATT GTT TGC GCA GC AAC CCA AAC AAG CCA CAA AG 416 
PDGFra AGA AGT GAA AGG CAA AGG CA CTT CCT TAG CAC GGA TCA GC 407 
CNPase AAC TGA CCC TCC CTT CCT GT GGT AAA TAG CCC CAG CCT TC 523 
PLP GGC GAC TAC AAG ACC ACC AT AGG TGG TCC AGG TGT TGA AG 247 
MBP GCG TCA CAG AAG AGA CCC TC GGA GCC GTA GTG AGC AGT TC 291 
MOG TTG GTG AGG GAA AGG TGA CT TCA AAA GTC CGG TGG AGA TT 280 
NSE CGG TCA CTG AAG CCA TCC AA CAG CAC ACT GGG ATT ACG GA 256 
NFM GAA AGG CAA GTC TCC TGT GC CCA AGT GCA CCT TTA CCG AT 323 
MAP2 GGC ATT GAA GAA TGG CAG AT TCC TTG CAG ACA CCT CCT CT 291 
GFAP CGC TGG TAG AGA TGG AGG AG CTG GGG TTA AGA AGC AGC AG 266 
Oct-4 GAC AAC AAT GAA AAT CU CAG GAG A TTC TGG CGC CGG TTA CAG AAC CA 218 
Nanog TAC CTC AGC CTC CAG CAG AT AAT GTT CCA GGT CTG GTT GC 267 
Table 2.02. PCR Primers used to evaluate clitterentiation. ror aii taut 
experiments GAPDH was used as a loading control. Nestin, notch-1 and 
Musashi were studied as neural progenitor markers. Oligl and 2, NKx2.2 are 
transcription factors important in oligodendrocyte specification with PDGFra, 
CNPase, PLP, MBP and myelin oligodendrocyte glycoprotein (MOG) used to 
study the oligodendrocyte lineage. Other neural markers studied were the 
neuronal markers NSE, NFM, MAP2 and the astrocyte marker, GFAP. I also 
undertook preliminary studies of two more primitive embryonic markers Oct-4 
(Nichols et al, 1998) and Nanog (Chambers et al, 2003). 
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2.3.5.2. Sequencing of PCR products 
In most differentiation experiments human embryonic brain cDNA was used as 
a positive control. In those experiments where I did not have a satisfactory 
positive control (ie embryonic and neural progenitor markers, musashi and 
notch) the products were also sequenced to confirm the result. This was kindly 
performed by Dr. K. Doudney. In order to sequence PCR products from 
genomic DNA, 1.5 µl was cleaned with the addition of equal volumes of 
microclean (Microzone Ltd. UK), mixed gently and incubated at room 
temperature for 5 mins in a microcentrifuge tube. Thereafter, the tube was 
centrifuged at 13,000g for 5 mins and the supernatant decanted. The DNA 
pellet was resuspended in 9µI of distilled water and 1 pl of forward primer (50ng) 
before handing this over to the Genomics Core Laboratory at Imperial College 
where an automated ABI 3700 sequencer was used to produce the DNA 
sequence from the PCR products. The output was analysed by inserting the 
sequences into BLAST programs at the NCBI website 
http: //www. ncbi. nlm. nih. qov/BLAST/Blast. cgi and identifying the matching cDNA 
sequences. 
2.3.6. Western blotting 
2.3.6.1. Protein extraction 
At defined time points following differentiation, cells were washed with cold PBS 
and collected (by scraping) and centrifuged. Cell pellets were then resuspended 
in 1% SDS (90°C) and heated for a further 5 minutes. Resulting lysates were 
centrifuged at 10,000g at 4°C for 5 minutes and the supernatant collected for 
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western analysis. Protein concentrations were calculated by the BCA method 
(Pierce Chemical Co., Rockford, IL, USA). 
2.3.6.2. Western analysis 
Equal amounts (50pg) of protein were loaded onto 10% acrylamide gels and the 
resolved proteins were transferred onto polyvinylidine difluoride (PVDF) 
membranes (Immobilon, Millipore Corporation, Bedford, MA, USA). Non-specific 
binding on PVDF membranes was blocked by incubation at room temperature 
for 1 hour in 5% non-fat dry milk powder in PBS containing 0.1% Tween 20 
(PBST). Membranes were then incubated overnight at 4°C with primary 
antibodies diluted 1: 1000 in PBST containing 5% non-fat dry milk, washed with 
PBST, and incubated for 1 hour at room temperature with a 1: 1000 dilution of 
horseradish peroxidase-conjugated secondary antibody (Amersham, Arlington 
Heights, IL, USA) in PBST containing 5% non-fat dry milk. After washing with 
PBST, detection was with enhanced chemiluminescence (ECL kit, Amersham). 
The antibodies used were to vimentin (Dako) and CNPase (Chemicon) with a- 
tubulin as a loading control (Sigma-Aldrich). 
2.3.7. Electrophysiological recordings 
Electrophysiological experiments were kindly performed by Dr. S. Fraser, 
Department of Biological Sciences, Imperial College London. Following neuronal 
differentiation with medium containing BHA (Woodbury et al, 2000), single cell 
recordings were undertaken using patch-clamp apparatus to determine whether 
there was evidence of functional voltage-gated sodium channel (VGSC) 
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upregulation with differentiation. Similar methodology has been used to define 
functionality in neuronal cells derived from MAPC (Jiang et al, 2003). Standard 
whole-cell patch-clamp recording methodologies were used to examine the 
physiological properties of cultured fetal MSC. Prior to each experiment, the growth 
medium was replaced with an external bathing Ringer solution containing (in mM): 
NaCl 144, KCI 5.4, MgCl 21, CaCI2 2.5, D-glucose 5.6, and HEPES 5, adjusted to 
pH 7.2 with 1M NaOH. Electrophysiological recordings were performed as 
previously described (Fraser et al, 2003). In brief, patch pipettes (of resistances 
between 5-15 MQ) were filled with a solution designed to block the outward K+ 
currents; the composition was as follows (in mM): NaCl 5, CsCI 145, MgC12 2, 
CaCI2 1, HEPES 10 and EGTA 11, adjusted to pH 7.4 with 1M CsOH. Whole-cell 
membrane currents were recorded from cells that appeared 'isolated' in culture, 
using an Axopatch 200B (Axon Instruments) amplifier. Analogue signals were 
filtered at 5 kHz using a lowpass Bessel filter and series resistance errors were 
compensated by up to 80% using the Axopatch 200B. Electrophysiological signals 
were sampled at 50 kHz and digitised using a Digidata (1200) interface. Data 
acquisition and analysis of whole-cell currents were performed using pClamp 
software (Axon Instruments). A holding potential of -100 mV was applied, unless 
indicated otherwise. Standard voltage-clamp protocols were used to study the 
electrophysiological and pharmacological properties of the Na+ currents. Specific 
details are given in the results section, the individual figure legends or have been 
explained in detail previously (Grimes et al, 1995). The effect of external 
tetrodotoxin (TTX, 100nM - 10pM) was studied, using single voltage pulses from - 
100 mV to -10 mV. In these experiments, an internal pipette solution in which KCI 
had been replaced with CsCI to abolish outward currents was used. The effect of 
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TTX was determined by measuring the current 3 min after drug application. 
Current density was calculated from the maximal current generated by pulsing 
from a holding potential of -100mV and dividing this value by the capacitance (as 
determined from the capacitance compensation feature on the Axopatch 200B). 
2.4. Lentiviral eGFP transduction of fetal MSC 
2.4.1. Infection of fetal MSC 
Fetal MSC were seeded at 5x105 per well in 6 well tissue culture plates. To 
constitutively express eGFP, cells were infected with a self-inactivating HIV-1 
based lentiviral vector (Demaison et al, 2002) with a multiplicity of infection 
(MOI) of between 1 and 20, and after 12 hours the medium exchanged for fresh 
growth medium. This lentivirus pHR' SIN-cPPT-SEW is a self-inactivating (SIN) 
LTR vector that expresses eGFP under the control of the spleen focus forming 
virus (SFFV) U3 promoter/enhancer and carries a modified Woodchuck post- 
transcriptional regulatory element (WPRE) to improve virus titre and the central 
polypurine tract (cPPT) sequence of HIV-1 to aid nuclear entry by vector 
genomes (a simplified diagram of the vector is shown in Figure 2.02. ). 
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Figure 2.02. Lentiviral vector used to constitutively express eGFP in fetal 
MSC. This lentivirus pHR' SIN-cPPT-SEW (as described by Demaison et. al. 
(Demaison et al, 2002)) is a self-inactivating (SIN) LTR vector that expresses 
eGFP under the control of the spleen focus forming virus (SFFV) U3 
promoter/enhancer and carries a modified Woodchuck post-transcriptional 
regulatory element (WPRE) to improve virus titre and the central polypurine 
tract (cPPT) sequence of HIV-1 to aid nuclear entry by vector genomes thus 
improving transduction efficiency. 
Vector particles were produced using human embryonal kidney 293T cells and 
titred as previously described (Waddington et al, 2004). In early experiments 
fetal MSC were pre-treated with cationic polybrene (1 to 10 pg per ml, Sigma- 
Aldrich) to facilitate transduction, but this was found to lead to cell death, and be 
unnecessary. eGFP transduction efficiency was determined by flow cytometry. 
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2.4.2. Enrichment of eGFPf cells 
For in vivo studies, the proportion of eGFP+ cells after initial infection was 
enriched by fluorescence activated cell sorting on a Becton Dickinson 
FACSVantage with a Digital upgrade (DiVa), using an air cooled Argon gas 
488nm laser. After trypsinisation, transduced fetal MSC were resuspended in 
`Sort Buffer'. `Sort Buffer' was prepared with 1x Phosphate Buffered Saline 
(Ca/Mg" free), 1 mM EDTA, 25mM HEPES pH 7.0,1 % FBS (Heat-Inactivated) 
and filtered (0.2pm) before use. The proportion of eGFP+ cells before and after 
enrichment was confirmed by flow cytometry and fluorescence microscopy, with 
the nuclei counterstained with DAPI. When sorting, cells with very high eGFP 
expression were gated out so as not to enrich for cells with many viral 
integration sites. After enrichment the cells were plated in normal growth 
medium and their eGFP expression re-examined 48hrs later. 
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2.5. Clonal populations of fetal MSC 
2.5.1. Generation of single cell clones 
Clonal expansion of single fetal MSC was attempted using several different 
approaches. Single fetal MSC were picked up using a glass micropipette under 
light microscopic guidance (Figure 2.03. ) and deposited into individual wells. 
Figure 2.03. Single fetal MSC in suspension can be picked up and plated 
using a micropipette. Single fetal MSC in suspension (orange arrow) can be 
picked up with a micropipette (blue arrow) under direct vision with an inverted 
light microscope. 
Alternatively, fetal MSC were plated in 96 well plates in growth medium by 
limiting dilution - with serial dilutions across the plate (starting at average of 20 
cells / well, halving with each dilution; 24 wells / cell dilution). The 96 well plate 
setup is shown in Figure 2.04. In these experiments, wells were checked for the 
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presence of single cells by inverted light or fluorescence microscopy (for eGFP 
cells) after overnight culture. Wells with a single cell were marked and observed 
daily. Culture medium was changed three times weekly. 
Average 
number of 
cells / well 
Cells diluted across the 96 well plate 
20 10 5 2.5 1.25 0.63 0.31 0.16 0.08 0.04 0.02 0.01 
Figure 2.04. Template of 96 well plates in limiting dilution experiments to 
obtain clonal populations of fetal MSC. There were 12 wells where single 
cells were confirmed in wells where the average number of cells plated was <1. 
The culture of single eGFP+ cells in 96 well plates (Triple Red, Thame, UK), or 
in NunclonTM MicrowellTM Plates, with a culture volume as little as 5-10pl, did 
not yield clonal populations either when cultured in complete medium or in 
conditioned medium from healthy fetal MSC cultures. In these experiments 
single cells were visible and survived for several days without division. Having 
failed to generate clonal populations by pipetting single cells on mitomycin c 
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(concentrations up to 50pg/ml) treated feeder layers of fetal MSC, clones were 
eventually obtained by growing single male eGFP+ cells on a feeder layer of 
senescent female MSC (cell source 40XX, 2x 103 / well) in DMEM / 10% FCS. 
Male eGFP+ colonies were cultured in 96 well plates and then expanded 
through 24,12 and then 6 well plates (Triple Red). eGFP+ cells were used in 
clonal differentiation experiments and for tracking cells in the in vivo 
experiments. Fluorescence in-situ hybridisation (FISH) was used to confirm 
male genotype. 
2.5.2. Confirmation of clonality by analysis of provirus 
copy number in transduced fetal MSC 
Southern analysis was used to determine whether the transduced fetal MSC 
clone contained single or multiple proviral insertions and to gain an indication of 
clonality. The method used was that previously described (Sambrook et al, 
1999). Briefly, lOpg of genomic DNA was digested with the Pstl restriction 
enzyme (present as a unique site in the vector backbone) and fragments were 
separated on agarose gels before transfer to Nylon membranes (Hybond-N TM ) 
A 600 bp probe was generated by Not I digestion of the vector representing the 
woodchuck post-transcriptional regulatory element (WPRE, also present on the 
vector) which was gel purified and labelled using a random primer labelling kit 
(Mega-primeTM system Amersham) according to the manufacturers instructions 
with 50 mCi of a-32P-CTP (3000Ci/mM) to generate a probe with specific activity 
of 109 cpm/mg. A Bio-SpinTM 6 column (Bio-rad) was used to remove 
unincorporated nucleotides. Following hybridisation overnight the membrane 
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was washed as required and the membrane exposed to Kodak XAR-2 X-ray 
film. 
2.5.3. Confirmation of the sex of clonal populations of 
fetal MSC by FISH 
The sex of clonal populations of fetal MSC was confirmed by FISH for human X 
and Y chromosomes on cytospin samples. Cytospun slides were prepared with 
10-40,000 cells and were fixed with 100pl of 3: 1 v/v methanol: glacial acetic 
acid (Carnoy's fixative) and air-dried. Slides were dehydrated through 70%, 
90% and 100% ethanol for 2 minutes each. Chromosome-specific centromeric 
repeat probes DXZ1, labelled with SpectrumOrangeTM, and DYZ1, labelled with 
SpectrumGreenTM (Vysis, Abbott Laboratories Ltd. ) were used. The 
hybridisation buffer contained 50% formamide and 10% dextran sulphate in 2x 
SSC (sodium salted citrate) at pH 7.0.3-5 pl of the probe, diluted 1: 4 in the 
hybridisation buffer were added to each cytospin under a 13mm diameter 
coverglass sealed with Parafilm. Target deoxyribonucleic acid (DNA) was 
denatured directly on the in situ hybridisation block (Genetic Research 
Instrumentation Ltd) at 71 °C for 7 minutes followed by a 4-hour hybridisation at 
37°C. Following hybridisation, cells were washed with 2x SSC for 2 minutes 
and incubated with 0.4 x SSC in a water bath at 72° ±1 °C for 2 minutes. Next, 
cells were incubated with 2x SSC / 0.1 % nonylphenoxy polyethoxy ethanol-40 
(NP-40) at room temperature for 2 minutes and shielded from direct light 
throughout. Slides were air-dried and mounted in a fluorescence antifade 
medium containing DAPI (diamidino-2 phenylindole; Vector Laboratories Ltd. ), 
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covered with 22 x 22 mm coverslips and sealed with clear nail varnish. Slides 
were analysed by epifluorescence microscopy (fluorescence microscope; Zeiss 
Axioskope, Carl Zeiss, Germany), using single band pass filters for Aqua, 
Orange and DAPI and the triple band pass filter set. Images were captured 
using a cooled charge-coupled device camera and reviewed in Quipps m-FISH 
software (Vysis, Abbott Laboratories Ltd. ). The FISH images were exported into 
other image file-types by conversion through IPLab Software (Digital Scientific) 
and were transferred without alteration. The XY probes used have been 
optimised for identifying chromosomes in interphase nuclei and hybridisation to 
its target chromosomes is marked by red/orange and green. Nuclei with two red 
signals were classified as female (XX) and those with one red signal and one 
green signal as male (XY). Each slide was scanned for hybridisation efficiency 
and analysed only if >_ 80% of nuclei contained both signals. These were 
counted when the intensity and diameter of the fluorescent signals was 
approximately equal and inside a distinct nucleus with an intact border, as 
indicated by DAPI staining. 
2.5.4. Differentiation of the clonal population 
Oligodendrocyte differentiation was performed on clonal populations of eGFP+ 
cells. In addition, to determine whether cells had retained mesodermal 
differentiation potential, osteogenic differentiation was assessed on the same 
clone by incubating the cells with DMEM with 10% FCS supplemented with 
10-8M dexamethasone, 0.2mM ascorbic acid, and 10mM , B-glycerophosphate 
(Sigma-Aldrich) for 2 weeks as previously described (Reyes et al, 2001). Bone 
mineralisation was confirmed by Von Kossa staining. 
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2.6. Animal Model for in vivo differentiation 
2.6.1. Intraventricular injections of fetal MSC into the 
embryonic day 15 (E15) fetal mouse 
In order to investigate the behaviour and neural development of fetal MSC in 
vivo, they were transplanted into the ventricular system of the developing 
murine brain. Timed-pregnant female MF1 mice (Harlan UK, Bicester, UK) at 15 
days gestation were used in this study. All procedures were carried out by Dr. 
S. Waddington, Gene Therapy Research Group, Imperial College in accordance 
with the Animal Scientific Procedures Act, and under Home Office approval. 
Under isofluorane anaesthesia, the uterus was exposed through a full-depth 
midline laparotomy. 5x 104 cells (in 5pl DMEM) were injected into the anterior 
horn of the lateral ventricle on the left side via trans-uterine injection using a 33- 
gauge needle (Hamilton, Reno, NV). This is shown in the photograph in Figure 
2.05. Up to six fetuses were injected per dam (n=15). The laparotomy was 
closed in two stages using interrupted stitches of 6-0 silk suture and the mouse 
permitted to recover in a warm cage. For endpoint analysis, mice were 
anaesthetised with isofluorane and perfusion-fixed with 4% paraformaldehyde 
(PFA). Brains were removed and prepared for frozen sectioning, or fixed 
overnight in PFA at 4°C prior to paraffin embedding. 5pm sections were cut for 
analysis. In utero, injected fetuses were identified by their uterine position, and 
by tattooing with colloidal carbon which could be visualised after birth. The fate 
of transplanted cells was examined immediately following injection and at time 
points up to 4 weeks (Immediately post injection, E18, P0, P7, P14, P28). 
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Figure 2.05. Animal model: embryonic day 15 (E15) murine embryo. The 
animal model involved injection of fetal MSC into the lateral ventricle of day 15 
MF1 murine embryo (A). The size of the embryo at this stage of development is 
demonstrated (B). 
2.6.2. Tissue processing 
2.6.2.1. Wax embedding and microtome sectioning 
Sacrificed embryos were fixed whole overnight in neutral buffered 4% 
paraformaldehyde, and then dehydrated through an ethanol series (70%, 90%, 
100% x 2) for one hour each, and placed in HistoClearTM (Fisher Scientific, 
Loughborough, Leicestershire, UK) overnight. Sacrificed postnatal mouse pups 
had their brains removed which were fixed as above. Specimens were then 
placed in molten wax within plastic moulds for 2 hours at 60°C. Cassettes were 
placed over the moulds and the wax-embedded embryos allowed to cool and 
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harden. Thin sections (approximately 300 per embryo) of 5pm were cut on a 
microtome and mounted on polylysine-coated slides. Every tenth slide was 
stained with haematoxylin and eosin (H&E) in order to identify areas of 
abnormality or interest. BrdU incorporation, anti-human antibodies and human 
specific XY FISH were all used to detect injected cells. 
2.6.2.2. Haematoxylin and eosin (H&E) staining 
For H&E staining, formalin-fixed paraffin-mounted tissue slides were dewaxed 
by immersion twice in Histo-ClearTM (Fisher Scientific) for 2 minutes each and 
rehydrated in an ethanol series (100% x2,70%) for 2 minutes each. They were 
then immersed in Erlich's haematoxylin for 2 minutes, rinsed in running water, 
dipped in acid ethanol for 10 seconds and washed in running tap water for 5 
minutes. After 5 minutes in eosin, the slides were dehydrated in an ethanol 
series (70%, 100% x2), air-dried, dipped in Histo-ClearTM and mounted with 
coverslips over DPX mountant (BD Biosciences). 
2.6.2.3. Cryofixation and cryostat processing 
Brains from transplanted mice were harvested and snap frozen in liquid 
nitrogen-cooled isopentane then transferred onto cork boards with OCT 
(Optimal Cutting Temperature, Tissue-Tek) mounting medium. Serial sections 
of 5-8µm thickness (transverse sections) were cut and collected on poly-lysine 
coated slides via a cryostat (CM 1900, Leica). Like the paraffin sections, these 
were examined by immunohistochemistry and with haematoxylin and eosin 
staining. 
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2.6.3. Cell tracking 
Injected human fetal MSC were tracked in vivo using BrdU labelling, anti-human 
antibodies, FISH for human X and Y chromosomes and finally eGFP expression 
in transduced cells. 
2.6.3.1. Immunohistochemistry 
Paraffin-embedded tissue sections were dewaxed by immersion in HistoClearTM 
for 2 minutes each and rehydrated. For BrdU staining, sections were treated for 
1 hour with 1M HCI at room temperature to hydrolyse the DNA and expose 
incorporated BrdU. Non-specific protein interactions were blocked with 5% BSA 
and 5% normal goat serum (NGS) in PBS for 1 hour at room temperature. 
Slides were incubated with the following primary antibodies: anti-BrdU; human- 
specific vimentin (Dako Ltd. ); or anti-human ribonuclear protein (Chemicon) for 
4 hours at room temperature. Primary antibodies were diluted 1: 50 in 0.5% 
BSA, 0.5% NGS with the addition of Exonuclease III 400u/ml (Promega, 
Maddison, WI) for BrdU staining. Biotinylated goat anti-mouse Ig (Dako) was 
used as a secondary antibody, and stained with either streptavidin-fluoresceine, 
streptavidin-Texas Red (diluted 1: 50 in PBS), or ABC reagent followed by 
visualisation of the horseradish peroxidase with NovoRed (Vector Laboratories 
Ltd) according to the manufacturer's instructions. 
2.6.3.2. Human XY FISH 
Slides were dewaxed and rehydrated as described above. Sections were heat- 
treated with 2x SSC for 15 minutes at 80°C and then washed twice in PBS. 
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Slides were then treated with 100pl of pre-warmed Proteinase-K (100pg/ml) 
(BDH Merck Eurolab Ltd. ) for 15 minutes at 37°C, and washed as before. 
Secondary fixation was with 2: 1 v/v methanol: acetone, prepared ice-cold for 15 
minutes. Finally the slides were dehydrated and prepared for FISH. 
Chromosome-specific centromeric repeat probes DXZ1, labelled with 
SpectrumOrangeTM and DYZ1, labelled with SpectrumGreenTM (Vysis, 
Downer's Grove, IL) were used. The hybridisation buffer contained 50% 
formamide and 10% dextran sulphate in 2x SSC at pH 7.0.5pl of probe, diluted 
1: 1 in hybridisation buffer were added to each section under a 13mm 
coverglass and sealed with parafilm. Target DNA was denatured directly on the 
in situ hybridisation block (Genetic Research Instrumentation Ltd) at 71 °C for 7 
minutes followed by a 4-hour hybridisation at 37°C. After hybridisation, sections 
were washed with 2x SSC for 2 minutes and further incubated with 0.4 x SSC at 
72°C for 2 minutes. Next, sections were incubated in 2x SSC, 0.1% NP40 at 
room temperature and shielded from direct light throughout. Finally slides were 
air-dried and mounted in a fluorescence anti-fade medium containing DAPI 
(Vector Laboratories Ltd. ) and 22 x 22mm coverslips for analysis. Nuclei with an 
orange/red and a green signal were categorised as human male fetal MSC. 
2.6.3.3. eGFP expression 
As described in 2.4., fetal MSC were transduced with a lentiviral vector leading 
to constitutive expression of eGFP. The mixed population of cells was then 
sorted by flow cytometry (2.4.2. ) to enrich the eGFP expressing cell proportion 
to 98%. These cells were used in vivo and their eGFP expression enabled 
successful cell tracking. In both paraffin-embedded and frozen sections eGFP 
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was easily visualised either directly with fluorescence microscopy or by 
detection with anti-GFP antibodies. 
2.6.4. Immunohistochemistry 
2.6.4.1. PFA-fixed paraffin embedded tissues 
2.6.4.1.1. Unmasking technique 
PFA fixation and paraffin embedding can mask the antigens being probed and 
therefore hinder detection by antibody methods, giving weak or false negative 
results. 5pm tissue sections on polylysine-coated slides were dewaxed by 
immersion three times in Histo-clearTM (Fisher Scientific) for 2 minutes each and 
rehydrated in an ethanol series (100%, 90%, 70%) for 2 minutes each. They 
were then placed within a pressure cooker (Tefal Delicio, commercially 
available high-pressure cooker) containing 1,500 ml distilled water with 15ml of 
the stock antigen unmasking solution (Vector Laboratories Ltd. ) at a boil. The 
slides were then pressurised for 5 minutes before collecting them in cooled 
distilled water, followed by rinsing in PBS before immunohistochemistry. 
2.6.4.1.2. Immunohistochemistry by peroxidase method 
For immunostaining using the Vectastain® ABC method (Vector Laboratories 
Ltd. ), sections were incubated with 3% hydrogen peroxide (H202) (Sigma- 
Aldrich Company Ltd. ) for 30 minutes at room temperature to quench 
endogenous peroxidase. After washing three times with PBS for 5 minutes, 
slides were blocked with 5% NGS + 5% bovine serum albumin (BSA, Sigma- 
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Aldrich) + 0.3% Triton-X-100 in PBS for 60 minutes at room temperature. Slides 
were then incubated with the appropriate antibody (outlined in Table 2.02. ) 
diluted 1: 50-1: 500 in 0.5% NGS / 0.5% BSA (or 0.5% serum of species 
overnight at 4°C. Subsequent incubations were with a biotin-labelled secondary 
antibody, followed by the avidin : biotinylated enzyme complex (ABC, Vector 
Laboratories Ltd. ). In the last step of the procedure, the tissue antigen was 
localised by incubation with a substrate for the enzyme (Vector NovaRed or 
DAB substrate kit, Vector Laboratories Ltd. ). In these experiments, postnatal 
murine brain, or post-mortem human brain sections were used as positive 
controls. Negative controls were either generated by using an isotype control 
antibody (at the same concentration and from the same species) rather than the 
primary antibody or simply by omission of the primary antibody. 
2.6.4.1.3. Immunofluorescence staining of tissue 
For fluorescence immunostaining, streptavidin-FITC (green) or streptavidin- 
Texas Red (red) (Vector Laboratories Ltd. ), diluted in 1: 100 in PBS with 0.5% 
NGS / 0.5% BSA, replaced the avidin : biotinylated enzyme complex conjugate 
in the previous section. DAPI was used to counterstain the nuclei and slides 
viewed using fluorescence microscopy. 
Where double labelling was utilised, primary antibodies were used from 2 
different species (ie mouse and rabbit) to allow detection. To visualise this 
fluorochrome-labelled secondary antibodies (from goat) raised against IgG from 
the species of the primary antibody were used (dilution 1: 50). Obviously when 
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staining eGFP+ cells (green) for neural antigens a Texas Red-labelled 
secondary antibody was utilised and positive cells stained yellow (red+green = 
yellow). Images were obtained using a Nikon, Eclipse E600 fluorescence 
microscope. 
Antibody 
reactive to 
Host 
species 
Specific for 
human 
Dilutions 
used 
Manufacturer 
GFP Mouse No 1: 100 Chemicon 
Nestin Mouse Yes 1: 50-1: 200 Chemicon 
Nestin Rabbit Yes 1: 100 Chemicon 
Vimentin Mouse Yes 1: 50-1: 200 Dako 
NG2 Mouse No 1: 100 Bd Biosciences Pharmin en 
NG2 Rabbit No 1: 200 Chemicon 
CNPase Mouse No 1: 50-1: 200 Chemicon 
Gal. C Rabbit No 1: 100 Chemicon 
MBP Mouse No 1: 100 Biogenesis 
A2B5 Mouse No Neat-1: 10 Hybridoma (ATCC) 
ß11I Tubulin Mouse No 1: 100 Chemicon 
NSE Mouse No 1: 100 Chemicon 
NeuN Mouse No 1: 50 Chemicon 
MAP2 Mouse No 1: 50 
Bd Biosciences 
Pharmingen 
GFAP Rabbit No 1: 200 Sigma 
Table 2.03. Antibodies used in immunohistochemistry to determine ceii 
fate in vivo. 
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2.6.4.2. Cryopreserved tissues 
Cryosections sections were air-dried and blocked with 5% NGS, 5% FCS, 0.3% 
Triton-X100 for 1 hour at room temperature before treatment with the 
appropriate monoclonal antibodies. Slides were then incubated with the 
appropriate antibody (antibodies used for immunohistochemistry are outlined in 
Table 2.02. ) diluted 1: 50-1: 500 in 0.5% NGS / 0.5% BSA (or 0.5% serum of 
species overnight at 4°C. Slides were then incubated with goat secondary 
antibodies raised against either mouse or rabbit IgG and conjugated to either 
FITC or Texas Red (Green and red respectively, Vector Laboratories Ltd. ), for 
analysis by fluorescence microscopy (Nikon, Eclipse E600). 
2.6.5. Exclusion of cell fusion: human - mouse FISH 
Paraffin or frozen sections were fixed with either 100 pl of 3: 1 v/v methanol: 
glacial acetic acid or in 1: 1 methanol: acetone. Sections were dehydrated 
through an ethanol series, air-dried and then denatured in pre-warmed 
denaturation solution: 70% deionised formamide (Sigma-Aldrich), 30% 2X SSC 
(sodium salted citrate) at 65°C for 2 minutes. 2pl of probe was added to each 
slide, a coverslip applied and sealed with rubber cement. The probe was 
allowed to hybridise overnight in a dark humidified box at 37°C. After the 
coverslip was removed, slides were washed (for two minutes each) twice in 1: 1 
formamide: 1x SSC, once in 1x SSC and finally once in 4x SSC, 0.05% 
Tween20 at 45°C. To rule out cell fusion, fluorochrome-labelled human (Cy3) 
and mouse (FITC) specific pan-centromeric paints (Cambio, Cambridge, UK) 
were used in combination. These paints generate multiple nuclear signals in 
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each cell - co-localisation of mouse and human signals could indicate cell 
fusion. Slides were analysed with epifluorescence microscopy (fluorescence 
microscope; Zeiss Axioskope, Germany). Images were captured using a cooled 
charge-coupled device camera and reviewed in Quipps m-FISH software (Vysis 
Inc. ). 
2.7. The study of apoptotic signalling in fetal MSC 
2.7.1. Materials for apoptosis experiments 
All plastics, including 10cm dishes, 96-well microtitre plates, 6-well plates, and 
8-well chamber slides were provided by Triple Red. Dulbecco's Modified Eagle 
Medium (DMEM), magnesium sulphate- and calcium chloride-free Hank's 
Balanced Salt Solution (HBSS), Fetal Calf Serum (FCS), Trypsin-ethylene 
diamine tertraacetic acid (EDTA) solution, Penicillin Streptomycin (P/S) solution, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
dimethylsulfoxide (DMSO), sodium dodecyl sulphate (SDS), powdered 
ammonium persulphate (APS), N, N, N', N'-Tetramethylethylenediamine 
(TEMED), staurosporine (SSP), bovine serum albumin (BSA), 
paraformaldehyde (PFA), DL-dithiothreitol (DTT) and all other reagents and 
chemicals including N, N-Dimethylformamide (DMF) were obtained from Sigma- 
Aldrich. Human recombinant Fas ligand was obtained from Alexis Corporation 
UK Ltd (Nottingham, U. K. ) and caspase inhibitors from Gentaur (Brussels, 
Belgium). The BCA protein assay reagent kit was obtained from Pierce 
Chemical Company (Rockford, IL, USA). The gel plates and the 30% 
acrylamide solution were provided by BioRad (Hercules, CA, USA). Polyvinyl 
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difluoride membrane immobilon-P (PVDF) membrane was obtained from 
Millipore (Bedford, MA, USA). The radiographic film and Lumi-Glo 
chemiluminescence kit were obtained from Amersham Biosciences (Chalfont, 
UK). Polyclonal rabbit anti-human cleaved caspase 9 and cleaved caspase 3 
antibodies, Phopho-Akt (Thr308 amd Ser473), and Phospho-Forkhead (FKHR) 
antibodies were obtained from Cell Signalling Technology (Beverly, MA, USA). 
Purified mouse anti-cytochrome c monoclonal antibody was obtained from BD 
Biosciences (Oxford, UK). The anti-rabbit and anti-mouse horseradish 
peroxidase (HRP)-linked secondary antibodies were provided by Amersham 
Biosciences. and Vector Laboratories Ltd. provided the fluorochrome-labelled 
secondary antibodies, the Vectastain ABC kit, the DAB and NovaRed 
peroxidase substrates, the Normal Goat Serum (NGS) and the 4,6-diamidino-2- 
phenylindole-dihydrochioride (DAPI) mountant. The biotinylated anti-mouse and 
anti-rabbit antibodies were obtained from DAKO Ltd. Aquamount mountant was 
supplied by BDH (Poole, UK). Non-fat dry milk was provided by Fluka 
(Switzerland). The ApoTag In Situ Detection Kit was supplied by Intergen 
Company (Oxford, UK). Spectrophotomery readings were performed using the 
Optimax Microplate Reader from Molecular Devices and slides were visualised 
using a Nikon Elipse E600 microscope. 
2.7.2. Cell culture 
Low passage (Passage <15) human first trimester MSC (24mmXY lineage) 
were used in all experiments. Stocks stored in liquid nitrogen were swiftly 
thawed, washed in growth medium, centrifuged, plated out and kept at 37°C in 
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a humidified 10% CO2 incubator to maintain optimal pH and temperature for cell 
viability thereafter. Cells were grown on uncoated 10cm plastic tissue culture 
dishes in 10ml of DMEM supplemented with 10% filtered, heat-inactivated fetal 
calf serum (HI-FCS) and antibiotics (1% Penicillin-Streptomycin). Medium was 
changed every three days, and when cells reached approximately 80% 
confluence, they were passaged using the following method: cells were washed 
twice with HBSS and were detached from the sub-stratum by incubating for 2 
minutes with 0.5ml trypsin-EDTA solution. Approximately 1 ml of DMEM 10% 
HI-FCS was used to neutralise the action of trypsin and cells were collected. 
Collected cells were again re-plated at a concentration of 2.5 x 105 cells/dish in 
10 ml DMEM 10% HI-FCS. 
2.7.3. Inducers of cell death 
Apoptosis was investigated in fetal MSC subjected to three different death 
stimuli: exposure to staurosporine, serum withdrawal or Fas ligation using 
cross-linked human recombinant Fas ligand. For all experiments (apart from 
those comparing cell death at different cell densities), cells were plated at a 
density of 5x104/cm2 in DMEM with 1% FCS overnight to allow adherence. 
2.7.3.1. Staurosporine (SSP) 
SSP is a bacterial alkaloid and non-specific kinase inhibitor that triggers 
mitochondrial-dependent apoptosis. In all experiments, cells were seeded 
in 
100 µl of DMEM / 1% HI-FCS in a 96-well plate and allowed 
to settle overnight. 
Previous experiments have shown that at this serum concentration cells survive 
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and adhere, but do not proliferate. In dose-response experiments, fetal MSC 
were treated for 24 hours with defined doses of SSP. Time-course experiments 
were also performed to assess the time-dependent aspect of SSP-induced 
apoptosis. Survival of cells was subsequently assessed using the MTT assay 
and counting experiments (described below). Untreated cells acted as a control, 
and % survival calculated as a proportion of untreated cells. 
2.7.3.2. Serum Withdrawal 
Serum withdrawal was used as an inducer of cell death by depriving cells of 
growth signals. Following plating of fetal MSC, cells were washed twice with 
DMEM and the medium was replaced with 100µI DMEM alone. The serum 
withdrawal treatment was carried out over a period of 2 weeks, unless stated 
otherwise, with cells washed and their medium being replaced (for DMEM 
alone) every 3 days. 
2.7.3.3. Fas Ligation 
Fas ligand (FasL) was used as the stimulus to examine the death receptor 
pathway. Fas Ligand (FasL; APO-1 L; CD95L; CD178) is a 40kDa type 11 
transmembrane protein belonging to the TNF family. Interaction between 
aggregated FasL and the Fas receptor induces apoptosis of sensitive cells. The 
FasL was reconstituted as per manufacturer's instructions, and cross-linked 
prior to usage with the supplied `enhancer' (Alexis Corporation UK Ltd). Cells 
were exposed to cross-linked FasL for 72hours. 
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2.7.4. Experimental treatments 
At the beginning of each experiment cells were washed three times with HBSS. 
For SSP and Fas ligand experiments, cells were cultured in DMEM 
supplemented with 0.5% FCS. For serum withdrawal experiments, cells were 
cultured in DMEM alone with no supplements. At the end of the experiments, 
fetal MSC were investigated for cytochrome c release, caspase activation and 
apoptosis as described below. Caspase inhibitor studies were performed to 
investigate their role in cell death triggered by exposure to SSP or Fas ligand. 
ZVAD. fmk (20-100 NM) was used as a pan-caspase inhibitor, whilst IETD. fmk 
was used to preferentially inhibit caspase 8 and Z-LEHD. fmk to preferentially 
inhibit caspase 9 activity (20-8OpM). In these experiments the caspase inhibitor 
was added one hour prior to the apoptotic stimuli, and was present at the same 
concentration for the duration of the experiment. 
2.7.5. MTT assay 
Cell viability was estimated by an optimised colorimetric method, which is based 
on the ability of mitochondrial dehydrogenases of viable cells to reduce MTT [3- 
(4,5 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] from a yellow water- 
soluble dye to a dark blue insoluble formazan product (Hansen et al, 1989). 
(Figure 2.06). 
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Figure 2.06. Phase contrast image of fetal MSC metabolising MTT. Cell 
viability can be estimated by an optimised colorimetric method based on the 
ability of mitochondrial dehydrogenases in live cells to reduce MTT from a 
yellow water-soluble dye to a dark blue insoluble formazan product (seen as 
black intracellular precipitate). At the end of each experiment cells can be lysed 
and MTT metabolism estimated by absorbance at 562nm. 
Fetal MSC were seeded in 96-well plates at 1.6x104 cells/well (5x104/cm2) and 
allowed to attach overnight. This cell number was determined in preliminary 
experiments examining MTT metabolism (measured by absorbance 562nm) 
with different cell numbers. The optimal cell number used in MTT assays was 
found to be around 16,000 cells per well; this density is within the steep linear 
portion of the absorbance-cell number graph (Figure 2.07. ). 
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Figure 2.07. The optimal cell number for MTT assays. The optimal cell 
number for MTT assays with Fetal MSC lies between 7,000 and 25,000 
cells/well. Cells were seeded in quadruplicates in serial dilutions ranging from 
100 to 100,000 cells per well in 100pl of 1% FCS DMEM including wells with 
medium alone to provide the blanks for absorbance readings. 1% FCS was 
used as opposed to normal medium because it was the planned medium to be 
used for future experiments. After overnight incubation, to allow the cells to 
recover from handling, an MTT assay was performed. (mean ± SD, of 8 data 
points/cell number) 
Within the steep linear portion of this relationship a small change in cell number 
produces the biggest change in optical density. Hence, cell viability assays 
using cells within that range are most accurate and sensitive to change. At high 
densities the MTT reaction is saturated and a plateau is obtained, whereas at 
very low cell numbers the signal is too small to determine differences 
accurately. 
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Cell monolayers were washed three times, and then treated with one of the 
three stimuli for the period of the experiment. At the end of each experiment, 
MTT 25pl (5mg/ml) was added to all wells and incubated in the dark at 37°C for 
90 minutes. During this stage, metabolising (live) cells precipitate the 
intracellular, purple, punctate formazan product. This precipitate was then 
solublised in 100pl MTT lysis buffer (10%w/v sodium dodecyl sulphate [SDS] in 
a solution of 50% (v/v) dimethyl formamide, DMF) which immediately lyses the 
cells, terminating the MTT reaction. After 16 hours at 37°C, the plates were read 
with an OPTImax microplate reader (Molecular Devices, California, USA) at 
wavelength of 562nm for quantification of the MTT metabolism. Controls were 
untreated cells (positive control), medium alone + treatment, and treated cells 
that had been lysed prior to MTT exposure (negative control). All MTT assay 
data points were in quadruplicate and expressed as mean +/- SD unless 
otherwise stated. Cell survival was expressed as a percentage of untreated 
controls (defined as 100% survival). 
2.7.6. Cell counting experiments 
Cells were again plated at 5x104/cm2 in 10cm dishes and incubated with the 
three stimuli. At the end of each experiment, non-adherent cells were collected, 
the plate washed and the remaining adherent cells trypsinised. All cells were 
pooled together, centrifuged (2000g for 5 minutes) and resuspended in 100 pI of 
DMEM/10% FCS. The cell aliquots were diluted 1: 1 with trypan blue and were 
examined microscopically to determine viability by trypan blue exclusion. Each 
value is the average of at least five fields on the haemocytometer. All assays 
were performed in triplicate plates. 
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2.7.7. Terminal deoxynucleotidyltransferase-mediated 
dNTP nick end labelling assay (TUNEL) 
DNA fragmentation in late apoptotic cells was confirmed by TUNEL using 
ApopTag Peroxidase In Situ Apoptosis Detection Kit (Intergen, Oxford, UK). 
Briefly, cells were plated in eight-well chamber slides and exposed to the 
apoptotic stimulus as described. Cells were fixed by adding paraformaldehyde 
(final concentration 4%) to each chamber for 20 minutes (room temperature), 
and then washed twice with cold PBS. The cells were then incubated with 
digoxigenin-labelled nucleotides in the presence of terminal 
deoxynucleotidyltransferase (TdT). Finally, digoxigenin labelled nucleotides 
were detected using an anti-digoxigenin antibody conjugated to peroxidase, and 
colour was developed using a diaminobenzidine (DAB) substrate which gave a 
brown stain when positive. TUNEL-positive cells were visualised by light 
microscopy. For the TUNEL experiments, Rat-1 fibroblasts exposed to SSP 
(200nM) for 2 hours were used as positive controls. 
2.7.8. Immunofluorescence staining 
Fetal MSC were plated at 5x104/cm2 in 8 well chamber slides and exposed to 
SSP or serum withdrawal for defined periods of time. Cell monolayers were 
then fixed in 4% paraformaldehyde for 10 minutes at room temperature, washed 
twice in PBS, permeabilised in 0.2% Triton X-100 for 10 min, washed once in 
PBS, blocked for 1 hour in 5% normal goat serum / 5% bovine serum albumin 
(in PBS) and then incubated overnight at 4°C with a 1: 200 dilution of defined 
antibodies: cytochrome c (BD Biosciences, Oxford, UK) or to the cleaved forms 
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of caspases 3,9 and 8 (Cell Signalling, Hitchin, U. K. ). Slides were washed 
three times in PBS followed by 30 minutes incubation with appropriate 
biotinylated secondary antibodies (Sigma-Aldrich) diluted 1: 100 in 1% BSA (in 
PBS). Detection of secondary antibodies was with diluted (1: 100) streptavidin- 
fluoresceine or streptavidin-TexasRed (Vector Laboratories Ltd. ). 
Immunostained cells were then washed three times in PBS and the nuclei 
counterstained with DAPI. Images were obtained using a Nikon, Eclipse E600 
fluorescence microscope. Additionally, for the staining of Fas receptor and 
FADD, untreated fetal MSC were used. Fas staining did not involve the 
permeabilisation step (with Triton X-100) as surface expression was important, 
but other steps were identical. Antibodies to Fas and FADD were obtained from 
BD Biosciences (Oxford, UK), and were used at dilutions of 1: 100. 
2.7.9. Immunoblotting 
At defined time points following exposure to apoptotic stimuli, cells were 
collected (by scraping), rinsed twice with cold PBS, and centrifuged. Cell pellets 
were then resuspended in 1% SDS (90°C) and heated for a further 5 minutes. 
Resulting lysates were centrifuged at 10,000g at 4°C for 5 minutes and the 
supernatant collected for western analysis. Protein concentrations were 
calculated by the BCA method (Pierce Chemical Co. ) by reference to a 
standard curve generated each time, Equal amounts (50pg) of protein were 
loaded onto 12% acrylamide gels and the resolved proteins were transferred 
onto polyvinylidine difluoride (PVDF) membranes (Immobilon, Millipore 
Corporation). Non-specific binding on PVDF membranes was blocked by 
incubation at room temperature for 1 hour in 5% milk (from non-fat dry milk 
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powder in PBS) containing 0.1% Tween 20 (PBST). Membranes were then 
incubated overnight at 4°C with primary antibody diluted 1: 1000 in PBST 
containing 5% milk, washed with PBST, and incubated for 1 hour at room 
temperature with a 1: 1000 dilution of horseradish peroxidase-conjugated 
secondary antibody (Amersham) in PBST containing 5% non-fat dry milk. After 
washing with PBST, detection was with enhanced chemiluminescence (ECL kit, 
Amersham). Primary antibodies to cleaved caspases 8,9,3, phosphorylated 
AKT (ser 473) and phosphorylated FKHR were obtained from Cell Signalling 
(Hitchin, U. K. ) with a-tubulin used as a loading control (Sigma-Aldrich). 
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CHAPTER 3 
OLIGODENDROCYTE 
DIFFERENTIATION OF FETAL MSC 
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3.1 Introduction 
The brain has a limited capacity for repair following injury or degeneration and, 
although endogenous neural stem cells (NSC) proliferate following injury they 
are inadequate to affect repair. This has led to considerable interest in whether 
exogenous stem cells could be used to repair the injured brain. Stem cells have 
now been isolated from most adult organs (Weissman, 2000; Gage et al, 1995; 
Poften, 1998; Watt, 1998; Alison & Sarraf, 1998; Pittenger et al, 1999). 
Originally, it was believed that such cells were limited in their differentiation 
potential to cells of the tissue from which they were derived. This concept has 
recently been challenged by research that demonstrates the potential of 
somatic cells of one tissue type to differentiate into another, a process referred 
to as transdifferentiation. For example, the data suggest NSC can give rise to 
blood and muscle (Bjornson et al, 1999), whilst bone marrow MSC can 
contribute to non mesoderm-derived tissues including liver, lung, gut and skin 
(Krause et al, 2001). 
Recent studies have indicated that MSC may have neurogenic potential both in 
vitro and in vivo and are thus attractive candidates for the study of neural cell 
replacement therapy. Indeed, a variety of in vitro approaches (Hermann et al, 
2006) using MSC have demonstrated the acquisition of the neural markers 
including exposure to growth factors and cytokines (Sanchez-Ramos et al, 
2000; Hermann et al, 2004), retinoids (Sanchez-Ramos et al, 2000; Cho et al, 
2005), reducing (Black & Woodbury, 2001; Woodbury et al, 2000; Jori et al, 
2005) and demethylating agents (Kohyama et al, 2001), compounds that 
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increase intracellular cAMP (Deng et al, 2001; Kim et al, 2005) and indeed co- 
culture with other neural cells (Bossolasco et al, 2005; Abouelfetouh et al, 
2004). None of these studies convincingly demonstrate the generation of 
maturing oligodendrocytes. 
In vivo work has provided data supporting neural potential of MSC in both 
animal models and in humans. In murine models of bone marrow 
transplantation, infused bone marrow cells migrate and integrate into the brain 
acquiring neuronal markers (Brazelton et al, 2000; Mezey et al, 2000). MSC 
have been used with success in the treatment of animal models of CNS 
diseases. In a murine model of the neurodegenerative Niemann Pick disease 
(sphingomyelinase deficiency), MSC engineered to express the deficient 
enzyme attenuated the disease process and donor-derived Purkinje neurones 
were identified (Jin et al, 2002). Recent human post mortem data examining 
women who had male-derived bone marrow transplantation showed donor- 
derived cerebellar Purkinje cells (Weimann et al, 2003a) and neurones, 
astrocytes and microglia within the hippocampus (Cogle et al, 2004) suggesting 
possible plasticity of bone marrow cells to brain lineages. These data supporting 
in vivo neural differentiation of bone marrow or purified MSC are controversial 
and some results can be explained by cell fusion between transplanted and 
host cells (Wells, 2002). Indeed, apparent donor-derived Purkinje cells following 
bone marrow transplantation described by Weimann et al. were later shown to 
result from this process (Weimann et al, 2003b). Others have suggested that 
an alternative explanation for the broader differentiation capacity of bone 
marrow is the presence of very rare populations of multipotent cells, and the 
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reports of multipotent adult progenitor cells (MAPC) perhaps adds weight to this 
argument (Reyes & Verfaillie, 2001; Jiang et al, 2002b). MAPC can be 
differentiated to mesodermal and endodermal tissues, and stimulated with 
growth factors to neurectodermal fates. With neural differentiation protocols, the 
majority of differentiated MAPC express neuronal neurofilament 200, with only 
11 % of cells expressing the mature oligodendrocyte marker myelin basic protein 
(MBP) on day 10 declining to 2% by day 22 (Jiang et al, 2003). Although these 
oligodendrocyte data are interesting, the low frequency of oligodendrocyte 
differentiation and decline in number over time would not make them a good 
model to study differentiation at present. Indeed there is no easily available 
source of human oligodendrocyte precursors for study or therapy although 
oligodendrocyte precursors have recently been isolated human fetal brain and 
adult subcortical white matter and used successfully to remyelinate shiverer 
mice (Windrem et al, 2004). 
To date, the majority of neural differentiation studies from bone marrow MSC 
have focused on the generation of neurones rather than oligodendrocytes and 
in the majority of studies described above, either oligodendrocyte markers were 
not found, or examined. An understanding of oligodendrocyte development and 
differentiation, particularly in a damaged brain environment would be essential 
for future cell therapy in many diseases including multiple sclerosis, stroke and 
newborn brain injury. In one of the few oligodendrocyte studies, murine bone 
marrow cells expressing GFP injected in a spinal cord demyelination model 
appeared to acquire the oligodendrocyte marker, myelin basic protein (Akiyama 
et al, 2002). These data are controversial and other studies demonstrate a 
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functional improvement after MSC injection in spinal injury models without 
demonstrable neural differentiation (Chopp et al, 2000). 
Our group has recently identified a population of MSC in the human fetus. They 
can be easily isolated from blood, bone marrow and liver. These fetal MSC are 
highly proliferative, and readily differentiate into mesoderm-derived tissues such 
as bone, cartilage, fat and muscle (Campagnoli et al, 2001; Chan et al, 2003). 
This present study describes for the first time, in vitro and in vivo 
oligodendrocyte differentiation of primary MSC isolated from fetal blood. 
3.2 Results 
3.2.1 Culture and properties of fetal MSC 
3.2.1.1 Isolation, culture and growth kinetics 
First trimester fetal blood was plated at 5x104 nucleated cells /cm2 on plastic 6 
well culture dishes in complete growth medium. With culture, an adherent layer 
of fibroblast-like cells became evident (Figure 3.01. ). Following removal of non- 
adherent cells after 48-72 hours culture, these colonies grew rapidly and 
became confluent after 8-10 days culture. 
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Figure 3.01. Culture of fetal MSC from first trimester fetal blood. Phase 
contrast micrographs demonstrating adherent cells seen underlying the non- 
adherent RBC and other cells early in the culture of fetal blood (A-D). Later, 
these cells rapidly proliferated forming fetal MSC colonies. Magnification x10 
(A, C, D) x20 (B). 
To establish the characteristics of fetal MSC, fetal blood samples (n= 30; 
median gestation 10+5 weeks, range 7+6-13+5; Table 3.01. ) were collected by 
our group and isolated and cultured as previously described. The cells were 
identified by their number, crown-rump length of the fetus from which they were 
derived, and their gender determined by XY FISH. 
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Fetus Gestation (weeks+daYs) Crown-Rump Length (mm) Gender 
#1 11+4 47 XY 
#2 13+5 76 XY 
#3 9+ 26 XX 
#4 +5 10+5 38 XX 
#5 10+3 35 XX 
#6 12+5 61 XY 
#7 11+3 46 XX 
#8 11 +6 51 XY 
#9 9+2 24 XX 
#10 10+5 38 XX 
#11 12+3 58 XY 
#12 10+6 40 XY 
#13 7+6 14 XX 
#14 12+3 58 XY 
#15 8+1 16 XX 
#16 11 +4 47 XX 
#17 8+4 18 XX 
#18 11 +5 48 XY 
#19 13+1 67 XY 
#20 10 29 XY 
#21 10+6 39 XY 
#22 9+2 24 XY 
#23 11 40 XX 
#24 10+1 30 XY 
#25 10+3 35 XY 
#26 7+6 14 XY 
#27 11+6 50 XX 
#28 9+5 28 XX 
#29 12 52 XX 
#30 9 22 XY 
Table 3.01. First trimester fetal blood samples. 
10 weeks and 5 days (10+5), range 7+6 - 13+5. All 
were performed on sample #22 (24XY), with key 
samples #18,23,24,27,29 and 30. 
Median gestation age was 
differentiation experiments 
experiments repeated on 
After 5-7 days colonies were trypsinised and expanded until confluent in large 
volume flasks. Adherent cells were passaged and counted in order to 
determine the population doubling time at each stage (as described in 2.2.5. ). 
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As well as being propagated, early-passage cells were stored in liquid nitrogen 
at 106 / MI in freezing medium for future use. Fetal MSC could be readily 
cultured in DMEM, 10% FCS for at least 40 passages. The growth kinetics, 
morphology and phenotype did not change significantly until passages 20-25 
with a doubling time of approximately 30 hours (Figure 3.02. ); this is in 
accordance with the published work of Campagnoli et al (Campagnoli et al, 
2001). After passage 25, cell growth slowed and cells became increasingly 
large (Figure 3.02. ). Cells cultured between 2 and 25 passages were used in 
all differentiation experiments. 
A 1o0 
90 
80 870 
60 
50 
40 
30 
20 
10 
0 
B 
rý 
i'-+. &.. 
Passage 2 
Passage Number 
.I "% 
,' ,1t ->-* 
Passage 40 
Figure 3.02. Doubling time of fetal MSC over time in culture. Doubling time 
remains steady until passages 20-25, and then steadily increases (A). Cell 
division completely ceased after passage 45. At later passages cells become 
larger (B) with a slowing in proliferation. The data presented is a representative 
experiment of the growth characteristics of fetal MSC from a single source 
(24XY) and graphical data expressed as mean ± SD (5 plates counted at each 
data point). 
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3.2.1.2 Fetal MSC had mesenchymal morphology and phenotype. 
Fetal MSC had characteristic fibroblast-like morphology. The immunophenotype 
of confluent adherent cells was assessed with a panel of antibodies (Table 
3.02. ). Naive, undifferentiated fetal MSC expressed markers including SH-2, SH-3, 
SH-4, and produced the extra-cellular matrix proteins laminin, fibronectin and 
vimentin (Figure 3.03. ). They did not express markers associated with 
haemopoietic or endothelial lineages and were consistently CD45-, CD34-, CD14-, 
CD31- and vWF negative. Undifferentiated fetal MSC expressed low levels of 
nestin, but did not express markers of mature neurons, oligodendrocytes or 
astrocytes. 
Antigen Reactivity 
CD45 - 
CD 14 - 
CD68 - 
CD29 + 
CD44 + 
CD34 - 
CD31 - 
CD 105 + 
CD 106 + 
SH-2 + 
SH-3 + 
SH-4 + 
Fibronectin + 
Laminin + 
Vimentin + 
Type I Collagen - 
HLA-DR - 
HLA Class / +/- 
Table 3.02. Immunophenotype of fetal MSC determined by 
immunocytochemistry. 
(+ = positive, -= negative, +/- = not consistent). 
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Figure 3.03. Undifferentiated fetal MSC morphology and phenotype. 
Undifferentiated fetal MSC have typical fibroblast-like morphology and have a 
phenotype similar to that described in other MSC. These fluorescence 
micrographs demonstrate positive staining (green) of undifferentiated fetal MSC 
for a series of markers known to be expressed on MSC, nuclei are 
counterstained with DAPI. Fetal MSC do not express markers associated with 
haemopoietic or endothelial differentiation. They are consistently CD45-, CD34- 
, CD14-, 
CD31- and vWF negative. Like adult-derived MSC, they express a 
large number of adhesion molecules including CD44, VCAM-1 and CD29 and 
in their undifferentiated state are positive for markers such as fibronectin (A), 
laminin (B; courtesy of Dr. K O'Donoghue, Imperial College, London), vimentin 
(C) and for mesenchymal markers such as SH-2 (D). SH-3 (E) and SH-4. 
(Campagnoli et al, 2001; Gotherstrom et al, 2004; In 't Anker et al, 2003a). 
Staining for undifferentiated MSC markers was repeated regularly over time in 
culture for all MSC cell sources. 
3.2.1.3 Multilineage potential of fetal MSC 
Fetal MSC underwent differentiation into adipocytes and bone using published 
protocols (Campagnoli et al, 2001) modified from work on adult-derived MSC 
(Figure 3.04. ). In addition, they have been driven to differentiate into desmin- 
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staining, multinucleated myotubes (Chan et al, 2006). This multi potentiality, 
along with their ability to self-renew, allows this population of cells to be defined 
as stem cells. 
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Figure 3.04. Multilineage potential of fetal MSC. Fetal MSC underwent 
adipogenic differentiation; cells demonstrate accumulation of lid vacuoles 
stained with Oil Red-O (A). Osteogenic differentiation was shown by the 
accumulation of insoluble bone deposits (B); the presence of hydroxyapitate 
crystals was confirmed by Von Kossa staining. Fetal MSC have also been 
previously induced to differentiate into cartilage, as shown by type II collagen 
staining (C; (Campagnoli et al, 2001)) and muscle with myotubes that stain 
positive (green) for desmin (D; courtesy of Dr J. Chan, Imperial College, 
London). 
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3.2.2 Oligodendrocyte differentiation of fetal MSC 
3.2.2.1 Differentiation of fetal MSC in `oligodendrocyte 
differentiation medium' 
3.2.2.1.1 Morphological changes 
Dramatic morphological changes occurred when fetal MSC were exposed to 
B104 conditioned medium with supplements. Within 10 days, over 50% of cells 
changed morphology to phase bright bipolar cells that resembled 
oligodendrocyte precursors. This effect was concentration-dependent, but there 
was increasing cell death in cultures with greater than 60% conditioned medium 
(Figure 3.05. ). For subsequent differentiation experiments, 40% conditioned 
medium was used (this is referred to as oligodendrocyte differentiation medium, 
ODM). The generation of bipolar cells in ODM was time-dependent as well, with 
the first bipolar cells becoming evident within 3-4 days with over 50% of cells 
bipolar by 1 week (Figure 3.06. ). 
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Figure 3.05. The acquisition of bipolar morphology was dependent on 
concentration of B104 conditioned medium. This graph shows the 
proportion of phase bright bipolar cells after 10 days of exposure to B104 
conditioned medium. The bipolar cells resembled oligodendrocyte precursors. 
Increasing cell death occurred in >60% conditioned medium (data expressed 
as mean ± SD, n=5). Formal time course experiments were repeated on four 
occasions. 
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Figure 3.06. The acquisition of bipolar morphology occurred in a time- 
dependent manner over the first week. In 40% conditioned medium 
approximately 50% of cells had bipolar morphology within 1 week (Data 
expressed as mean ± SD, n=5 for each data point). This experiment was 
repeated twice. 
After the initial morphological change to bipolar cells, the morphology of cells in 
time-course experiments, up to 28 days, became increasingly complex over 
time, with cells becoming multipolar and branched, resembling more mature 
oligodendrocytes (Figure 3.07. ). 
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Figure 3.07. Fetal MSC differentiate into complex multipolar cells over 4 
weeks. This figure shows the marked morphological changes that occur in fetal 
MSC after exposure to B104 conditioned medium (A, B). >50% fetal MSC 
become phase bright and bipolar between 4-7 days, with later maturation into 
multi-processed cells, resembling mature post-mitotic oligodendrocytes (C). 
3.2.2.1.2 Exposure to differentiation medium results in acquisition of 
neural progenitor phenotype 
Exposure to B104 conditioned medium led to a concentration dependent 
change in cell morphology, and this was associated with a dramatic increase in 
the expression of the neural progenitor marker, nestin. The upregulation of 
nestin was dependent on the concentration of B104 conditioned medium 
(Figure 3.08. ). As described earlier, 40% conditioned medium (ODM) was used 
for future experiments. 
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Figure 3.08. Nestin expression after 4 days exposure to B104 conditioned 
medium. Dramatic morphological changes are seen with bipolar cells becoming 
strongly nestin+ (brown). There was considerable cell death above 40% B104 
conditioned medium. 
Following exposure in vitro to oligodendrocyte differentiation medium (ODM), 
dramatic morphological change was seen within 2-4 days: undifferentiated 
fibroblast-like fetal MSC acquired a bipolar phenotype with phase-bright nuclei 
and strongly resembled oligodendrocyte precursor cells, OPC. After 2 days 
89% (±7%) strongly expressed the neural progenitor marker nestin, with 
upregulation confirmed at both the protein and mRNA (Figure 3.09) level. 
Other markers of early neural development including Notch 1 and Musashi 
were also upregulated (Figure 3.09). Prolonged exposure to ODM resulted in 
an increase in the morphological complexity of fetal MSC and an associated 
reduction in nestin expression. 
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Figure 3.09. Induction of nestin and neural progenitor transcripts. There is 
the induction of nestin and neural progenitor transcripts early after exposure to 
`oligodendrocyte differentiation medium', ODM. Immunocytochemistry 
demonstrated low levels of nestin expression in undifferentiated cells, after 
exposure to ODM expression was markedly upregulated with a large increase 
on day 2; this expression subsequently declined with differentiation (A). In 
these experiments, nestin protein is labelled in green, with the nuclei 
counterstained in blue with DAPI. The increase in nestin was mirrored by an 
increase in nestin mRNA at a similar time. A representative RT-PCR time- 
course demonstrated in panel B. Similar time-course experiments 
demonstrating nestin upregulation were repeated more than 5 times. RT-PCR 
demonstrated that other neural progenitor markers, such as Notch-1 and 
Musashi, are also upregulated early, although the time course is different (C). 
GAPDH was used as a loading control in the PCR reactions. 
3.2.2.1.3 Oligodendrocyte-specific transcripts are appropriately 
upregulated over time through differentiation 
RT-PCR analysis was carried out on fetal MSC samples obtained from time- 
course experiments following exposure to ODM for up to 2 weeks. Three 
transcription factors known to be important in oligodendrocyte specification, 
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Oligl, Olig2 and NKx2.2, were investigated along with CNPase and the mature 
oligodendrocyte marker myelin oligodendrocyte glycoprotein (MOG). An 
increase in Olig1, OIig2 and NKx2.2 was observed within 2-4 days and, 
although CNPase mRNA was expressed in undifferentiated MSC, this 
increased early in the differentiation process. MOG expression appeared much 
later at 9 days (Figure 3.10. ); however, at the protein level myelin proteins 
could not be detected by immunocytochemical staining at this time or later. In 
these PCR experiments cDNA from fetal human brain was used as positive 
controls, with negative controls being reactions where the cDNA was omitted 
(to rule out contamination) and where reverse transcriptase was omitted from 
the prior reaction (to rule out DNA contamination). All PCR products were run 
with a standard DNA ladder to ensure products were the expected size, and in 
several experiments products were sequenced. 
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Figure 3.10. Induction of oligodendrocyte-specific gene transcripts. The 
induction of oligodendrocyte-specific gene transcripts in fetal MSC treated with 
oligodendrocyte differentiation medium (ODM) in an appropriate temporal 
pattern. As well as the early upregulation of nestin, RT-PCR analysis 
demonstrates increased mRNA expression of three transcription factors 
important in oligodendrocyte specification Oligl, Olig2 (A) and NKx2.2 (B; 
arrow). Although there is a low baseline level of CNPase mRNA in 
undifferentiated fetal MSC, this is upregulated over time. The transcription of 
the mature oligodendrocyte myelin protein, MOG, begins much later on day 9. 
In these experiments GAPDH is used as a loading control. These experiments 
were repeated three times. 
3.2.2.1.4 Analysis of protein expression of fetal MSC undergoing 
differentiation 
Undifferentiated cells did not express specific early or late markers of 
oligodendrocyte differentiation, but did express the PDGFra (Figure 3.11. ) and 
low levels of nestin and vimentin. The PDGFra thus was not helpful in our 
system to define oligodendrocytes at immature stages of development. 
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Figure 3.11. Undifferentiated fetal MSC express the PDGF receptor a 
(PDGFra). Undifferentiated fetal MSC express PDGFra demonstrated by 
fluorescence immunocytochemistry (A, PDGFra stained green, nuclei 
counterstained with DAPI). B shows an RT-PCR time course of PDGFra 
expression. It confirmed expression of PDGFra in undifferentiated cells (DO, B), 
with some upregulation at D2. The negative control (-ve) in B, was a reaction 
where the cDNA was omitted and rules out contamination, GAPDH was used 
as a loading control. This experiment was repeated twice. As naive fetal MSC 
expressed PDGFra, this therefore was not a useful marker to assess the 
development of oligodendrocyte phenotype from naive cells. 
Cells undergoing differentiation were also assayed for the expression of A2B5, 
NG2 and DM20-PLP as early markers of the oligodendrocyte lineage, with 
CNPase, 04 and GaIC defining more mature cells. Staining techniques were 
optimised using primary rat oligodendrocyte precursors (courtesy of Dr. J. 
Beesley, Imperial College, London, Figure 3.12. ) which mature over time in 
culture, or the CG4 oligodendrocyte cell line grown on 8 well chamber slides as 
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previously discussed. In later experiments, these cells were also used as 
positive controls. 
A B C 
Figure 3.12. The maturation stage of oligodendrocytes can be defined by 
a series of phenotypic markers. The lineage-specific staining protocols were 
optimised on primary rat oligodendrocyte precursors and CG4 cells. This figure 
shows the characteristic increase in cell complexity through oligodendrocyte 
maturation (in CG4 cells) - from the dividing bipolar oligodendrocyte precursor 
(stained with A2B5; A), though an intermediate stage (stained with 04; B) to 
the more mature highly elaborate mature oligodendrocyte (stained with GaIC; 
C). The nuclei are counterstained with DAPI. 
Bipolar cells induced by exposure of fetal MSC to ODM expressed the early 
oligodendrocyte marker A2B5, and DM20 and NG2 were expressed in large 
proportions (66 and 51% of MSC respectively). After 1 week in ODM, the 
emergence of 04 (22%) and GaIC expression (32%) was observed in more 
complex, multipolar cells at later time points. Expression levels of both 
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vimentin, and the oligodendrocyte marker CNPase, (detected by both 
immunocytochemistry and western blotting) also markedly increased over the 
first week of differentiation ((Figures 3.13. - 3.18. ) 
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Figure 3.13. Acquisition of oligodendrocyte markers with exposure to 
ODM over one week. Following exposure to ODM, the early marker DM20 is 
upregulated, with the later acquisition of other lineage-specific markers over 
time. Maturation-specific oligodendrocyte markers (04, GaIC) appear later and 
are expressed on multipolar cells. Graphical data are expressed as the mean 
+/- SD of a representative experiment (n=4 at each data point). Time course 
experiments quantifying acquisition of oligodendrocyte markers were performed 
on three occasions. 
Overall, these in vitro data suggest that circulating human fetal MSC exposed 
to ODM undergo morphological changes consistent with differentiation along 
the oligodendrocyte lineage. Our results also indicate that these MSC initially 
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give rise to cells with phenotypic characteristics of oligodendrocyte precursors 
that differentiate into more mature oligodendrocytes with time in culture. 
Figure 3.14. The oligodendrocyte marker A2B5 is upregulated in bipolar 
cells after exposure to ODM. Naive, undifferentiated fetal MSC do not 
express A2B5. Following exposure to ODM, bipolar cells resembling 
oligodendrocyte precursors acquire this marker. A2B5 is labelled with FITC 
(green), the nuclei are counterstained with DAPI. The upregulation of A2B5 was 
confirmed in at least eight experiments although the proportion of positive cells 
was variable. Upper panels magnification x10, lower panels x50. 
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Figure 3.15. Oligodendrocyte markers NG2 and PLP/DM20 are 
upregulated early in differentiation. There is an increase in the expression of 
NG2 (stained with HRP/DAB system, brown), an early oligodendrocyte marker, 
over the first week in ODM with a further increase in more complex cells over a 
further week (A). In A the nuclei are counterstained with haematoxylin. 
Undifferentiated cells do not express DM20/PLP, but over the first week cells 
are clearly identified expressing the oligodendrocyte protein, negative cells are 
also clearly seen (B). The primary antibody utilised in B, reacts with both PLP 
and its truncated form DM20. 
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Figure 3.16. CNPase and vimentin expression increases with exposure to 
ODM. There was an increase in CNPase expression with maturation and the 
development of morphological complexity. Panel A demonstrates an increase 
in CNPase, demonstrated by immunocytochemistry, particularly on the more 
processed cells. In these experiments the rat oligodendrocyte cell line, CG4, or 
primary rat oligodendrocytes were used as positive controls. Negative controls 
were identical experiments where the primary antibody was omitted, or 
replaced by an isotype control antibody. Upregulation of vimentin and the 
oligodendrocyte marker, CNPase was confirmed by western blotting. The 
positive controls for these experiments were CG4 cells. The small difference in 
molecular weight of the positive control in the CNPase blot (B) is due to minor 
species differences in the protein between rat (47.2kD) and human cells 
(47.5kD). Interestingly there appears to be a small amount of CNPase 
expression in undifferentiated cells, which is in keeping with the RT-PCR data. 
These data were consistent in five repeat experiments. 
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Figure 3.17. The later oligodendrocyte marker 04 is upregulated in highly 
processed cells. 04 expression is not evident in naive cells (A), and increases 
by immunocytochemistry late in the time-course of ODM exposure (B, day 15). 
04 expression is evident in multipolar cells (inset). The nuclei in these 
experiments are counterstained with haematoxylin; cells negative for 04 remain 
clearly seen (arrow). 
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Figure 3.18. GaIC expression is seen to increase over time with exposure 
to ODM. Immunocytochemistry experiments demonstrate undifferentiated fetal 
MSC do not express GaIC. Expression increases over the time course of the 
experiment (7-14 days, A). Interestingly the expression pattern (brown) is 
particularly around the cell body rather than the processes, although a few cells 
have more elaborate patterns of expression, B. Positive controls in these 
experiments were differentiated primary rat oligodendrocytes or CG4 cells (not 
shown). The upregulation of GaIC was confirmed in three repeat experiments. 
Importantly, these data demonstrate that the differentiation of fetal MSC into 
oligodendrocytes is an ordered process with the acquisition of neural progenitor 
markers followed by the upregulation of lineage-specific transcription factors 
(Oligl, 2 and NKx2.2) and the expression of oligodendrocyte-specific antigens 
(DM20,04 and GaIC) in the correct developmental sequence; indeed, by nine 
days of culture we observed an increase in transcription of mature myelin 
genes in cultures containing large numbers of multi-processed cells resembling 
mature oligodendrocytes. 
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3.2.2.2 Effects of conditioned medium from other neural cells 
To determine whether the morphological and phenotypic changes that were 
observed with ODM were related to the B104 conditioned medium, similar 
experiments exposing fetal MSC to conditioned medium prepared in the same 
way from two further cell types (SHSY-5Y and primary rat astrocytes) were 
undertaken. In these experiments there was no overt change in cellular 
morphology and in time-courses up to 2 weeks, and in dose-response 
experiments there were no cells identified that had acquired oligodendrocyte 
(A2B5, DM20, GaIC), astrocyte (GFAP) or neuronal (NFM, NeuN, MAP2) 
markers. 
3.2.3 Generation of a fetal MSC clone 
To exclude the possibility of a rare neural cell contaminant in our fetal MSC 
cultures, the findings were confirmed using clonal populations of stem cells and 
both mesodermal and neuroectodermal differentiation from a single fetal MSC 
clone was demonstrated. 
eGFP expression was used for in vivo cell tracking and proviral integration site 
analysis was used to prove clonality. To express eGFP, cells were infected with 
a HIV-1 based lentiviral vector (Demaison et al, 2002) (Figure 2.02. ) with low 
multiplicity of infection (MOI = 1-18). 
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Figure 3.19. Fetal MSC are readily transduced with a lentiviral vector to 
express eGFP. There was a dose-dependent increase in eGFP expression in 
fetal MSC following a single infection with the increasing MOI of retroviral 
vector. At MOI =1 only 6.2% expressed eGFP (A), increasing to 44% with MOI 
=5 (B), and 80% with MOI = 10 (C). At MOI = 18 there was increasing cell 
death. In panels A-C the nuclei are counterstained with DAPI. Quantification of 
eGFP expression by direct fluorescence microscopy is shown in D, results are 
expressed as mean ± SD (n=5). The quantification of eGFP transduction was 
performed in one experiment by fluorescence microscopy and confirmed by 
flow cytometry. 
Transduction efficiency was also confirmed by flow cytometry. The eGFP 
expression determined this way agreed with our microscopy. With MOI = 10, 
80% became eGFP+ with a single infection (Figure 3.19. ). For in vivo studies, 
cultured cells were enriched by fluorescence activated cell sorting to 98% 
eGFP+ with a single sort (Figure 3.20. ). 
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Figure 3.20. Fetal MSC can be FACS sorted to further enrich the eGFP 
fraction. With MOI = 10, nearly 80% of cells expressed eGFP with a single 
infection (A). This population of cells was FACS sorted to 98% purity (B, C) with 
a single step and these eGFP+ cells used for future in vivo experiments. 
Cells with very high eGFP expression were gated out to minimise the number 
of cells with multiple viral integration sites. eGFP+ cells could be expanded in 
culture without the loss of eGFP expression for future experiments (data not 
shown). 
Attempts at culturing single eGFP+ cells by limiting dilution, or by micropipette- 
aided single cell selection did not yield clonal populations either when cultured 
in complete medium or in conditioned medium from healthy fetal MSC cultures. 
In these experiments single cells were visible and survived for several days 
without division. Clones were eventually obtained by growing single male 
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eGFP+ cells on a feeder layer of senescent female-derived fetal MSC grown in 
DMEM / 10% fetal calf serum (FCS). Wells with single male eGFP+ cells were 
obtained by limiting dilution and were initially cultured in 96 well plates and then 
expanded through 24,12 and finally to 6 well plates. When setting up the 
expansion of clones, wells were identified with a single eGFP+ cell by 
examining the plate the day after seeding with an inverted fluorescence 
microscope. 
Interestingly, analysis of the plates used in limiting dilution experiments 
demonstrated that eGFP+ colonies were generated in all wells (n=32 wells / per 
cell number) where, on average, >5 cells were plated (Figure 3.21. ). 
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Figure 3.21. eGFP colonies expanded in wells with a senescent fetal MSC 
feeder layer. In one experiment, eGFP+ cells were plated in increasing 
dilutions (n=32 wells / dilution). All wells where on average >5 GFP+ cells were 
seeded generated GFP+ colonies. To be confident of generating populations 
from a single cell, wells with on average less than 1 cell were examined the day 
after seeding and marked if only one eGFP+ cell was visible. Over time 
resulting eGFP+ colonies from single cells were expanded and clonality proven 
by Southern analysis (Figure 3.24. A). 
All cells from the resulting clones were eGFP+ (confirmed by fluorescence 
microscopy) and expressed a male karyotype (XY) with no evidence of male to 
female cell fusion by human XY chromosome FISH (Figure 3.22. ). 
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Figure 3.22. The cell clone was confirmed to have male genotype by FISH. 
Clonal cell populations were confirmed to be male by FISH for human X (red) 
and Y (green). Male cells therefore contained a single red and a single green 
signal. There was no evidence of multiple female signals indicating cell fusion 
with the senescent feeder layer (female fetal MSC). All cells of the clone 
strongly expressed eGFP (not shown). 
After 6 weeks culture and expansion, Southern analysis of digested genomic 
DNA from a transfected eGFP+ clone (derived from a single fetal MSC) 
demonstrated a single integration site (Figure 3.23. A), confirming clonality. 
3.2.3.1 A clonal population of fetal MSC can give rise to at least 
2 lineages 
To determine whether clonal fetal MSC could undergo oligodendrocyte and 
mesodermal differentiation, cells were exposed to both oligodendrocyte 
differentiation medium and differentiation medium for bone. The clonally- 
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derived population gave rise to oligodendrocyte-like cells with early expression 
of nestin, A2B5 on bipolar cells and the acquisition of CNPase and GaIC at 
later time points (Figure 3.23. ). The clone was also differentiated into bone 
confirmed by Von Kossa staining (Figure 3.23. ). 
D B C 
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Figure 3.23. Differentiation of a fetal MSC clone. A clone with a single 
proviral integration site was expanded, and clonality confirmed by DNA analysis 
demonstrating a single integration site (A). The dual developmental potential of 
this clone was demonstrated, in a single experiment, by acquisition of nestin 
and then oligodendrocyte markers A2B5, CNPase and GaIC following exposure 
to ODM (B), or bone differentiation confirmed by Von Kossa staining (C) 
following exposure to bone differentiation medium (10-8M dexamethasone, 
0.2 mM ascorbic acid, and 10 mM ß-glycerophosphate). 
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3.2.4 Oligodendrocyte differentiation of fetal MSC - 
in vivo work 
3.2.4.1 Introduction 
The encouraging in vitro results suggest fetal MSC can respond to external 
signals and differentiate into cells with oligodendrocyte morphology and 
phenotype. If fetal MSC are to be considered for cell therapy, their 
differentiation must be explored in an in vivo model. In this study, fetal MSC 
were injected into the brains of embryonic mice. The timing of injection 
(E14/15) was chosen as this is a point in brain development of rapid 
oligodendrocyte precursor proliferation and differentiation, before myelination. 
At this time the injected cells will be exposed to factors important in this lineage 
development. Initial experiments were designed to develop methods to identify 
injected cells. Subsequent longer term experiments will determine cell fate. 
3.2.4.2 Cell Tracking 
3.2.4.2.1 Haematoxylin and eosin 
Injected Fetal MSC can be identified by haematoxylin and eosin (H&E) staining 
Every tenth slide was examined in all embryos studied. No obvious needle 
tracts were seen. Following injection, fetal MSC could be clearly identified in the 
cerebral ventricular system, and these cells aggregated over their first 72 hrs in 
vivo (Figure 3.24. ). Fetal MSC could be easily identified whilst in the ventricle 
but could not be easily identified by H&E staining alone at later time points. 
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Figure 3.24. Identification of injected fetal MSC by microscopy of H&E 
stained tissue sections. An aggregate of injected cells can be identified using 
H&E staining in the lateral ventricle of an injected fetus - in this case the embryo 
was sacrificed 48 hours after injection (A). Panel (B) shows this aggregate 
(arrow) at high power magnification (x60 objective). Such injected cells were 
later confirmed as human using methods described below. 
3.2.4.2.2 BrdU incorporation 
3.2.4.2.2.1 In vitro BrdU labelling 
Fetal MSC were labelled with BrdU in vitro, and this labelling used for in vivo 
cell tracking. The incorporation of BrdU was determined in vitro following 
labelling in normal growth medium (DMEM, 10% FCS). Cells were pulse 
labelled for 24 hours with 10mM BrdU. Using immunocytochemistry with an 
anti-BrdU antibody, about 50% of cells were strongly labelled and staining was 
optimised for both colorimetric and fluorescence detection methods (Figure 
3.25. ). 
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Figure 3.25. BrdU incorporation into fetal MSC in vitro. Cells were pulse 
labelled for 24 hours with 10mM BrdU. Detection methods were optimised for 
fluorescence (A) and light microscopy (B). 
3.2.4.2.2.2 In vivo tracking of BrdU labelled fetal MSC 
After identification of areas of interest using H&E staining, adjacent sections 
were stained for BrdU incorporation. Similar BrdU labelling of stem cells has 
been used in a number of published transplantation studies (Reubinoff et al, 
2001). In my experiments, staining clearly identified injected cells both with 
fluorescence and light microscopy techniques. 
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Figure 3.26. Injected cells can be identified by BrdU incorporation after 
labelling in vitro. Examples of positive BrdU staining used to identify injected 
cells 2 days after injection. Colorimetric method identifying BrdU labelled cells 
within the murine brain parenchyma (A). BrdU labelled fetal MSC could also be 
clearly seen using a fluorescence detection method (FITC, green Bi). The 
murine cells in the cerebral ventricle wall can be clearly seen when the nuclei 
are counterstained blue with DAPI (Bii). Similar experiments were performed 
three times. 
BrdU incorporation, as described, although good for visualising injected cells 
(Figure 3.26. ) did however profoundly change the morphology of cultured fetal 
MSC. Cells became large and their doubling time was lengthened considerably. 
This led me to be concerned that the BrdU may affect other cell properties such 
as differentiation and so this method of cell tracking was not routinely used in 
later longer term in vivo experiments. Interestingly the observation that BrdU 
changes the biological characteristics of MSC is demonstrated in a recent paper 
where prolonged BrdU exposure actually increases the neural differentiation of 
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human bone marrow-derived stem cells in co-culture with neural stem cells and 
after transplantation into the adult rat brain (Qu et al, 2004). 
3.2.4.2.3 Anti-human antibodies 
Two human-specific antibodies were studied for cell tracking in vivo: anti-human 
ribonuclear protein, and anti-human vimentin. The anti-human ribonuclear 
protein antibody has been used successfully in a previous study tracking human 
ES-derived neural progenitors injected into the newborn murine brain (Reubinoff 
et al, 2001). This antibody stained the nuclei of human fetal MSC intensely in 
vitro (Figure 3.27. ), but in vivo produced high levels of background and thus 
was not specific (Figure 3.28. A). 
Figure 3.27. Anti-human antibodies were used to track injected cells. This 
fluorescence micrograph demonstrates staining of cultured fetal MSC with 
antibodies to human ribonuclear protein (detected with FITC secondary 
antibody, green) and vimentin (detected with Texas Red). 
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In fact, this antibody was subsequently tested in vitro with a co-culture of equal 
numbers of human fetal MSC and rodent-derived oligodendrocyte precursors 
(rat). The cells could be identified by their very different morphologies and the 
anti-human ribonuclear protein antibody stained the nuclei of both human and 
rodent populations (Figure 3.28. B). 1 therefore did not use this antibody for cell 
tracking in my experiments. 
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Figure 3.28. Anti-ribonuclear protein antibody staining. Aggregates of 
injected human cells in vivo (orange arrow, A) stained with this antibody (FITC 
conjugated secondary antibody, staining green). Unfortunately, in three 
separate experiments, there was high background staining of the murine tissue 
too (white arrow, A) so this antibody was not useful for cell tracking. A staining 
experiment with both cultured bipolar rat primary oligodendrocytes (white arrow, 
B) and human fetal MSC (orange arrow, B) plated together confirmed this 
antibody was not human specific. The different morphology of primary 
oligodendrocyte precursors and fetal MSC allowed direct comparison of 
staining. 
'No 
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The anti-human vimentin antibody however stained fetal MSC brilliantly in vitro 
(Figure 3.29. ), and clearly identified human injected cells in the rodent brain 
Figure 3.29. Anti-human vimentin stains fetal MSC. Intense vimentin staining 
(green) was observed in vitro, both in naive and differentiated fetal MSC. This 
antibody was therefore evaluated for defining injected human cells in vivo. 
Vimentin staining was strong and consistent and used in multiple experiments. 
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Figure 3.30. Anti-human vimentin antibody can be used to track human 
cells in the mouse brain. (Ai) clearly demonstrates an aggregate of injected 
cells within the cerebral ventricle (nuclei are stained blue with DAPI). Human- 
specific vimentin antibody (stained green, Aii) highlights the injected cells with 
little background on mouse tissue. Panel (Bi) demonstrates fetal MSC within the 
murine brain parenchyma stained with anti-human vimentin (green) with little 
background. Bii is the H&E staining of an adjacent section. 
3.2.4.2.4 Human-specific FISH 
FISH for human X and Y chromosomes is a sensitive and specific way of 
demonstrating human cells in transplanted tissue. After optimising this method, 
human cells could clearly be identified in the mouse brain with no background in 
the mouse tissue (Figure 3.31. ). 
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Figure 3.31. Human XY FISH can detect human injected human cells. In the 
left panel is an H&E stained section demonstrating a `ball' of injected cells. FISH 
of an adjacent section show cells with a green signal (Y chromosome) and a 
red/orange signal (X chromosome) indicating human male cells. 
3.2.4.2.5 eGFP expression 
Fetal MSC were transduced with high efficiency with an HIV-based lentiviral 
vector as previously described in 3.3.1.5. and then sorted by flow cytometry to 
express eGFP in >98% of cells (Figure 3.20. ). eGFP could then be used to 
visualise injected human cells directly by fluorescence microscopy (in both 
frozen and paraffin sections) or by immunohistochemistry using anti-GFP 
antibodies (Figure 3.32. ). eGFP expression in surviving cells was not lost over 
time in vivo. 
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Figure 3.32. eGFP expression was used to track injected cells in vivo. 
eGFP was easily visualised directly with fluorescence microscopy in both 
paraffin and frozen sections and used in the majority of in vivo experments. (A) 
demonstrates eGFP+ fetal MSC in the lateral ventricle immediately after 
injection. Nuclei are counterstained with DAPI (paraffin section). eGFP 
expression remains over time in vivo. (B) is a paraffin section of the brain four 
weeks after injection demonstrating easily visible eGFP+ cells adjacent to 
murine brain parenchyma. 
3.2.4.3 Fate of naive fetal MSC in the developing murine brain 
To explore oligodendrocyte differentiation of fetal MSC in vivo, we employed an 
embryonic mouse model of brain development. eGFP-labelled fetal MSC were 
injected into the cerebral ventricle of embryonic day 15 (E15) mouse fetuses in 
utero. In initial experiments, undifferentiated early passage (<15) fetal MSC 
were injected. The fate of transplanted cells was examined immediately 
following injection and at subsequent time points up to 1 month. Injected cells 
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were identified as described by three methods: eGFP visualisation, either 
directly or using specific antibodies, human-specific FISH or with the aid of 
human-specific antibodies. For in utero transplantation experiments, fetal MSC 
were injected into the left frontal horn of the lateral ventricle and cell survival, 
morphology, migration and phenotype were examined. Immediately following 
transplantation, naive fetal MSC were distributed widely throughout the 
ventricular system (Figures 3.33. and 3.34. ). Human cells were easily identified 
using eGFP and Human XY FISH and were negative for nestin, neuronal and 
oligodendrocyte markers (Figures 3.33. and 3.34. ). 
B 
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Figure 3.33. Fetal MSC were distributed in the ventricular system after 
injection. Immediately following injection fetal MSC were easily identified using 
eGFP (A, B, C; green) with fluorescence microscopy. Injected cells were 
negative for neural markers. (B) demonstrates eGFP cells in the cerebral 
ventricle (green), this section has been double labelled with the neuronal 
marker ß11I tubulin (red) which stains the murine neurons but injected cells are 
negative. (C) is stained for NSE (red), with the eGFP+ fetal MSC again negative. 
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Figure 3.34. Immediately following injection fetal MSC were negative for 
oligodendrocyte markers. (A) demonstrates eGFP+ (green) fetal MSC within 
the cerebral ventricle immediately following injection. This section is stained 
with an antibody that recognizes both human and murine CNPase (red) - both fetal MSC and the host immature brain parenchyma are negative. Nuclei are 
counterstained with DAPI. In this experiment P14 murine brain was used as a 
positive control (Bi, cerebellar section) with beautiful CNPase staining (red). 
CNPase staining was also optimised using for light microscopy using 
horseradish peroxidase conjugated secondary antibody and detection with DAB 
(Bii, brown). Injected cells were also negative for the early oligodendrocyte 
marker, A2B5 and myelin basic protein (MBP), again postnatal murine brain and 
human postmortem brain sections were used as positive controls. Five animals 
were studied at this time point. 
By 48 - 96 hours, fetal MSC had formed aggregates within the cerebral 
ventricles, with cells abutting and becoming continuous with the ventricular wall 
(Figure 3.35. ). Cells at this stage strongly expressed vimentin, but had acquired 
no other phenotypic markers consistent with neural differentiation. 
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Figure 3.35. In utero transplantation and in vivo integration of human fetal 
MSC. By E19 (4 days post injection), human cells had formed aggregates in the 
cerebral ventricle (A) which later became continuous with the ventricular wall 
(B, C). Human cells at this stage could be identified with human specific XY 
FISH (B) and by eGFP expression (C). 
Beyond 5 days, no fetal MSC were identified within the ventricles but were 
clearly detectable within the brain parenchyma suggesting migration (Figures 
3.36. - 3.38. ). Beyond this time, cells stained strongly for vimentin with 
increasing numbers becoming strongly nestin-positive (Figure 3.38. ). By 5 days 
after injection human fetal MSC had begun to develop extended processes and 
appeared to integrate into the developing brain tissue. 
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Figure 3.36.5 days following injection fetal MSC are clearly seen in the 
brain parenchyma. Panel (A) shows fetal MSC (stained with anti-human 
vimentin, brown) in the brain parenchyma adjacent to the ventricle. The choroid 
plexus is seen within the ventricular cavity. (B) demonstrates a vimentin positive 
(brown) injected cell developing processes with neural morphology and 
appearing integrated within the brain. These sections are counterstained with 
H&E. 
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Figure 3.37.5 days following injection fetal MSC are clearly seen in the 
brain parenchyma. The panel (A) shows sections show fetal MSC (eGFP+, 
green) in the brain parenchyma adjacent to the ventricular cavity 5 days after 
injection. Nuclei are counterstained with DAPI. In the lower panel (B) human XY 
FISH has been used to identify human cells in the murine brain. Five animals 
were studied at this timepoint. 
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Figure 3.38.5 days following injection fetal MSC became processed and 
many began to strongly express nestin and vimentin. (A) demonstrates 
eGFP+ fetal MSC (green) in the murine brain parenchyma 5 days after injection. 
This section is stained for nestin (red); eGFP positive cells can be seen strongly 
expressing nestin (arrows and inset image). Panel (B) demonstrates the 
morphology at this time and shows extended processes that stain for vimentin 
(green). Of note in (B), human Y chromosome FISH was performed as well and 
confirms the vimentin positive cells are indeed human (Y chromosome 
hybridised with red fluorochrome, arrows). 
By postnatal day 14 (19 days after injection), the majority of eGFP+ cells still 
appeared healthy and were located adjacent to the frontal cortex of the brain. 
These cells were now strongly vimentin positive and the majority had become 
strongly nestin positive (Figure 3.39. ). 
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Figure 3.39. At P14 fetal MSC are visualised close to the frontal cortex and 
strongly express nestin. Panel (A) shows that eGFP+ (green) fetal MSC are 
present 19 days post injection (P14) close to the frontal cortex in the murine 
brain parenchyma. Nuclei are counterstained with DAPI. These cells now 
strongly stain for human nestin (red, B) and have processes that run parallel to 
the brain surface. 
Exhaustive analysis of oligodendrocyte markers (A2B5, NG2, CNPase, MBP) at 
this time point (P14), did not demonstrate widespread differentiation, and 
identified very few eGFP+ cells that stained for CNPase (< 0.2% of eGFP* cells, 
Figure 3.40. ) and no cells expressed the mature oligodendrocyte marker, MBP 
Significantly, no mature neuronal (MAP2,8111 tubulin, neurofilament M) or 
astrocyte (GFAP) markers could be detected in these injected human cells. 
Again both post-mortem human brain sections and P14 murine brain were used 
as positive controls for the neural markers (Figure 3.41. ). 
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Figure 3.40. Occasional eGFP expressing fetal MSC that expressed 
CNPase at P14. eGFP+ cells (green) could be identified 19 days post injection 
(A). Sections were stained also for neural markers. CNPase staining (red) is 
demonstrated in (B), with the overlay in (C). There are occasional double 
labelled cells seen with yellow cytosol (D, arrows) indicating the acquisition of 
CNPase. In 10 sections (5 fields/section) the proportion of CNPase positive 
cells was <0.2%. There was no MBP staining, or staining indicating neuronal or 
astrocyte differentiation. Three animals survived for analysis at this timepoint. 
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Figure 3.41. Murine brain positive controls for mature oligodendrocyte 
markers. For immuno histochemistry for neural markers both murine P14 and 
human brain sections were used (fresh frozen and paraffin embedded). This 
figure shows CNPase staining (green, A) and MBP staining (red, B) of P14 
murine cerebellum. This staining was consistent in multiple staining 
experiments. 
Examination of murine brains at P28 (33 days post injection) failed to identify 
injected cells in all but one (4/5) animals. In all animals, every 5th section was 
examined for injected cells by H&E, eGFP expression and using anti-human 
vimentin. In all brains small cysts were evident in the subcortical white matter. 
Sections from the single brain where cells were identified are shown in Figure 
3.42. In this brain, eGFP+ cells can be identified in the brain with disrupted 
architecture and cyst formation. Several of the cells had apoptotic morphology 
with cytoplasmic retraction and pyknotic nuclei. In addition there were small 
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host mononuclear cells visible in the adjacent parenchyma and within the cysts. 
No injected cells were identified at this time point that stained for mature neural 
markers. 
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Figure 3.42. Section of murine brain at P28 (33 days post injection). 
Injected cells could be identified by eGFP expression in only one brain at this 
time point. The cells are present in an area with distorted cytoarchitecture, cyst 
formation and host small mononuclear cells (black arrows) can be seen in the 
parenchyma and within the cysts on H&E stained sections. 
The presence of cyst formation, loss of graft and host mononuclear cells 
suggests a host immune response may be responsible for the loss of injected 
cells. Once this phenomenon was recognised, sections from the animals 
sacrificed at earlier time-points were re-examined and indeed host mononuclear 
cells were evident close to the cell transplants in sections at P14 as well 
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(Figure 3.43. ). The infiltrates were not evident at PO (5 days after injection). The 
nature of this cellular response will be a part of future studies. 
. 
dý. t 
"LS ý-týý. r 
'- 
: ý. S+ ý- 
~. 
r 
"ýý-, -'' 
"y 
, 
1" ß 
4. 
ý, . 
ti 
46 
"+"! :\"1,; `"(. 
10 
Figure 3.43. H&E stained murine brain at PO demonstrating the cell araft v 
and clusters of host 
vv 
mononuclear cells. This section demonstrates a cell 
graft (orange arrows) adjacent to 
Small clusters of host mononuclear 
arrows). 
3.2.4.4 Pre-exposure of 
more eosinophilic host brain parenchyma. 
cells can be seen in nearby tissue (black 
fetal MSC to ODM enhances 
oligodendrocyte differentiation in vivo 
I next investigated whether pre-exposure of fetal MSC to ODM in vitro could 
enhance oligodendrocyte differentiation in the same developmental model. 
Cells were injected following 2 days of in vitro incubation in ODM; previous in 
vitro experiments had demonstrated that fetal MSC could still divide, and were 
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nestin-positive at this time point. Following transplantation, cells were again 
identified in suspension within the ventricular system and were indeed strongly 
positive for vimentin and nestin (Figures 3.44. and 3.45. ) but negative for more 
mature oligodendrocyte markers (CNPase, MBP). 
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Figure 3.44. Immediately following injection fetal MSC strongly express 
nestin after pretreatment in vitro. After 48 hrs exposure to ODM fetal MSC 
were injected into the cerebral ventricle as before. Panels (A) and (B) 
demonstrate eGFP+ cells within the ventricular system straight after injection. 
These sections were double labelled and cells strongly expressed the neural 
progenitor marker nestin (red) at this time. 
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Figure 3.45. Immediately following injection fetal MSC can be identified by 
vimentin staining after pretreatment in vitro. After 48 hrs exposure to ODM 
fetal MSC were injected into the cerebral ventricle. In this figure, eGFP+ cells 
within the ventricular system are double labelled with anti-human vimentin 
antibody. This result was confirmed in three experiments. 
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Similar to the experiments using undifferentiated fetal MSC, the human cells 
aggregated within the ventricles between 2-5 days after injection, and remained 
nestin positive (Figure 3.46. ). 
Figure 3.46. Cell aggregates form within the cerebral ventricle 2-5 days 
following injection. Between E18-E20 aggregates of injected cells can be see 
in the cerebral ventricles. This figure demonstrates that they can be visualised 
by eGFP expression and cells remain strongly nestin positive. This result was 
confirmed in three experiments. 
The expression of neural markers was studied on the aggregates of cells at 5 
days post injection. As well as the strong expression of vimentin and nestin, 
cells co-expressing the early oligodendrocyte marker NG2 and eGFP could be 
identified at the edges of aggregates of transplanted cells (Figure 3.47. ). In the 
cell `balls', there were no cells that expressed neuronal (ßlll tubulin), astrocyte 
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(GFAP) or mature oligodendrocyte (CNPase, MBP) markers. For these 
experiments, P14 murine brain, and human post-mortem brain sections (frozen 
and paraffin embedded) were used as positive controls (Figure 3.48. ). 
Figure 3.47. NG2 expression of transplanted fetal MSC following pre- 
exposure to ODM. 5 days following injection eGFP+ human cells on the outer 
edge of the aggregate expressed NG2. The lower panels demonstrate eGFP+ 
(green) cells that also express NG2 (red). Co-localisation results in 
yellow/orange staining. NG2 expression studies were repeated in two 
experiments. 
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Figure 3.48. Adult human post mortem brain sections were used as 
positive controls for mature neural markers. Both panels show 
representative sections of human brain stained for the astrocyte marker, GFAP 
(A, red) and another section (B) double-labelled for GFAP (green) and ß11I 
tubulin (red). Nuclei are counterstained with DAPI. 
After 7 days post-injection, human cells could be identified within the cerebral 
parenchyma of 1/3 animals and eGFP+ cells clearly stained with A2B5 (Figure 
3.49. ), CNPase and MBP (Figure 3.50. ) indicating oligodendrocyte 
differentiation. Thus, pre-treatment of fetal MSC with ODM reduced the time in 
vivo for cells to develop oligodendrocyte markers, and increased the proportion 
of MSC-derived human oligodendrocytes up to nearly 4% of the transplanted 
cells. 
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Figure 3.49. Fetal MSC acquired A2B5 after 7 days in vivo following pre- 
exposure to ODM. This figure shows low and high power sections of P2 murine 
brain demonstrating an eGFP+ cell graft with green cells staining for A2135, an 
early oligodendrocyte marker. 
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Figure 3.50. Fetal MSC acquire CNPase and MBP after 7 days in vivo 
following exposure to ODM in vitro. This figure shows a high power section 
of P2 murine brain demonstrating an eGFP+ cell graft with 2 cells staining for 
CNPase (A). (B) shows an adjacent section within the same animal with GFP+ 
staining for MBP (red). The proportion of injected cells at this time point with 
oligodendrocyte markers was 3.7%. A2B5 3.3% ± 1.1; CNPase 4.9% ± 2.9, 
MBP 3.1% ± 2.3 (mean ± SD, 15 fields counted). This experiment was 
performed on a single animal. 
3.2.4.5 Oligodendrocyte differentiation in vivo was not as a 
result of cell fusion 
In order to determine whether fusion of eGFP+ cells with host neural cells could 
account for the oligodendrocyte phenotype, a novel FISH approach was 
developed. Adjacent sections (7 days post injection) to those with eGFP+ 
oligodendrocytes were studied using double (mouse / human) FISH. In early 
experiments FISH was optimised in paraffin embedded murine and human 
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sections separately, and later optimised on sections with large numbers of 
human and mouse cells (obtained from animals sacrificed immediately after 
injection of fetal MSC). With the single X or Y probes mouse or human specific 
probes, hybridization efficiency was poor (and the signal may not be in the 
particular section of the nucleus) and the signal difficult to visualise. Later 
experiments used pan-centromeric probes (Figure 3.51. ) that gave multiple 
signals per nucleus and were easily visualised. By adjusting DNA denaturation 
(heat and formamide) and hybridisation conditions, a method was devised 
whereby these specific pan-centromeric probes for mouse and human 
chromosomes could be applied to the same sections, giving multiple signals in 
each nucleus. In these experiments mouse and human probes were labelled 
with different fluorochromes (Figure 3.52. ). 
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Figure 3.51. FISH with pan-centromeric probes was optimised for mouse 
and human cells separately at first. This figure shows 4 panels demonstrating 
FISH on paraffin embedded mouse brain sections using FITC (green)-labelled 
mouse pan-centromeric probes giving multiple green signals in murine nuclei 
(counterstained with DAPI, blue). This FISH approach was optimised to 
hybridisation efficiencies (nuclei with FISH signals / total nuclei) of >95%. The 
human and mouse pan-centromeric FISH was optimised separately with mouse 
and human probes before they were combined to study the possibility of cell 
fusion. 
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Figure 3.52. FISH with pan-centromeric probes identify murine and human 
cells. This figure shows FISH on a paraffin embedded mouse brain section 
using FITC (green)-labelled mouse pan-centromeric probes and Texas Red 
(Red)-labelled human pan-centromeric probes (nuclei counterstained with 
DAPI, blue). This FISH approach was optimised in sections from mice sacrificed 
immediately after injection where numerous human cells were easily identified 
in the cerebral ventricles. This section has several eGFP+ (green cytosol) 
human cells with multiple red signals in the nuclei (red arrows), and murine cells 
with multiple green signals in the nuclei (green arrows). 
Sections from mice, 7 days after injection, with apparent donor-derived 
oligodendrocytes were used to evaluate the possibility of cell fusion. The 
adjacent sections to those with human cells expressing oligodendrocyte 
markers were subjected to human: mouse FISH with pan-centromeric probes as 
described above (red probes binding human DNA and green probes binding 
murine DNA). If fusion had occurred between human and mouse cells, co- 
localisation of human and mouse signals within a single nucleus would be 
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observed. This FISH method was optimised to give a hybridisation efficiency 
(FISH labeled nuclei / total nuclei) of >95% (mouse and human nuclei) with little 
background. In no section did we see co-localisation of murine and human 
signals (Figure 3.53. ). Therefore there was no evidence that the 
oligodendrocyte differentiation was a result of cell fusion. 
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Figure 3.53. Human and mouse pan-centromeric FISH to investigate cell 
fusion. This figure shows three sections from mice sacrificed 7 days following 
injection of fetal MSC pre-differentiated in ODM. Adjacent 5 pm sections had 
donor (human) cells strongly staining for oligodendrocyte markers A2B5, 
CNPase or MBP. In no section studied was there co-localisation of mouse and 
human signals within a single nucleus and therefore we had no evidence to 
suggest apparent oligodendrocyte differentiation was a result of cell fusion. Of 
interest, in (A), a donor human cell was seen dividing in vivo (arrow). This 
experiment was repeated three times. 
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3.3 Discussion 
3.3.1 Summary of results 
In this study, I confirmed the published immunophenotype and growth 
characteristics of fetal MSC (Campagnoli et al, 2001), and circulating fetal MSC 
were induced to differentiate into cells with morphological and phenotypic 
characteristics of oligodendrocyte precursors, which matured with time in 
culture. This differentiation appears an ordered process with the acquisition of 
neural progenitor markers followed by the upregulation of transcription factors 
Oligl, 2 and NKx2.2, and finally the expression of oligodendrocyte-specific 
antigens. Data were obtained from a defined clonal population of fetal MSC with 
mesodermal (bone) and ectodermal (oligodendrocyte) differentiation observed 
from the same clone. Clonality in this experiment was proven by DNA analysis. 
The potential for oligodendrocyte differentiation was explored in the embryonic 
murine brain. After injection into the cerebral ventricles of immuno-competent 
E15 mice, the fate of injected cells was studied over time. Fetal MSC migrated, 
appeared to integrate into the brain parenchyma and become strongly positive 
for neural progenitor markers, but there was little evidence of widespread 
differentiation to mature neural markers. Only <0.2% of injected cells expressed 
oligodendrocyte markers. In addition, at later time-points there was evidence of 
a host cellular infiltrate around the grafts with eventual cell and tissue loss. 
As well as injection of naive undifferentiated fetal MSC, I investigated whether 
pre-differentiation of fetal MSC in vitro with ODM for 48 hours could enhance in 
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vivo oligodendrocyte generation. In contrast to the experiments using 
undifferentiated cells, acquisition of NG2 within 48 hours and then cells positive 
for A2B5, CNPase and MBP by 7 days albeit in only 4% of injected cells were 
observed. Using a novel FISH method for labelling mouse and human 
chromosomes with different fluorochromes in the same sections - cell fusion 
between host and injected cells was excluded as underlying the acquisition of 
oligodendrocyte markers. 
3.3.2 Critical analysis 
3.3.2.1 In vitro oligodendrocyte differentiation 
3.3.2.1.1 Oligodendrocyte differentiation medium 
The differentiation cocktail was based on conditioned medium from B104 
neuroblastoma cells (Schubert et al, 1974). This medium has been 
demonstrated to be a potent source of growth factors which when applied to 
neonatal rat brain cultures (Bottenstein et al, 1988), enriching oligodendrocyte 
precursors whilst inhibiting type 1 astrocytes. Indeed B104 conditioned medium 
is routinely used in the propagation of primary rat oligodendrocyte precursors as 
well as several oligodendrocyte cell lines (for example CG4 (Louis & Irving, 
1974)) and is known to commit rat and canine multipotent neural progenitors to 
the oligodendrocyte lineage (Zhang et al, 1998b; Zhang et al, 1998a; Hu et al, 
2004; Fu et al, 2005). There have been few published studies defining the 
growth factors in this medium, although insulin like growth factor binding 
proteins (IGFBPs) (Cheung et al, 1994; Matsumoto et al, 1996), platelet derived 
growth factor as homodimers and TGFß1 and 2 (Asakura et al, 1997) have 
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been identified. In addition B104 conditioned medium is known to induce AP1 
activity in O-2A lineages cells (FitzGerald & Barnett, 2000). 
This medium has been shown to generate oligodendrocytes from rat and canine 
neural progenitor cells, but to our knowledge there is no published work 
exploring its effect on fetal MSC or adult-derived bone marrow stem cells. The 
addition of B104 conditioned medium led to a dose-dependent increase in the 
generation of bipolar cells resembling neural precursors. With the change in 
morphology, a marked increase in the intermediate filament protein, nestin 
(Lendahl et al, 1990) was observed, both at RNA and at protein level. Other 
neural precursor markers, Notch 1 (Frisen & Lendahl, 2001) and Musashi 
(Good et al, 1998; Okano et al, 2002; Sakakibara et al, 2002) were also studied 
and noted to be upregulated although their transcription was less transient than 
nestin and maintained over the time course of the in vitro experiments. 
3.3.2.1.2 Acquisition of oligodendrocyte markers 
The development and maturation of oligodendrocytes has been very well 
characterised in vitro (Temple & Raff, 1986). Once committed to the 
oligodendrocyte lineage, precursors can be identified by their bipolar 
morphology and by the presence of some neural progenitor markers like nestin 
and vimentin as well as more specific surface antigens. These include those 
recognised by the monoclonal antibody A2B5 (Raff, 1989), the PDGFra (Pringle 
et al, 1992), the chondroitin sulphate proteoglycan NG2 (Dawson et al, 2000) as 
well as oligodendrocyte-specific transcription factors Oligl, 2 and Nkx2.2 (Zhou 
et al, 2001). The further differentiation is characterised by withdrawal from the 
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cell cycle, expression of CNPase and the major myelin glycolipid, GaIC (Raff et 
al, 1978). The final stage is the generation of a multi-processed phenotype and 
the coordinated, elevated expression of a number of major myelin components 
including PLP, MBP and MOG (Campagnoni, 1988) and in vivo this step is 
largely regulated by axonal signals. Candidates for important axonally-derived 
soluble factors include FGFs (Bansal et al, 1996), thyroid hormones (Barres et 
a/, 1994) whilst cell-cell contact between neuron and oligodendrocyte is 
essential in regulating myelin sheath formation (Payne & Lemmon, 1993). 
To study oligodendrocyte development in my system, the expression of three 
transcription factors known to be central to oligodendrocyte specification was 
explored, Oligl, 2 (Zhou & Anderson, 2002; Ross et al, 2003; Woodruff et al, 
2001) and NKx 2.2 (Zhou et al, 2001; Qi et al, 2001), and found their 
upregulation towards the end of the first week. With time, phase-bright bipolar 
cells resembling oligodendrocyte precursors became more complex in 
morphology and many resembled mature oligodendrocytes. A2B5, vimentin and 
nestin immunoreactivity was seen in bipolar cells, and positive staining 
(CNPase, 04, GaIC) and transcriptional upregulation of more mature markers 
over time. Indeed, by nine days of culture we observed an upregulation of the 
terminal myelin protein, MOG, by RT-PCR. Although cells became positively 
stained with an antibody to PLP, this antibody also recognised its truncated 
isoform, DM20 which can be found earlier in the oligodendrocyte lineage 
maturation. There was no MBP seen at protein level. This is unsurprising as 
oligodendrocytes in culture and indeed oligodendrocyte cell lines generally do 
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not myelinate spontaneously in cell culture and require cell-cell contact with 
neurons to initiate this process. 
3.3.2.1.3 Generation and differentiation of fetal MSC clones 
One challenge in stem cell work is the derivation of clonal populations of cells. 
The generation of a clone has the particular advantage of ensuring that any 
observed differentiation is not the result of contamination by rare populations of 
more multipotent cells. Colonies did not easily grow from single cells in standard 
96 well plates, in small volume (5-10NI) wells or with mitomycin-treated feeder 
layers either in normal growth medium or medium obtained from growing fetal 
MSC cultures. Single cells remained visible in the wells without division for up to 
2 weeks. Clonal populations of fetal MSC were eventually obtained by growing 
single eGFP-expressing male cells on a feeder layer of senescent female cells. 
I decided on this approach on the basis that a clonal population of GFP+ cells 
could be identified easily by their fluorescence, and by human XY FISH 
compared to the feeder layer, and fusion between male and female cells could 
be identified by XY FISH. In addition, unlike other papers claiming differentiation 
single cell clones, using transduced cells with proviral integration site(s) for 
these experiments clonality could be proved by southern blot analysis for the 
integrated sequence in a clone with a single integration site. Oligodendrocyte 
differentiation was successfully demonstrated with this clonal population of fetal 
MSC, with the acquisition of nestin, A2B5, CNPase and GaIC, and importantly 
the same clone was shown to alternatively differentiate into mesoderm 
(bone) 
using published methods. 
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3.3.2.2 In vivo differentiation of fetal MSC 
3.3.2.2.1 Neural differentiation after injection of naive fetal MSC 
With the encouraging in vitro data, the potential for oligodendrocyte 
differentiation in vivo was studied. Injection of undifferentiated fetal MSC into 
the cerebral ventricles of E15 mice was used. This is a time of rapid brain 
development and before oligodendrocyte development, maturation and 
myelination. If extrinsic cues could influence oligodendrocyte differentiation, one 
may expect them to be most potent at this time. The majority of normal 
myelination occurs postnatally. The murine pregnancies were allowed to 
continue and animals sacrificed at time points up to post-natal day 28. Methods 
of cell tracking were developed including the use of human-specific antibodies, 
human-specific FISH and the use of eGFP+ transduced cells. In my study, 
aggregation of fetal MSC was observed within the ventricle prior to their 
migration towards the frontal cortex associated with dramatic morphological 
change. Fetal MSC became strongly positive for the neural progenitor markers, 
nestin and vimentin, but there was little evidence of widespread differentiation to 
mature neural markers with fewer than 0.2% of injected cells acquiring 
oligodendrocyte markers, and no cells seen with mature neuronal or astrocytic 
phenotype, even at the later time points. These data have many similarities, but 
some important differences compared with a recent in vivo study exploring the 
fate of adult-derived rat bone marrow stromal cells in a similar rodent embryonic 
model (Munoz-Elias et al, 2004). That study demonstrated the aggregation of 
injected within the ventricles, with subsequent migration into the parenchyma 
and acquisition of neural morphology but in contrast, this study showed mature 
neuronal markers in the majority of injected cells. Perhaps, the differences in 
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cell and animal species, isolation, cell culture and mode of cell labelling may 
account for the differences between these similar in vivo studies. Other 
investigators have failed to demonstrate large scale in vivo neural differentiation 
of injected MSC in animal models of brain development and disease, even in 
the context of the transplant having function benefits to the animal. Indeed, 
Chopp and collaborators, and others, have shown that MSC can promote 
improved neurological function when introduced directly or systemically into the 
injured brain (Chen et al, 2003; Li et al, 2005). MSC-mediated restoration of 
coordinated function in old rats occurs even though MSC do not differentiate 
into neurons or neuronal support cells. In this model, it is proposed that the 
MSC supply bioactive agents that inhibit scar formation, inhibit apoptosis, 
increase angiogenesis, and stimulate the action of intrinsic neural progenitor 
cells to regenerate functional neurological pathways (synaptogenesis, 
neurogenesis) with the resulting gain of coordinated function. In a further study 
primary rat marrow-derived or human MSC were introduced in a model of adult 
stroke (Li et al, 2005), functional improvement and more favourable brain 
histology was seen but again labelled MSC did not differentiate into neural cells. 
3.3.2.2.2 Loss of cell grafts 
Our in vivo experiments, rather disappointingly, demonstrated graft loss with 
only a small number of injected cells identified at P28 (33 days post 
injection); 
several of which had apoptotic morphology with cytoplasmic retraction and 
pyknotic nuclei. In all animals examined at this time-point, small cysts were 
evident within the brain parenchyma indicating tissue loss. Detailed analysis of 
tissue sections from earlier time-points showed infiltrates of host mononuclear 
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cells close to the cell transplants from P14 (Figure 3.43. ). The appearance of 
cyst formation, loss of graft and host mononuclear cells suggests that a host 
immune response may be responsible for the loss of injected cells. Whether the 
delayed cellular response to the graft reflects maturation of the host response 
and loss of tolerance, enhanced immunogenicity of differentiated cells (perhaps 
because of upregulation of MHC molecules) compared to naYve cells, or simply 
a response to dying graft cells that have lost survival signals is not known. 
Further studies to characterise the response are planned. We were conscious, 
from the start, that immunocompetent mice may mount an immune response 
leading to graft loss, but there are in vivo studies where graft survival occurs 
with embryonic injection of MSC (Munoz-Elias et al, 2004; Chou et al, 2006). 
We felt graft survival was possible because tolerance to foreign antigens may 
occur early in development; the brain is an immune privileged site; MSC are not 
inherently immunogenic (failing to induce alloreactivity to T cells and freshly 
isolated natural killer cells) (Di Nicola et al, 2002; Krampera et al, 2003) and 
they also have immunomodulatory properties - being capable of suppressing T- 
cell and NK responses (Sotiropoulou et al, 2006) and modifying dendritic cell 
differentiation, maturation, and function (Zhang et al, 2004a). Although these 
immunomodulatory actions imply immunosuppressive therapy may not be 
necessary for allogenic transplantation, recent data point towards their need in 
xenotransplantation experiments like ours, where stem cells are from a different 
species to the host. In a study of MSC transplantation into the rat myocardium 
allogenic transplants were tolerated without immunosuppression, but xenograft 
rejection could be seen (Grinnemo et al, 2004). Another recent study evaluated 
immunosuppression with cyclosporin A in a model where human NSC were 
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transplanted to the site of a focal brain injury in the rat and found graft survival 
was markedly prolonged with immunosuppression (Wennersten et al, 2006). 
The graft rejection that we observed clearly has implications in the design of 
future studies, and in particular, the need to consider immunosuppression in the 
host, or the use of an immuno-compromised mouse strain as the host. 
3.3.2.2.3 In vivo differentiation of pre-differentiated fetal MSC 
Our study also investigated whether pre-differentiation of fetal MSC in vitro 
could enhance in vivo oligodendrocyte generation. Indeed, in another stem cell 
system there is evidence that pre-differentiation of porcine neural stem cells in 
B104 conditioned medium enhances oligodendrocyte generation, grafting and 
remyelination in a rat demyelination model (Smith & Blakemore, 2000). Fetal 
MSC were injected at a nestin positive progenitor stage following two days of in 
vitro differentiation in ODM. We demonstrated that, as with naive cells, they 
survived injection into the cerebral ventricles and could be identified by eGFP 
expression, anti-human antibodies and FISH. Nestin expression was 
maintained following injection, and after their aggregation in the ventricles, fetal 
MSC migrated into the parenchyma. In contrast to the experiments using 
undifferentiated cells, acquisition of NG2 within 48 hours and then cells positive 
for A2B5, CNPase and MBP were seen by 7 days. The proportion of cells 
staining for oligodendrocyte markers at 7 days approached 4%. Using a novel 
FISH approach with mouse and human probes, the upregulation of 
oligodendrocyte markers did not appear to result from MSC: host cell fusion. 
This exciting finding adds weight to our proposal of oligodendrocyte 
differentiation of fetal MSC. Although beyond the scope of this study, further 
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work is underway to examine whether the cell environment particularly following 
injury could further enhance oligodendrocyte differentiation. 
3.3.3. Conclusion 
The mechanisms underlying these in vitro and in vivo morphological and 
phenotypic changes of fetal MSC remains unknown. We have shown with clonal 
experiments that this differentiation is not due to rare contaminating more 
multipotent cells, and our in vivo work suggests differentiation is not due to cell 
fusion. Whether de-differentiation, or transdifferentiation of fetal MSC to a more 
multipotent cell, or whether these cells in the fetal circulation are more 
multipotent per se warrants further investigation. 
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CHAPTER 4 
NEURONAL DIFFERENTIATION 
OF FETAL MSC 
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4.1. Introduction 
The apparent differentiation of MSC into neural cells has aroused considerable 
interest both for the study of the mechanisms of cell transdifferentiation (or 
plasticity) and the potential of MSC for cell replacement therapy for neurological 
disorders. Neural differentiation has been described in vitro using human adult- 
derived or rodent MSC but, prior to this work, has not been studied in human 
fetal MSC derived from first trimester blood sampling. 
Woodbury et al. (Woodbury et al, 2000) reported the induction of neuronal 
phenotype by exposure of rat and human adult-derived MSC to DMEM with 
combinations of reducing agents, ß mercaptoethanol or butylated 
hydroxyanisole, with dimethylsulfoxide (DMSO). Such cocktails resulted in 
impressive rapid adoption of neuronal and astrocytic morphology and 
phenotype. Treated MSC exhibited a neuronal phenotype, expressing neuron- 
specific enolase (NSE), NeuN, neurofilament-M (NFM), and tau. At best, almost 
80% of the cells expressed NSE and NFM. None of the cells were positive for 
the astroglial marker, GFAP, and oligodendrocyte markers were not studied. 
Similar claims of MSC plasticity were made in studies of cultured human and 
rodent bone marrow cells treated with EGF with retinoic acid (Cho et al, 2005), 
or retinoic acid followed by BDNF (Sanchez-Ramos et al, 2000). In these 
experiments, the neuronal markers NeuN, ßlll tubulin and astrocytic marker, 
GFAP, were upregulated. In addition Sanchez-Ramos studied the influence of 
soluble factors and cell-cell contact. This data demonstrated that co-culture of 
MSC with mesencephalic cells enhanced neural differentiation (increasing 
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NeuN and GFAP expression) (Sanchez-Ramos et al, 2000). Other co-culture 
experiments have also shown neuronal differentiation. For example, when 
cultured with hippocampal brain slices, differentiation to neuron-like cells 
(NeuN+) ensued with direct cell to cell contact necessary (Abouelfetouh et al, 
2004). In that series of experiments, the addition of retinoic acid (1 NM) greatly 
increased the number of differentiated cells. 
Following the work of Woodbury et al. and Sanchez-Ramos et al., an increasing 
number of groups have reported neuronal differentiation of MSC using a variety 
of other stimuli including combinations of growth factors (Jin et al, 2003), 
conditioned medium (Bossolasco et al, 2005), demethylating agents (Kohyama 
et al, 2001), retinoids ± growth factors (Kim et al, 2002a) and agents that raise 
intracellular cAMP (Deng et al, 2001; Kim et al, 2005). In the majority of above 
studies, the expression of neuronal markers, either at mRNA or at protein level, 
was used to define neuronal differentiation. Clearly more detailed morphological 
and functional data is needed to confirm truly their differentiation (Svendsen et 
a/, 2001). This would include their ability to connect and form synapses (Cho et 
al, 2005) with other neurons, as well as single cell recordings confirming 
neuronal electrophysiological parameters such as excitability and voltage-gated 
sodium channels (Svendsen et al, 2001). 
Even accepting the lack of functional data, the published work suggesting the 
transdifferentiation of MSC to neural subtypes still remains controversial. As 
described previously, cell fusion may be the explanation for the `plasticity' 
observed in co-culture or transplantation studies (Wurmser & Gage, 2002; 
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Terada et al, 2002; Ying et al, 2002; Weimann et a/, 2003b). Also, most in vitro 
studies have not used defined clonal cell populations and therefore one criticism 
is that rare primordial stem cells may contaminate the culture, and lead to 
erroneous conclusions. An example of such a primordial cell is the MAPC from 
bone marrow (Reyes & Verfaillie, 2001; Jiang et al, 2002b). 
Lastly, some investigators have urged caution interpreting data where there are 
very rapid changes in morphology and phenotype, as they may result from 
cytotoxic change rather than the ordered sequence of gene expression required 
for neurogenesis. Lu et al. (Lu et al, 2004) exposed MSC, fibroblasts, 
keratinocytes, HEK293 and PC12 cells to a variety of stressors including 
induction medium used by Woodbury et al. (Woodbury et al, 2000), extremes of 
pH, high molarity sodium chloride, and detergents. They discovered similar cell 
shrinkage and adoption of neuron-like morphologies in all cell lines, and 
acquisition of staining for NSE and NeuN without increases in mRNA for these 
markers. Also, the changes in morphology occurred even in the presence of 
cycloheximide (blocking protein synthesis). These data were reinforced by 
Neuhuber et al. (Neuhuber et al, 2004) who found morphological changes in 
response to the protocol of Woodbury et al. (Woodbury et al, 2000) were a 
result of disruption of the actin cytoskeleton and retraction of the cell edges. In 
these studies, the reducing agent ß mercaptoethanol induced neuronal 
morphology in a concentration-dependent manner and induced cell death. 
Butylated hydroxyanisole, the other reducing agent used by Woodbury et al. 
also induces cell death (Yu et al, 2000). Rismanchi et al. further examined cell 
viability and neural differentiation after exposure of MSC to the protocols of 
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Woodbury et al. (Woodbury et al, 2000) and Deng et al. (Deng et al, 2001). 
They demonstrated increases in NeuN over hours using Woodbury's protocol 
and a significantly increased cell death in differentiated cells (Rismanchi et al, 
2003). The maintenance of neuronal morphology required continued exposure 
to differentiation medium, and was lost in normal growth medium. This rapid 
acquisition and loss of neuronal morphology argues against ordered cell 
differentiation, and may well reflect cytotoxic changes. This idea has been 
reinforced by recent data from Croft et al. which showed that targeted disruption 
of the cytoskeleton itself leads to activation of kinases and the acquisition of 
neural markers; this was reversible and a result of cell stress (Croft & 
Przyborski, 2006). 
The aim of this chapter was to recapitulate, in fetal MSC, some of these data 
suggesting adult-derived MSC may be differentiated towards neuronal 
phenotype in a differentiating medium containing the reducing agent BHA 
(Woodbury et al, 2000; Black & Woodbury, 2001; Safford et al, 2002; Martin et 
a/, 2002) and with retinoids ± BDNF (Sanchez-Ramos et al, 2000; Cho et al, 
2005). The effects were explored both in mixed populations of fetal MSC and in 
a defined clonal population. The acquisition of neuronal phenotype was studied 
by RT-PCR and protein analysis, single-cell electrophysiological recordings and 
staining experiments to evaluate synaptophysin expression. 
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4.2. Results 
4.2.1. Neuronal differentiation in medium with BHA 
4.2.1.1. Morphological changes 
Following addition of medium containing BHA, fetal MSC displayed rapid 
changes in morphology within 1 hour similar to that described by Woodbury et 
al. (Woodbury et al, 2000). Initially, cytoplasm retracted towards the nucleus 
and the cell body became spherical and refractile. Over time the number of cells 
with this morphology increased, and cell processes became evident (Figure 
4.01. ). The beginning of the cytoplasmic retraction could be visualised within 5- 
10 minutes after exposure to differentiation medium. Throughout the time 
course of these experiments, there was considerable cell death observed with 
almost all cells dead before 48 hrs (with typical apoptotic morphology). In later 
experiments, the longevity of cultures was prolonged when the BHA was 
dissolved in ethanol rather than DMSO. This only improved cell survival to 72- 
96 hours. The apparent cell processes did not obviously further elongate or 
become more complex over time. Interestingly if the cells were washed, and 
differentiation medium replaced with normal growth medium after 6 hours 
exposure, surviving fetal MSC resumed normal fibroblast-like morphology within 
48 hours. 
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Figure 4.01. Morphological changes with BHA induction. Phase contrast 
images of fetal MSC before, and 6 and 24 hours after neuronal differentiation 
demonstrating acquisition of more complex neuronal-like morphology with 
extending processes, in the context of considerable cell death. In this 
experiment differentiation was induced using a protocol derived from Woodbury 
et al. (Woodbury et al, 2000). Such morphological changes were confirmed in 
more than five repeat experiments. 
4.2.1.2. Neuronal markers were acquired with exposure to BHA. 
Fetal MSC displayed acquisition of neuronal markers by immunocytochemistry 
and western blotting following culture with BHA. Undifferentiated cells did not 
stain for the neuronal markers NSE, ß1l1 tubulin (Figure 4.02. ) and the more 
mature neuronal markers NFM or MAP2 (Figure 4.03. ). However, positive 
staining for these markers could be detected within 6 hours of differentiation, 
and by 24 hours strong staining was present on cells with neuronal morphology. 
The increases in NSE and ß11I tubulin were confirmed by western blotting 
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(Figure 4.02. ). As with oligodendrocyte differentiation, there was an 
upregulation of nestin, although this did not clearly pre-date the staining for 
mature neuronal markers. In these differentiation experiments the human 
cortical neuronal cell line, HCN-2 and SHSY-5Y neuroblastoma cells were used 
as positive controls. 
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Figure 4.02. Upregulation of neuron specific enolase (NSE) and ß11I 
tubulin at 24 hours. After 24 hours in differentiation medium fetal MSC 
resembling neurons expressed NSE demonstrated by immunocytochemistry (A, 
NSE stained in red) and western blotting (C). Cells also acquire the neuronal 
marker ß11I tubulin (B, D). This upregulation of neuronal markers was confirmed 
in two repeat experiments. 
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Figure 4.03. Mature neuronal markers are seen following neuronal 
differentiation. Fetal MSC expressed NFM (A) and MAP2 (B) within 24 hours 
of exposure to differentiation medium. The staining appears to be predominantly 
in the processed cells with neural morphology. Naive fetal MSC do not stain for 
these proteins. This result was consistent in three repeat experiments. 
4.2.1.3. RT-PCR data supports neuronal phenotype 
RT-PCR provided further support of neuronal differentiation. Increases in 
expression of the neural progenitor marker nestin, and neuronal markers NFM, 
NSE and MAP2 were observed within 24 hours of treatment. As in the paper of 
Woodbury et al. (Woodbury et al, 2000), pre-incubation of cells with bFGF 
seemed to enhance differentiation, with more pronounced morphological 
changes, the expression of NFM before BHA exposure, and the earlier 
appearance of MAP2 expression (Figure 4.04. ). Nestin expression in these 
experiments, both with and without bFGF pre-treatment, did not clearly precede 
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that of more mature neuronal markers. 
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Figure 4.04. Differentiation increases expression of neuronal-specific 
mRNA transcripts. Medium containing BHA enhanced expression of NFM and 
NSE at 6 hrs with expression of MAP2 by 24 hours (A). GAPDH was used as a 
loading control. The right panel (B) demonstrates that pre-incubation with bFGF 
itself cause expression of NFM, and brings forward expression of the mature 
marker MAP2. The upregulation of neuronal mRNA transcripts was confirmed in 
four repeat experiments. 
4.2.1.4. Clonal fetal MSC give rise to cells with neuronal 
phenotype 
It was important to repeat these experiments on a clonal population of fetal 
MSC to determine whether clonal fetal MSC could undergo similar changes to 
the heterogeneous populations. A GFP+ clone of fetal MSC (as previously 
described in 3.2.3. ) was exposed to DMEM, 20% FCS + long/ml bFGF 
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overnight, and the following day, medium was changed to DMEM with 200nM 
BHA, 5mM KCI, 2pM valproic acid, 10NM forskolin, 1pM hydrocortisone, and 
ýu C. insulin in ethanol (2%). At the same time, the same clone was 
differentiated to bone using DMEM with 10% FCS supplemented with 10-8M 
dexamethasone, 0.2 mM ascorbic acid, and 10 mM ß-glycerophosphate 
described in 2.3.2.2. 
The clonal population generated cells that stained strongly for the neural 
progenitor marker, nestin (Figure 4.05. ) and the more mature neuronal marker 
MAP2 (Figure 4.06. ). Additionally, in this experiment differentiated cells were 
stained with an antibody for NeuN. NeuN is a neuron-specific, DNA-binding 
nuclear protein in vertebrates. Indeed cells with clear nuclear staining for NeuN 
became evident with this protocol (Figure 4.07. ). 
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Figure 4.05. Nestin is upregulated in a GFP+ clone following exposure to 
medium containing BHA. Within 6 hours of exposure to medium containing 
BHA processed cells became strongly nestin positive (red). Examples of nestin 
positive cells (between 6 and 48 hours of exposure) are demonstrated in all four 
panels. This increase in nestin expression was confirmed in four experiments. 
Magnification x10 left panels (A), x40 right panels (B). 
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Figure 4.06. MAP2 immunoreactivity is observed in clonal fetal MSC 
(eGFP+) following exposure to medium containing BHA. Undifferentiated 
fetal MSC do not express MAP2. MAP2 is the major microtubule associated 
protein in neuronal tissues. Within 6 hours of exposure to medium containing 
BHA processed cells became strongly MAP2 positive (red) with appropriate 
cytoplasmic localisation. Examples of MAP2 positive cells (between 6 and 48 
hours of exposure) are demonstrated in all three panels. These data were 
consistent in three repeat experiments. 
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Figure 4.07. NeuN is acquired in clonal fetal MSC following exposure to 
medium containing BHA. NeuN is a good marker for neurons in primary 
cultures and in retinoic acid-stimulated P19 cells. It is a neuron-specific, DNA- 
binding nuclear protein in vertebrates. NeuN is observed in most neuronal cell 
types throughout the nervous system. This figure shows the acquisition of NeuN 
in a GFP+ (green) clonal population of fetal MSC. Within 6 hours of exposure to 
medium containing BHA processed cells became strongly NeuN+ (red) with 
appropriate nuclear localisation. Examples of NeuN positive cells (between 6 
and 48 hours of exposure) are demonstrated in A, B (x10 magnification), C (x20 
magnification) and D (x60 magnification). 
Neural Differentiation of Fetal Mesenchymal Stem Cells Chapter 4 
262 
4.2.1.5. Electrophysiological measurements 
Single cell recordings were undertaken using patch-clamp apparatus to 
determine whether there was evidence of excitability and functional voltage- 
gated sodium channel (VGSC) upregulation following 48 hours differentiation in 
medium containing BHA. Excitability, the activation of voltage-gated channels, 
was assessed in undifferentiated naive cells and those differentiated for 48 
hours. It was evaluated by applying hyperpolarising and depolarising voltage 
steps from a holding potential of -90 to -100mV (-70 to +110mV in 5-10mV 
increments). The ion currents demonstrated are summarised below. 
4.2.1.5.1. Inward current 
An inward current was detected in n=4/17 differentiated cells (23.5%) compared 
to n=3/9 naive non-differentiated cells (33%). In differentiated cells, activation 
was at -36.7 ± 1.7 mV (n=3) compared to -40 ± 
2.9 mV (n=3) for non- 
differentiated cells (P=0.374) with the peak current at -6.7 ± 1.7 mV (n=3) 
compared to at -13.3 ± 3.3 mV (n=3) for non-differentiated cells 
(P=0.148). 
Peak current density was 1.8 ± 0.45 pA/pF (n=4) for differentiated cells 
compared to 3.8 ± 1.8 pA/pF (n=3) for non-differentiated cells (P=0.282). 
Tetrodotoxin (TTX, at 100 nM and 10 NM) blocked the current by 100% (n=1 for 
each); there was complete recovery from the 100 nM tetrodotoxin application. 
The inward current was also abolished in Na+ free solution (n=2) indicating that 
this was a sodium current. 
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Figure 4.08. A typical current-voltage (I-V) relationship generated in 
undifferentiated fetal MSC. This graph was generated by pulsing the 
membrane potential from a holding voltage of -100 mV to test potentials 
between -70 to +70 mV in 5 mV increments. Voltage pulses were applied with a 
repeat interval of 20 s. 
4.2.1.5.2. Outward current 
In Cs+ containing intracellular patch medium, there was a peak current density 
of 2.4 ± 1.0 pA/pF (n=3) compared to 20.5 ± 2.1 pA/pF (n=12) for normal 
medium (P=0.001). Therefore, the majority of outward current is probably driven 
by K+ flux. A sustained outward current was detected in n=15/17 differentiated 
cells (88%) compared to n=7/9 non-differentiated cells (78%). Activation was at 
-23.5 ± 11.5 mV (n=11) compared to -9.1 ± 13.3 mV (n=6) for non-differentiated 
cells (P=0.43). 
Neural Differentiation of Fetal Mesenchymal Stem Cells Chapter 4 
264 
The peak current was at 95 mV for both differentiated and non-differentiated 
cells with the peak current density of 20.5 ± 2.09 pA/pF (n=7) compared to 13.2 
± 1.1 pA/pF (n=7) for non-differentiated cells (P=0.02). 
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Figure 4.09. Electrophysiological measurement from fetal MSC. (A) 
demonstrates voltage-gated membrane currents recorded in undifferentiated 
mesenchymal stem cells. The currents were generated by pulsing the 
membrane potential from a holding voltage of -90 mV, in 10 mV steps, to +110 
mV for 200 ms. Voltage pulses were applied with a repeat interval of 20 s. Only 
every second current trace generated is displayed. (B) shows a typical current- 
voltage (I-V) relationship generated in undifferentiated mesenchymal stem cells. 
These data were generated by pulsing the membrane potential from a holding 
voltage of -90 mV to test potentials between -70 to +110 mV in 10 mV 
increments. Voltage pulses were applied with a repeat interval of 20 s. 
During the electrophysiological recording experiments no significant differences 
were demonstrated between naive and differentiated fetal MSC resting 
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potentials and indeed there was no evidence of increased excitability and 
functional VGSC upregulation following differentiation. Quantitative evidence for 
this comes from the fact that the percentage expression levels (from the two 
separate experiments) were 3 out of nine cells (33.3%) from the non- 
differentiated stem cell population expressing VGSC whilst 4 out of seventeen 
cells (23.5%) from the differentiated stem cell population expressed them. In 
addition, there was no statistical significance in the peak current density 
between the two cell populations: non-differentiated stem cell population = 3.8 
+/- 1.8 pA/pF (n=3) differentiated stem cell population = 1.6 +/- 0.4 pA/pF (n=5), 
P=0.18. 
Following this result, immunocytochemistry confirmed that there was no 
difference in the staining with the pan-specific antibody to voltage-gated sodium 
channels between naive, non-differentiated and differentiated fetal MSC 
populations (Figure 4.10. ) further supporting a lack in functional differentiation. 
Staining for synaptophysin was also negative. 
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Figure 4.10. Voltage-gated sodium channel (VGSC) expression did not 
change through differentiation. This figure demonstrates the expression 
pattern of VGSC in GFP+ fetal MSC after 48hrs of neuronal differentiation. 
There was no difference in expression pattern (red) pre and post differentiation 
with perinuclear and membrane staining (arrows) evident in some cells. VGSC 
expression did not increase with differentiation. This is the result of a single 
experiment, confirming the result of the electrophysiological recordings. 
4.2.2. Effects of exposure to retinoic acid ± BDNF 
Fetal MSC exposed to `neuronal growth medium' that was used in the neuronal 
differentiation of adult bone marrow MSC (Sanchez-Ramos et al, 2000) (which 
contained 0.5pM retinoic acid), proliferated to confluence within 4 days. No 
overt morphological changes were seen. The addition of BDNF did not appear 
to promote neural cell morphology. Experiments were also performed in DMEM 
with higher concentrations of retinoic acid (up to 1 0NM) alone (Cho et al, 2005), 
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up to 14 days, with no evidence of neuronal differentiation either 
morphologically or phenotypically. A dose response-cell survival experiment 
had demonstrated that fetal MSC tolerated 10NM retinoic acid, but with 
increasing cell death above this concentration (Figure 4.11. ). 
Figure 4.11. Dose response of retinoic acid concentration against fetal 
MSC survival. This graph demonstrates that exposure of fetal MSC to 
concentrations of retinoic acid up to 15pM were well tolerated by fetal MSC 
without cell death following 48 hr exposure. Cell death in this experiment was 
estimated by MTT assay. Data are expressed as mean ± SD of three values per 
data point. Experiments using retinoic acid were repeated four times. 
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4.3. Discussion 
4.3.1. Summary of results 
It is demonstrated here, for the first time, that fetal MSC can be directed into 
cells with processed morphology and phenotypic characteristics of neurons 
using a previously published protocol (Woodbury et al, 2000). 
Fetal MSC were exposed to a cocktail that included the potent reducing agent 
BHA. Within minutes, the cell cytosol shrank, leaving behind neurite-like 
processes giving `neural-like' morphology. This protocol leads to considerable 
visible cell death, probably by apoptosis, within 48-72 hours. At the protein 
level (staining and western blot analysis), upregulation of nestin, NFM, NeuN, 
NSE and ß11I tubulin were observed in time-course experiments both in 
unselected and clonally-derived fetal MSC. There were increases in mRNA 
expression of neural markers nestin, NFM, and NSE over 6-24 hours. 
Interestingly pre-exposure of cells to bFGF enhanced this response, and also 
lead to the upregulation of NFM prior to addition of medium containing BHA. In 
order to study the function of these `differentiated' cells generated in vitro, single 
cell recordings were undertaken to determine whether there was evidence of 
excitability and functional VGSC upregulation. These experiments revealed no 
significant differences between naYve and `differentiated' cells and, in addition, 
there was no staining for synaptophysin when studying the possibility of 
differentiated fetal MSC developing synapses. 
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4.3.2. Critical analysis 
4.3.2.1. Morphological changes 
The morphological changes seen when fetal MSC were exposed to neuronal 
differentiation medium were dramatic, and occurred within minutes of exposure. 
The cells that stained positively for neuronal markers had cytoplasmic retraction 
and were elongated, and appeared processed. Although this clear difference 
between naive and exposed MSC cytoarchitecture was impressive, the speed 
of change argues against the organised and coordinated development of 
functional neurons (Neuhuber et al, 2004; Croft & Przyborski, 2006). The 
development of neuronal cells is a highly regulated, ordered process with the 
early development of a specialised growth cone, the laying down of an axonal 
fibre, the generation of a dendritic tree and ultimately the forming of synapses 
with other neurons (Svendsen et al, 2001). None of the published work using 
protocols derived from the original Woodbury protocol (Woodbury et al, 2000; 
Black & Woodbury, 2001; Safford et al, 2002; Martin et al, 2002), although 
claiming neural morphology of differentiated cells, have evaluated the 
morphology in such detail, or demonstrated the coordinated development of a 
single cell. The rapid change in morphology, the considerable cell death in the 
cultures, the inability to maintain `differentiated' cells in culture, the return to 
MSC morphology after the BHA-containing differentiation mix is removed, all 
point to the morphological changes being a result of toxic effects of the medium 
rather than a true change in fate to neuronal cells. 
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4.3.2.2. The acquisition of neuronal markers 
Undifferentiated cells were negative for all mature neuronal markers studied. In 
the time-course experiments I observed upregulation of nestin, NFM, NeuN, ßl11 
tubulin and NSE by immunocytochemistry within 6 hours. The rise in ßIJI tubulin 
and NSE were confirmed with western blotting. This concurs with work by 
Woodbury et al. with other sources of MSC (Woodbury et al, 2000). Studies of 
mRNA expression of neuronal markers by RT-PCR confirmed the upregulation 
of nestin, NSE, NFM and MAP2 by 6-24 hours. Woodbury described 
upregulation of neuronal gene transcripts in his work following this protocol as 
well, but this was at variance with Lu et al. who observed staining for neuronal 
proteins but no upregulation of their mRNAs (Lu et al, 2004). Once again the 
upregulation was very rapid, and was not linked to a coordinated increase in 
the neural progenitor marker nestin prior to more mature neuronal markers. This 
may be because the process was so rapid, or influenced by the high rates of 
cell death in these experiments biasing towards particular cell types, or most 
likely because the transcriptional upregulation is not coordinated and probably 
represents a less-directed transcriptional upregulation driven by severe cell 
stress. Although the results of my study confirmed the expression of a several 
neuronal markers, immunophenotype alone is not sufficient to define a neuronal 
cell. In fact, there needs to be considerable care in interpreting neural markers 
in isolation. For example, ßlll tubulin, although used extensively to label newly- 
formed neurons, should be used with caution as it can also be expressed in 
other cell types including astrocytomas (Katsetos et al, 2001). NSE similarly can 
be found in many different non-neural cell types (Sensenbrenner et al, 1997). 
On the other hand, the upregulation of the neurofilaments (Huneeus & Davison, 
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1970) and the presence of synaptophysin (Wiedenmann & Franke, 1985) point 
toward a neuronal phenotype. I also studied the expression of MAP2 which falls 
into 2 groups: MAP2c which identifies neurons but also neural progenitors 
which can differentiate into neurons or glia (Rosser et al, 1997; Garner et al, 
1988), and MAP2ab which is specific for mature neurons and will not be present 
on immature cells. The antibody used reacts with all known forms of MAP2. 
Even NeuN which is one of the best neuronal markers, does not label all 
neuronal subtypes (Mullen et al, 1992). Although a combination of neuronal 
markers was used to define phenotype, the ultimate classification of a neuronal 
cell depends on its function. This was studied using single cell recordings and 
immunostaining for synaptophysin. 
4.3.2.3. Functional studies 
Electrophysiological comparisons were performed between nave and 
`differentiated' fetal MSC and found no significant differences between the two 
populations. Importantly there were cells with VGSC both in naive and 
`differentiated' populations. The presence of VGSC was confirmed by abolishing 
the inward current by treatment with the sodium channel blocker, TTX and the 
loss of the current when in sodium-free buffer. In addition, no spontaneous 
spiking activity was observed. A similar approach was used as that described 
for studying functional characteristics of differentiated MAPC (Jiang et al, 2003). 
In these experiments differentiating MAPC to cells of neuronal phenotype using 
growth factors, an upregulation of VGSC was observed over time. Interestingly 
the electrophysiological properties of undifferentiated cells were not studied, or 
presented (Jiang et al, 2003). Similarly, when Wislet-Gendebien et al 
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demonstrated action potentials and responsiveness to neurotransmitters of 
nestin+ MSC after co-culture with cerebellar granule neurons (Wislet-Gendebien 
et al, 2005), and Cho et al. claimed electrophysiological evidence of neuronal 
differentiation in response to retinoic acid (Cho et al, 2005), control 
undifferentiated MSC data was also not presented. Clearly functional studies 
are much stronger when the undifferentiated cell characteristics are more 
clearly defined. 
4.3.3. Conclusion 
Although my data do not rule out the potential of fetal MSC to differentiate into 
neurons, they demonstrate a very vigourous and rapid change in morphology 
and acquisition of neuronal phenotype without evidence of functional 
differentiation. Genuine neuronal differentiation of fetal MSC requires the 
ordered adoption of neuronal morphology and phenotype as well as acquisition 
of electrophysiological properties of neurons. Like that of Lu et al. (Lu et al, 
2004), Neuhuber et al. (Neuhuber et al, 2004) and Croft et ai. (Croft & 
Przyborski, 2006), the data presented here suggest that the dramatic changes 
induced by exposure of fetal MSC to medium containing BHA, although 
interesting, do not appear to result in functional neuronal cells and it is likely that 
they result from cytotoxic changes and cell stress. 
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CHAPTER 5 
APOPTOTIC SIGNALLING IN 
FETAL MSC 
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5.1. Introduction 
Although it might be expected that highly proliferative stem cells have effective 
and efficient death machinery, there is surprisingly little published work on 
apoptotic signalling pathways in MSC or bone marrow-derived stromal cells 
(Lepri et al, 1998; Kim et al, 2003), and few studies investigating apoptotic 
machinery in other stem cells (Sleeper et al, 2002; Ceccatelli et al, 2004). Until 
this study (Kennea et al, 2005), there were no published studies demonstrating 
functional intrinsic and extrinsic pathways in naive human MSC. A variety of 
intracellular signalling pathways have been shown to be involved in the 
regulation of the apoptotic death programme in eukaryotic cells (Muller-Ehmsen 
et al, 2002). One of the major pathways involves mitochondria. Stress signals 
are transduced to the mitochondria where they trigger release of cytochrome c 
(and other proteins) from the mitochondrial intermembrane space into the 
cytosol. Cytochrome c causes the oligomerisation of Apaf-1, which in turn 
activates the apoptotic protease, caspase-9 in an ATP dependent manner. 
Active caspase-9 then recruits and activates caspase-3 by cleavage 
(Hengartner, 2000). The second major apoptotic pathway is the death receptor 
pathway. When death receptors (for example CD95 / Fas) are bound by their 
specific ligand, they recruit adaptor molecules (eg. FADD) which in turn recruit 
initiator caspases (such as caspase-8), which cleave and activate caspase-3, 
an executioner caspase. Both these pathways are known to be important in the 
brain. 
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In this section, I exposed undifferentiated fetal MSC to three apoptotic stimuli 
(staurosporine, serum withdrawal and CD95 / Fas ligation) and investigated 
activation of the intrinsic (mitochondrial) and extrinsic (death receptor) 
pathways. I report the presence and activity of both death pathways, and 
demonstrate the sensitivity of fetal MSC to all three apoptotic stimuli. 
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5.2. Results 
5.2.1. Staurosporine (SSP) induces apoptosis 
In order to examine the effects of increasing concentrations of SSP on fetal 
MSC, I assessed cell survival following a 24 hour exposure, by MTT assay and 
cell counting experiments. As shown in Figure 5.01., SSP lead to death of fetal 
MSC in a concentration-dependent manner. Maximum toxicity was observed at 
approximately 200nM. The dead cells had typical late apoptotic morphology and 
apoptosis was confirmed with in-situ end labelling. 
100 
\° 0 
80 
60 
H 
ýj 40 
20 
0 
Concentration SSP / pM 
Figure 5.01. SSP kills fetal MSC in a concentration-dependent manner. 
Fetal MSC were plated at 16,000 cells per well (5x104/cm2). Cells were exposed 
to increasing concentrations of SSP in DMEM + 0.5% FCS for 24 hours. Cell 
survival was estimated by MTT assay, by comparison with a standard curve of 
untreated cells, and accounting for background absorbance using lysis controls. 
Repeat experiments were performed five times. Results are expressed as mean 
± SD (n=4). 
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To extend this study, a time course was carried out to determine the kinetics of 
SSP toxicity in MSC exposed to 200nM SSP for defined periods, with MTT 
metabolism measured at each time point. MTT metabolism started to decline 
within 1 hour of SSP addition. At 3.5 hours only 60% of the MTT metabolism of 
untreated cells remained (Figure 5.02. ). 
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Figure 5.02. Time-dependent cell death of fetal MSC following SSP 
exposure. Rapid cell death was seen with over 75% of cells dying within the 
first 5 hours. Fetal MSC were seeded in quadruplicate at 5x104/cm in 96 well 
plates. SSP was added to appropriate wells at defined time points to obtain a 
final concentration of 200nM (in DMEM + 0.5% FCS) for the time of the 
experiment. Cell survival was assessed by MTT assay, and confirmed in cell 
counting experiments. Untreated wells were used as lysis controls for 
background absorbance. These results were confirmed in four separate 
experiments, and data are expressed as percentage of untreated cells ± SD. 
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Morphological changes appeared within minutes of SSP exposure, and 
progressive cytoplasmic retraction and pyknotic nuclei were seen within two 
hours. Between 4 and 8 hours most cells looked abnormal, and many had 
detached leaving cellular debris visible (Figure 5.03. ). 
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Figure 5.03. Morphological changes of apoptosis over time with exposure 
to SSP. 200nM SSP caused time-dependent death of fetal MSC with 
characteristic apoptotic morphology. Before exposure (untreated), cells appear 
healthy and near confluent. By 2 hours cytoplasmic retraction is visible in most 
cells, with pyknotic nuclei becoming evident in some cells. This progresses and 
by 8 hours the majority of cells are dead, with phase bright pyknotic nuclei 
abundant. These morphological changes were consistent in more than ten 
repeat experiments. 
TdT-mediated Deoxyuridyltriphosphate Nick End Labelling (TUNEL) was 
performed in untreated and SSP-treated cells to label the 3' OH termini of DNA 
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fragments in apoptotic cells (Figure 5.04. ). As shown in Figure 5.04. A, 
untreated cells were TUNEL negative, while cells treated with a 200nM SSP for 
were positively stained with the proportion increasing from 2-8 hours (Figure 
5.04. C), indicating DNA fragmentation. 
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Figure 5.04. TUNEL confirmed apoptosis in cells treated with SSP. TUNEL 
was performed in untreated and SSP-treated cells to label 3' OH termini of DNA 
fragments in apoptotic cells. TUNEL+ cells were visualised by a peroxidase / 
DAB system with positive nuclei staining brown. Untreated cells were TUNEL 
negative, while cells treated with a 200nM SSP for were positively stained (A, 
x10). Cells that were TUNEL+ had typical late apoptotic morphology with 
cytoplasmic retraction and pyknotic nuclei, and some cells had nuclear 
fragmentation visible (inset) (B, x40). The proportion of TUNEL positive cells 
was quantified in cell counting experiments (performed in quadruplicate, 
repeated twice) and increased from 2-8 hours (C). In all experiments SSP- 
exposed fibroblasts were used as positive controls. 
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5.2.1.1. SSP triggers an early commitment to apoptosis 
SSP clearly triggered commitment to apoptosis early after exposure as 
morphological changes appeared within minutes. In order to study this further, 
fetal MSC were treated with SSP (200nM) for defined times and then washed 
thoroughly to remove SSP. The cells were then cultured in complete medium 
(1% serum, which allowed survival, but not proliferation) for 24 hours to allow 
surviving cells to recover. The proportion of surviving cells, compared to 
untreated cells washed in a similar way, was estimated the following day by 
MTT metabolism and counting experiments. With only a 15 minute exposure to 
SSP, 85% of fetal MSC were committed to apoptotic cell death (Figure 5.05. ). 
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Figure 5.05. SSP triggers early commitment to apoptosis in fetal MSC. 
Cells were exposed to SSP (200nM) for defined periods of time, washed 
thoroughly and allowed to recover in DMEM + 10% FCS for 24h. At the end of 
the experiment cell viability was assessed by MTT assay. This result was 
confirmed in four independent experiments. A representative experiment is 
shown and data are expressed as percentage of untreated cells ± SD. 
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5.2.1.2. The signalling pathways leading to apoptosis with SSP 
Having established that fetal MSC die by apoptosis when exposed to SSP, the 
apoptotic pathway was investigated in more detail. SSP has been previously 
reported to induce apoptosis via the mitochondrial (or intrinsic) pathway in 
numerous cell types (Ceccatelli et al, 2004; Chae et al, 2000; Feng & Kaplowitz, 
2002; Zhang et al, 2003; Zhang et al, 2004b). Therefore, the release of 
cytochrome c and the subsequent cleavage of relevant caspases was 
examined. 
5.2.1.2.1. SSP triggers cytochrome c release from mitochondria 
In time course experiments with SSP (200nM), cytochrome c localisation was 
studied by immunocytochemistry (Figure 5.06. ). In untreated cells cytochrome 
c staining had a punctate or reticular pattern demonstrating localisation to the 
mitochondria. Within 1 hour of exposure, cells with more diffuse cytoplasmic 
staining were apparent, indicating release from mitochondria into the cytosol. 
Interestingly, at this early time-point, cytochrome c release could be dissociated 
from subsequent nuclear pyknosis and fragmentation. However by 4 hours both 
cytochrome c release and nuclear pyknosis were evident, and at 8 hours 60% 
of cells were positive for cytosolic cytochrome c. 
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Figure 5.06. Cytochrome c is released early from mitochondria after SSP 
treatment. Immunofluorescence studies of cytochrome c localisation in time 
course experiments with exposure to SSP (200nM). In healthy cells, 
cytochrome c (antibody supplied by BD Biosciences, Oxford, UK), stained 
green, is located in the mitochondria and stains with a punctate or reticular 
pattern. Nuclei are counterstained with DAPI. When cytochrome c is released 
into the cytosol, staining becomes more diffuse. With 1 hour's exposure to SSP 
the staining is more diffuse in some cells, and progresses up to 4 hour's 
exposure. Cytochrome c release was quantified using immunocytochemistry in 
time-course experiments; 25% of cells had released cytochrome c by 4 hours 
exposure. This experiment was repeated five times and a representative 
experiment is shown here with data plotted as mean ± SD of 4 data points. 
5.2.1.2.2. SSP triggers activation of caspase 9 and caspase 3 
At defined time points of SSP (200nM) exposure caspase 9 and 3 cleavage 
were studied by immunocytochemistry (Figures 5.07. - 5.09. ) and western 
blotting (Figure 5.10. ) using primary antibodies specific for the active, cleaved 
fragments of caspase 9 and 3. Caspase activation was confirmed by both 
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methods; significantly caspase 9 activation began before caspase 3 and 
preceded nuclear pyknosis. Interestingly active caspase 9 staining 
demonstrated a nuclear or perinuclear pattern in many cells (Figure 5.07. ). 
SSP exposed Rat-1 fibroblasts were used as positive controls in these 
experiments. 
Caspase 9 cleavage 
Figure 5.07. Caspase 9 is activated early in response to SSP. Active 
cleaved caspase 9 (red) is evident in many cells by immunocytochemistry within 
2-4 hours of exposure to SSP (200nM). After 4 hours exposure, nearly 80% of 
fetal MSC are positive for cleaved caspase 9. Interestingly active caspase 9 
staining demonstrated a nuclear or perinuclear pattern in many cells (inset, 4 
hours) - this was a consistent finding in three repeat experiments. In these 
experiments nuclei are counterstained with DAPI. 
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Figure 5.08. Caspase 3 is cleaved in response to SSP. Active cleaved 
caspase 3 (green) can be seen by immunocytochemistry at 2-4 hours of 
exposure to SSP (200nM) in scattered cells, this contrasts with cleaved 
caspase 9 which is seen in the majority of cells by 4 hours. After 8 hours, the 
majority of fetal MSC are positive for cleaved caspase 3. 
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Figure 5.09. Caspase 9 activation precedes the appearance of active 
caspase 3. Immunocytochemical staining for cleaved caspases 9 and 3 was 
quantified in time-course studies of SSP exposure. This is displayed 
graphically, and demonstrates the cleavage of caspase 9 before 3. There was a 
significant (p<0.01, ANOVA) difference in the proportion of cells with cleaved 
caspase 9 compared with cleaved caspase 3 after exposure to SSP. These are 
representative data from a single experiment where proportions of positive cells 
were counted in 5 fields and data expressed as mean ± SD. 
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Figure 5.10. Western blot analysis of caspase activation. Caspase 9 
activation precedes the appearance of active caspase 3. Whole cell lysates 
were generated from fetal MSC at specific points in time-course studies of SSP 
(200nM) exposure. Western blot analysis was performed using cleavage- 
specific antibodies for active caspases 9 and 3. a tubulin was used as a loading 
control. Cleaved caspase 9 was first evident after 1 hour exposure, increasing 
dramatically between 2 and 4 hours, and diminishing after 12 hours. Cleaved 
caspase 3 was only evident after 6 hours. 
The cleavage of caspases 9 and 3, confirmed by immunocytochemistry and 
western blotting, is important and preceded nuclear pyknosis and DNA 
fragmentation. There was, however, no immunocytochemical evidence of 
caspase 8 cleavage following exposure to SSP (data not shown) in these 
experiments. 
Next I confirmed the central role of caspases 9 and 3 in the apoptotic process in 
studies using cell-permeable caspase inhibitors. SSP-induced cell death was 
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attenuated by incubation with both caspase 9 and pan-caspase inhibitors in a 
dose-dependent manner (Figure 5.11. ), while caspase 8 inhibition (with IETD- 
fmk) had no protective effect (data not shown). 
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Figure 5.11. Inhibition of caspase activity attenuates SSP induced 
apoptosis. Pre-treatment of cells for 1 hour prior to SSP exposure (200nM) 
with cell permeable pan-caspase inhibitor ZVAD. fmk or the caspase 9 inhibitor 
Z-LEHD. fmk (Gentaur, Brussels, Belgium) protected against cell death 
determined by MTT assay (at 24 hours). 80pM ZVAD. fmk lead to >50% 
survival, in an experiment where SSP-treated cells without inhibitor all died by 
24 hours. Cells not treated with SSP ± inhibitor were used as positive controls. 
Inhibition of caspase 8 had no effect (data not shown). Data are from a single 
experiment, and plotted as the mean ± SD. 
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5.2.2. Serum withdrawal induces apoptosis 
The SSP data establish that fetal MSC have intact and functional apoptotic 
machinery. To examine the response of fetal MSC under a more `physiological' 
stress, serum withdrawal was used as a death stimulus. In order to determine 
the effects of serum withdrawal, fetal MSC monolayers were washed thoroughly 
and the medium replaced with DMEM alone, without addition of FCS or growth 
factors. Death was determined by cell counting experiments (using trypan blue 
exclusion) and by MTT metabolism. Although fetal MSC died by apoptosis 
following serum withdrawal, this took days, with over 10% cells surviving 
greater than a week, and some cells even surviving 2 weeks (Figure 5.12. ). 
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Figure 5.12. Fetal MSC die slowly following serum withdrawal. Cells were 
plated overnight in 0.5% serum (to allow adherence), washed thoroughly and 
the medium replaced by DMEM alone with no additional growth or survival 
factors. At defined time points, cell survival was measured in cell counting 
experiments and by MTT metabolism after differing periods of withdrawal. This 
graph shows representative data from a MTT experiment performed in 
quadruplicate - these results were mirrored in the direct counting experiments. 
Data are presented as mean ± SD. Similar results were obtained in three repeat 
experiments. 
5.2.2.1. Serum withdrawal does not lead to differentiation or 
loss of mitotic potential. 
During serum withdrawal, cells became increasingly thin and elongated and at 
any time point very few cells had typical apoptotic morphology. Interestingly 
serum withdrawal did not commit these cells to a differentiated, post-mitotic 
state. Indeed, when serum was added back after 2 weeks of serum withdrawal, 
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cell proliferation was again rapid (Figure 5.13. ), and cell morphology returned 
to normal with no apparent change in phenotype (data not shown). 
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Figure 5.13. Serum withdrawal does not lead to differentiation or loss of 
mitotic potential. During prolonged serum withdrawal, cells became 
increasingly thin and elongated. Interestingly serum withdrawal did not commit 
these cells to permanently drop out of cell cycle. Indeed, when serum was 
added back after 2 weeks of serum withdrawal, cell proliferation was again 
rapid and cell morphology returned to normal with no apparent change in 
phenotype. 
5.2.2.2. Serum withdrawal leads to apoptosis though activation 
of the mitochondrial pathway. 
During serum withdrawal cells died with typical apoptotic morphology. It was 
interesting that during serum withdrawal experiments; very few adherent cells 
showed typical apoptotic morphology or had TUNEL positive nuclei at any given 
time. Less than 2% of cells could be clearly seen with cytosolic cytochrome c, 
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and cleaved caspases 9 and 3 (Figure 5.14. ). No caspase 8 cleavage was 
observed. Although cleaved caspases 9 and 3 could be visualised by 
immunocytochemistry, western blot analysis was not sufficiently sensitive to 
detect caspase cleavage in such a small proportion of cells. 
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Figure 5.14. Serum withdrawal results in release of cytochrome c and 
caspase activation. After three days of serum withdrawal, there are occasional 
cells with diffuse cytochrome c staining (A), and cells with positive staining for 
active caspases 9 (B) and 3 (C) (highlighted with arrows). Serum withdrawal 
results in apoptotic morphology with release of cytochrome c and activation of 
caspases generally seen in cells with pyknotic nuclei. Fewer than 2% of cells 
stain for active cleaved caspases at any given time point (D). 
5.2.2.3. Cell density is important for fetal MSC survival 
Preliminary studies from our lab suggested that fetal MSC survival following 
serum withdrawal was cell density-dependent. Therefore, to investigate the 
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hypothesis that high density-plated cells survive better than low density-plated 
cells, fetal MSC were seeded at 20,000 or 10,000 cells/well in a 96-well plate. 
Cells were serum-starved for a period of 2 weeks and survival assessed by 
MTT assay. The results indicated that cells cultured at high density had 
increased survival, particularly towards the later time points of serum withdrawal 
(Figure 5.15. ). For example, after 9 days of serum deprivation, 20% of cells 
survived in high-density cultures whereas all cells had died in low-density 
cultures. 
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Figure 5.15. Serum withdrawal time course with high and low density 
cultures. Cells were serum-starved for a period of 2 weeks and survival 
assessed by MTT assay. Cells cultured at high density survived better, 
particularly towards the later time points of serum withdrawal. Data are 
presented as mean ± SD. 
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The survival of cells plated at higher density was further demonstrated by counting 
in replating experiments (Figure 5.16. ). In these experiments, cells were seeded in 
six-well plates at densities between 1,250 and 10,000 cells/cm2 overnight in 0.5% 
serum and the following day washed thoroughly and exposed to serum and growth 
factor withdrawal (in DMEM alone). After 72 hours, plates were washed, and the 
cells detached using trypsin/EDTA. After centrifugation, pellets were resuspended 
in 1 ml DMEM / 10% FCS and replated in 24 well plates. The next day plates were 
washed, cells detached and then resuspended in 125pl medium. The cells were 
examined and counted using a haemocytometer. 
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Figure 5.16. Higher cell density protects against serum withdrawal 
induced cell death. In replating experiments cells were seeded in six-well 
plates at densities between 1,250 and 10,000 cells/cm2 and exposed to serum 
withdrawal for 72 hours. Cells were trypsinised and replated in complete 
medium overnight and counted the following day. Cell survival was estimated 
as a proportion of the number of cells initially plated. All assays were performed 
in triplicate and data expressed as mean ± SD. 
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The enhanced survival in high density cultures could be as a result of cell-cell 
contact, and / or secreted soluble survival factors. To test the hypothesis that 
soluble signals released by the high density cultures confer protection against 
cell death, low density-cultured fetal MSC were serum-deprived over a period of 
2 weeks using either native culture medium (DMEM) alone or medium 
conditioned by high density (serum-starved) fetal MSC. In these experiments, it 
was evident that cells cultured in the conditioned medium had an increased 
survival over those that were cultured in DMEM alone (Figure 5.17. ) indicating 
that conditioned medium may protect low density cultures from cell death. These 
experiments do not explore the possible added protection by cell-cell contact. 
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Figure 5.17. Conditioned medium from high density cultures enhances 
survival in low density cultures during serum withdrawal. Low density- 
cultured fetal MSC were serum-deprived over a period of 2 weeks using either 
native culture medium (DMEM) alone or medium conditioned by high density 
(serum-starved) fetal MSC, the medium was changed every 3 days. Cells 
cultured in the conditioned medium had an increased survival over those that 
were cultured in DMEM alone indicating the presence of soluble factors from 
MSC enhancing survival. 
5.2.2.4. Molecular pathways involved in serum withdrawal 
I have begun to investigate the molecular pathways involved in apoptosis with 
serum withdrawal. The PI3K/AKT pathway has been previously implicated in 
promoting survival in the presence of growth factors (Kennedy et al, 1999) but 
never studied in human fetal MSC following serum withdrawal. I speculated 
that the absence of appropriate growth or trophic factors in serum withdrawal 
experiments could result in dephosphorylation of AKT and inactivation of this 
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pathway. We therefore studied the phosphorylation status of both AKT and one 
of its downstream targets FKHR. Western blot analysis demonstrated a marked 
reduction in phosphorylated AKT over time with serum withdrawal and, indeed, 
no phosphorylated AKT(Ser 473) was detected beyond 9 days by western blot 
analysis. One of AKT's downstream targets, forkhead (FKHR), was also studied 
and its phosphorylation declined albeit with a slower time-course than for AKT 
(Figure 5.18. ). These data implicate the P13 kinase / AKT pathway in serum 
withdrawal. 
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Figure 5.18. There is a decrease in AKT and FKHR phosphorylation during 
serum withdrawal. Western analysis with whole cell lysates, using phospho- 
specific antibodies, confirmed a reduction in phosphorylated AKT (ser 473) and 
FKHR over time a tubulin was used as loading controls (A). The reduction in 
phospho-FKHR (ser256) over this time-course was also demonstrated with 
immunocytochemistry (B). 
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5.2.3. Study of the death receptor pathway in fetal MSC 
The SSP and serum withdrawal experiments confirm the presence of a 
functional intrinsic, mitochondrial apoptotic pathway. I next extended the study 
to explore the role of the extrinsic, death receptor, pathway. Fas ligation was 
chosen as a stimulus as the Fas receptor has been demonstrated on murine 
bone marrow stromal cells (Lepri et al, 1998) and as detailed earlier Fas 
mediated cell death is known to be involved following perinatal brain injury. 
There have been no studies of the expression of Fas on fetal MSC, and no 
studies exploring the death receptor pathway in these cells. 
5.2.3.1. Fetal MSC express the Fas death receptor and the 
adapter protein FADD 
The expression of CD95 / Fas receptor was confirmed by western blot analysis 
(not shown) and its surface expression was demonstrated to be highly polarised 
using immunocytochemistry (Figure 5.19. ). FADD too, was present with a 
suggestion that its expression was both cytosolic and nuclear (Figure 5.19. ). 
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Figure 5.19. Fetal MSC express Fas and FADD in a functional death 
receptor pathway. Fas receptor could be detected by immunocytochemistry 
(red) with the pattern appearing polarised on untreated cells (A). FADD, stained 
in green (B) was present in the cytosol of fetal MSC, but staining also co- 
localised with the nucleus. The nuclei in these experiments were counterstained 
with DAPI. 
Neural Differentiation of Fetal Mesenchymal Stem Cells Chapter 5 
299 
5.2.3.2. Fas Ligand induced cell death in a concentration- 
dependent manner 
The addition of Fas ligand (FasL) to healthy fetal MSC induced cell death by 
apoptosis defined by cell morphology and TUNEL. In time-course experiments 
an exposure time of 72 hours was sufficient to kill maximally (56% of cells). 
Moreover, there was a dose-dependent increase in apoptosis following 
exposure to FasL (Figure 5.20. ) determined by MTT assay. These results were 
confirmed in cell counting experiments. A20 cells (Hetz et al, 2002), which are 
Fas-expressing cells that die by apoptosis on exposure to FasL, were used as 
positive controls for FasL-induced cell killing. 
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Figure 5.20. Fas ligand induces concentration-dependent cell death in 
fetal MSC. The Fas pathway was functional and apoptosis was induced over 72 
hours in a concentration-dependent manner using cross-linked recombinant 
Fas ligand (A). Cell death was estimated by MTT assay and survival presented 
as a percentage compared with untreated cells. Over this time course, Fas 
dependent apoptosis could be completely blocked using the pan-caspase 
inhibitor ZVAD. fmk (40pM), and attenuated by caspase 8 inhibition (IETD. fmk, 
10pM) (B). The data are from a single experiment and are plotted as the mean 
+/- SD of 3 data points. 
5.2.3.3. FasL induced death could be attenuated by caspase 
inhibitors 
FasL induced death could be inhibited by the pan-caspase inhibitor ZVAD. fmk 
and by the selective caspase 8 inhibitor, IETD. fmk. A1 hour pre-incubation with 
either inhibitor was sufficient to protect against Fas ligand induced apoptosis 
(Figure 5.20. ). Caspase 9 inhibition with Z-LEHD. fmk, at an effective dose 
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(defined as 20-8OpM by the SSP experiments) was not protective against Fas 
ligand induced death (data not shown). 
5.3. Discussion 
5.3.1. Summary of results 
The aim of this study was to determine whether human fetal MSC have functional 
apoptotic machinery in both the intrinsic (mitochondrial) and extrinsic (death 
receptor) pathways, and to investigate whether stem cell survival can be prolonged 
by inhibition of death signalling. Activation of the mitochondrial pathway by SSP was 
demonstrated by the release of cytochrome c from mitochondria and subsequent 
cleavage of caspases 9 and 3 followed by DNA fragmentation indicated by TUNEL. 
Serum withdrawal resulted in a similar pattern of molecular events, although the 
time course was significantly longer. In addition, the P13K/Akt pathway was down- 
regulated in serum-starved MSC cultures. Caspase 9 inhibition, and the pan- 
caspase inhibitor ZVAD. fmk attenuated apoptosis triggered by SSP treatment. Fetal 
MSC express the Fas receptor (CD95) and the adapter molecule FADD and the 
death receptor pathway was demonstrated to be functional by the rapid induction of 
apoptotic death by Fas ligand. This effect was attenuated by the selective caspase- 
8 inhibitor IETD. fmk as well pan-caspase inhibitors. 
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5.3.2. Critical Analysis 
5.3.2.1. Choice of death stimuli 
Understanding the mechanisms by which MSC undergo cell death may help in 
developing strategies to promote graft survival in stem cell therapy. In the 
present study, I show that primary human MSC can undergo cell death by 
apoptosis triggered by three different stimuli - exposure to SSP, serum 
withdrawal or Fas ligation. The choice of these stimuli was deliberate: SSP was 
used as a stress stimulus known to activate the mitochondrial pathway in many 
other cell types, serum withdrawal to mimic growth or trophic factor withdrawal, 
and Fas ligation to model death receptor-mediated apoptosis. 
5.3.2.1.1. SSP and serum withdrawal activate the mitochondrial 
pathway 
My results show that fetal MSC are very sensitive to SSP with a rapid 
commitment to apoptotic cell death via the mitochondrial pathway. SSP-induced 
apoptosis was preceded by cytochrome c release from mitochondria, cleavage 
of caspase 9 and then caspase 3. The mode of cell death was confirmed by 
morphological criteria (nuclear pyknosis and cytoplasmic shrinkage) and by 
TUNEL. Mitochondria are known to be central to the regulation of apoptosis 
(Green & Reed, 1998) and indeed a recent study of adult bone marrow stromal 
cells exposed to leptin (Kim et al, 2003) and studies of neural stem cell death 
(Sleeper et al, 2002; Tamm et al, 2004) have confirmed their role in apoptosis 
of early multipotent cells. In my study, mitochondrial localisation (punctate or 
reticular staining) of cytochrome c was confirmed in healthy fetal MSC. Within 2 
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hours of SSP exposure cytochrome c was seen diffusely throughout the cytosol 
and in some cells this occurred prior to nuclear pyknosis. Activation of caspases 
9 and 3, confirmed using cleavage-specific antibodies, was directly involved in 
cell death; cell-permeable inhibitors of these caspases attenuated SSP-induced 
apoptosis, whereas caspase 8 inhibition had no effect. Interestingly cleaved 
caspase 9 staining had a nuclear or perinuclear pattern in many cells 
undergoing apoptosis. This is consistent with a previous study of ischaemic 
neuronal death that demonstrated translocation of caspase-9 from mitochondria 
to the nucleus in cells undergoing apoptosis (Krajewski et a/, 1999). The role of 
cleaved caspase-9 may be to cleave and degrade nuclear substrates (Alnemri, 
1999). 
Cell death is the default pathway for many cells; survival depends on local 
survival signals (Raff, 1992). It may well be that stem cell grafts fail due to a 
lack of such signals. To examine the effect of growth and trophic factor loss, 
serum withdrawal was used. Cells cultured in DMEM alone with no additional 
factors underwent apoptosis albeit over a prolonged period of time. At any given 
time point after serum withdrawal, only a small proportion of cells showed 
cytochrome c release from the mitochondria, and cleavage fragments of 
caspases 9 and 3. Moreover, the temporal relationship between activation of 
caspase 9 and 3 was not evident as in the SSP experiments. This may reflect 
the observation that cell death was both asynchronous and occurred at a low 
rate in serum-deprived cultures. MSC were relatively resistant to serum 
withdrawal with over 10% of cells surviving even after 8 days in culture. These 
cells had not permanently exited the cell cycle and could proliferate again when 
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serum was added back. This is particularly relevant since serum withdrawal is 
one of the approaches inducing differentiation in embryonic and neural stem 
cells. We have begun to investigate the molecular pathways involved in 
apoptosis with serum withdrawal. We found a reduction in both AKT and FKHR 
phosphorylation in cultures over time following serum withdrawal. This 
observation is significant in the light of a recent study demonstrating that the 
over-expression of AKT in adult-derived MSC rendered these cells more 
resistant to apoptosis in a model of ischaemic heart repair (Mangi et al, 2003). 
Although beyond the scope of the present study, it would be interesting to 
investigate the involvement of other AKT substrates in serum withdrawal 
dependent cell death. For example, AKT has been shown to phosphorylate and 
inactivate Bad (Datta et al, 2000), and caspase 9 (Cardone et al, 1998), both 
important components of the apoptotic machinery. 
5.3.2.1.2. The death receptor pathway 
The SSP and serum withdrawal experiments confirm the presence of a 
functional intrinsic, mitochondrial apoptotic pathway. I next extended the study 
to explore the role of the extrinsic, death receptor, pathway. Fas ligation was 
chosen as a stimulus as Fas receptor has been demonstrated previously on 
murine bone marrow stromal cells. I found that Fas receptor is expressed on 
healthy fetal MSC in a highly polarised manner, and FADD expression was 
detected both in the cytosol and nucleus. The nuclear localisation of FADD is 
consistent with a recent report (Gomez-Angelats & Cidlowski, 2003), although 
its precise role is not well understood. FADD has been shown to interact with 
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several molecules in the nucleus involved in the regulation of apoptosis, 
including methyl-Cpg binding protein-4 (Screaton et al, 2003). 
The presence of CD95 / Fas alone does not prove the presence of an active 
extrinsic death pathway. Many Fas expressing cells do not undergo death when 
Fas receptor is bound by its ligand (Ahn et al, 2001). Indeed, alternative 
biological processes such as proliferation in T cells (Alderson et al, 1993) and 
fibroblasts (Aggarwal et al, 1995), activation of NFKB (Rensing-Ehl et al, 1995) 
and neurite formation in primary sensory neurones (Desbarats et al, 2003) have 
also been attributed to Fas ligation. Although Fas receptor expression has been 
demonstrated on neural stem cells, agonistic Fas antibody failed to induce 
apoptosis (Tamm et al, 2004), with authors speculating that either Fas has a 
separate role in these cells, or the extrinsic pathway may be developmentally 
regulated. The presence of Fas and FADD in human fetal MSC does however 
constitute an effective death receptor pathway leading to the dose dependent 
Fas ligand-induced apoptosis demonstrated herein. This cell death involved the 
cleavage of caspase 8 and 3 and could be effectively blocked by caspase 8 
inhibition. 
5.3.3. Conclusion 
In summary, I present the first evidence to demonstrate functional mitochondrial 
and death receptor apoptotic pathways in primary naive human fetal MSC. A 
thorough understanding of apoptotic signalling in these cells will be helpful in 
designing strategies for increasing the survival of stem cell grafts. In addition, 
these apoptotic pathways may be developmentally regulated, and further work 
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is underway to examine the effects of differentiation on the sensitivity of these 
cells to death stimuli. 
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CHAPTER 6 
GENERAL DISCUSSION 
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6.1 Hypotheses 
The pnniciple aim of my thesis was to examine whether human primary fetal MSC 
differentiate into neural lineages both using extrinsic soluble factors in vitro, and in 
vivo. I hypothesised that human fetal MSC would (i) be differentiated into 
oligodendrocytes in vitro using medium containing conditioned medium from B104 
cells; (ii) be induced to neuronal phenotype using extrinsic soluble factors similar to 
those described with other sources of MSC; (iii) differentiate into neural lineages in 
the developing murine brain; and (iv) have active and functional intrinsic and 
extrinsic apoptotic pathways that are influenced by caspase inhibitors. 
6.2 Findings 
6.2.1 Fetal MSC are differentiated into oligodendrocytes 
in vitro using conditioned medium from B104 cells 
Fetal MSC acquired oligodendrocyte morphology and phenotype when cultured in 
medium containing conditioned medium from B104 cells. A concentration and time- 
dependent effect of B104 conditioned medium was demonstrated on fetal MSC. 
With higher concentrations of B104 conditioned medium a greater proportion of cells 
underwent morphological change with the early upregulation of the neural progenitor 
marker nestin. Above 40-50% B104 conditioned medium, increasing cell death was 
observed, and therefore 40% was used in later experiments. The stepwise activation 
of neural progenitor markers (nestin, notchl and musashi), oligodendrocyte 
transcription factors Olig 1, Olig 2 and NKx2.2, followed by the appearance of early 
then more mature oligodendrocyte phenotypic markers was demonstrated. To my 
knowledge this is the first work using this approach in MSC, and indeed those 
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studies claiming low-level oligodendrocyte differentiation from other sources of MSC 
using other protocols have not demonstrated a coordinated differentiation 
programme that is implied by my results. Importantly, A novel method of deriving 
clonal populations of fetal MSC (clonality proved by Southern blot analysis) was 
developed and demonstrated both oligodendrocyte and mesodermal (bone) 
differentiation from the same clone. 
6.2.2 Fetal MSC can be induced to neuronal phenotype 
using extrinsic soluble factors 
Several initial approaches were tested to derive neuronal cells from fetal MSC using 
protocols based on published work on human adult-derived cells or rodent MSC. 
The addition of retinoids with or without BDNF (Sanchez-Ramos et al, 2000; Cho et 
a/, 2005) did not lead to morphological and phenotypic change. Moreover, the 
concentration of retinoic acid used in previously published experiments (30 NM) 
(Cho et al, 2005) lead to cell death in the present study. Controversial data 
suggesting neuronal differentiation of MSC using the potent reducing agent BHA 
were reproduced in fetal MSC. In these experiments there was a very rapid change 
in cell morphology (within minutes), with cytoplasmic retraction and the appearance 
of processes, and the acquisition of neuronal phenotypic markers both at RNA and 
protein levels. In these experiments, I could not demonstrate a temporal pattern of 
progenitor phenotype prior to the presence of mature neuronal markers. As in 
Woodbury's experiments (Woodbury et al, 2000), the observed changes were 
enhanced by pre-exposure to bFGF. The resulting cells, however, could not be 
maintained in culture, and exposure to BHA lead to massive cell death. Also, when 
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exposed cells were returned to growth medium (DMEM / 10% FCS) normal 
'fibroblastic' MSC morphology was observed in surviving cells. Single cell recordings 
comparing `undifferentiated' and `differentiated' cells found no difference in 
excitability and the presence of VGSC. Like others (Lu et al, 2004; Neuhuber et al, 
2004; Croft & Przyborski, 2006), 1 concluded that the morphological and phenotypic 
changes seen in these experiments are unlikely to represent true functional neuronal 
differentiation, and are more likely the result of cytoskeletal changes, and aberrant 
gene / protein expression due to toxic effects of the culture environment. 
6.2.3 Fetal MSC differentiate into neural lineages in the 
developing murine brain 
Fetal MSC were transplanted into the cerebral ventricles of E15 murine embryos 
and the pregnancies allowed to continue with the fate of transplanted cells 
determined at defined time points. Tracking cell fate involved the use of human- 
specific antibodies, human-specific FISH and constitutive eGFP expression (using 
lentiviral vector transduction). Although not the main focus of this study, the 
demonstration of high efficiency transduction of fetal MSC with an HIV-based 
lentiviral vector is important if this cell type is considered for ex-vivo gene therapy in 
the future. To this end, high level transduction with lentiviral and onco-retroviral 
vectors has been described by others in the group without deleterious effects on cell 
proliferation and differentiation (Campagnoli et al, 2002; Chan et al, 2005). My 
studies demonstrated that fetal MSC aggregate within the cerebral ventricles 
following injection and then migrate and appear to integrate into the host brain 
parenchyma. Although at later time-points an upregulation of nestin was observed, 
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there was no evidence of large scale neural differentiation with only 0.2% acquiring 
oligodendrocyte markers, this is very different to the results described by Munoz- 
Eliaz et al. (Munoz-Elias et al, 2004) who demonstrated that >77.3% of allogeneic 
MSC injected into embryonic rat brains adopted neuronal phenotype and had 
region-specific differentiation. In our experiments cell grafts were lost by about a 
month and there was evidence of a host response with host mononuclear cells 
present at the graft site. 
When fetal MSC were pre-exposed to ODM in vitro prior to injection for 48 
hours, injected cells were strongly nestin+ and they again aggregated in the 
ventricles before migration into the tissue. This pre-differentiation lead to 
enhanced acquisition (-4% of human cells) of oligodendrocyte markers (NG2, 
A2B5, CNPase and MBP). A FISH method was optimised to study the 
possibility of cell fusion using pan-centromeric FISH probes that gave multiple 
signals in any murine or human cell nucleus. Mouse and human probes were 
labelled with different colours and if cell fusion occurred, it would result in both 
colours being visualised in the same cell. When adjacent sections to those with 
apparent oligodendrocyte differentiation were studied there was no evidence of 
cell fusion. 
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6.2.4 Fetal MSC have active and functional intrinsic and 
extrinsic apoptotic pathways 
Next I demonstrated for the first time that SSP, serum withdrawal and FasL 
trigger apoptosis in human fetal MSC. The staurosporine and serum withdrawal 
experiments highlight that the mitochondrial pathway is present and functional. 
Cells died with typical late apoptotic morphology and DNA fragmentation was 
confirmed with TUNEL. A functional death receptor pathway was also 
demonstrated with apoptosis following exposure to FasL. 
Apoptosis was very rapid following SSP exposure, with almost all cells 
committed to death within one hour. In these experiments cytochrome c release 
preceded cleavage of caspase 9 which occurred before that of caspase 3. 
Caspase 9 is an initiator caspase and has a role in triggering the apoptotic 
machinery, while caspase-3 is an effector caspase at the end-point of an 
amplification cascade that orchestrates the cleavage of apoptotic substrates 
responsible for the morphological changes described in apoptosis. A selective 
Inhibitor of caspase 9 protected form SSP-induced cell death, confirming the 
reversibility of the mitochondrial pathway. 
Serum withdrawal triggered apoptosis with a small proportion of cells showing 
cytochrome c release and caspase activation at any of the time points. A 
temporal relationship between the activation of caspase-9 and caspase-3 was 
not clear because the rate of cell death itself was low, whereas the apoptotic 
process is rapid in any given cell. Fetal MSC were relatively resistant to serum 
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withdrawal, with approximately 10% of cells surviving even after a week. There 
was a density-dependent trend in survival, where high density populations had 
a survival advantage during serum withdrawal. This advantage might be 
attributed to cell-cell interactions or secreted factors. The effect of soluble 
factors was tested in experiments using conditioned medium from high density 
cultures and indeed this medium reduced cell death indicating the presence of 
undefined secreted survival factors. The PI3K/Akt pathway has been previously 
implicated in promoting cell survival in the presence of growth factors (Kennedy 
et al, 1997). 1 hypothesised that the absence of appropriate survival signals 
brought about by withdrawal of serum would result in dephosphorylation of Akt 
and the inactivation of the Akt pathway. The phosphorylation state of Akt and 
one of its downstream targets, FKHR was therefore studied. A reduction in the 
level of phosphorylation of Akt was seen over time. This result is significant in 
the context of studies demonstrating that Akt overexpression in adult-derived 
MSC render the cells more resistant to apoptotic cell death when transplanted 
in a model of ischaemic heart disease (Mangi et al, 2003). Western blotting and 
immunocytochemistry also indicated a decrease in FKHR over time of serum 
withdrawal although our results do not confirm the direct association between 
Akt and FKHR. 
The presence of a functional death receptor pathway was confirmed in 
experiments exposing fetal MSC to cross-linked FasL. The expression of Fas 
was shown by immunocytochemistry and western blotting, and the pattern of 
surface expression was localised in unstimulated cells. In addition, the 
presence of FADD was demonstrated with staining indicating 
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nuclear/perinuclear as well as cytosolic localisation as has been described in 
other cells (Gomez-Angelats & Cidlowski, 2003). FasL caused a concentration 
dependent increase in apoptotic cell death, which could be successfully 
inhibited by caspase 8 inhibition. 
6.3 Implications of this research 
6.3.1 Oligodendrocyte differentiation 
Although fetal MSC from chorion, amnion, and villous stroma have recently 
been shown to differentiate into neurogenic cells (Portmann-Lanz et al, 2006), 
this work represents the first demonstration of neural cell differentiation of fetal 
blood-derived MSC. The directed in vitro differentiation cells into oligodendrocytes is 
particularly exciting both for the development of a cell system to study plasticity / 
differentiation / transdifferentiation and the potential of fetal MSC for cell therapy. The 
stepwise appearance of neural progenitor markers, oligodendrocyte-specific 
transcription factors and then later oligodendrocyte proteins in this culture system will 
allow further exploration of the signalling events involved in somatic cell plasticity, 
differentiation, and then oligodendrocyte specification in a human cell source. The 
observation of ectodermal (oligodendrocyte) and mesodermal (bone) differentiation 
from a defined clonal population of fetal MSC is an important one. The 
oligodendrocyte differentiation is particularly interesting as there is no ready source 
of maturing human oligodendrocytes for study at present. Oligodendrocyte 
precursors have been derived from ES or NSC but the majority of work is in rodent 
cells and with current protocols human NSC seem to show a reduced capacity to 
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generate oligodendrocytes compared to rodent cultures. Inter-species 
differences in the capacity of neural precursors to generate oligodendrocytes 
emphasise the need for greater study of human-derived stem cell populations. 
There is a drive to consider different sources of stem cell for cell replacement 
therapy and the demonstration of enhanced proliferation and plasticity of fetal 
MSC compared to adult-derived cells warrants further investigation. With the 
development of improved fetal blood sampling methods, and the isolation of 
MSC from amniotic fluid (In 't Anker et al, 2003b) and placenta (In 't Anker et al, 
2004; Portmann-Lanz et al, 2006), it is likely that fetal MSC will be readily 
available from ongoing pregnancies in the future and therefore will represent a 
source of autologous cells for therapy. The evaluation of fetal MSC for therapy 
of human demyelinating / oligodendrocyte diseases is at an early stage and 
clearly requires improved understanding of the signalling pathways underlying 
the generation of oligodendrocytes but this research has provided an important 
first step. The engraftment of fetal MSC and low level oligodendrocyte 
differentiation, enhanced by prestimulation with B104 conditioned medium in 
vitro, following intrauterine cerebral injection in a murine model of development 
was interesting but rejection of grafts in our model was a problem. However it 
should be emphasised that our studies, unlike many others in the literature, did 
not use immunosuppressed animals. Importantly the low level differentiation 
observed did not appear to be a result of cell fusion. The development of a 
dysmyelinated or injury model may enhance oligodendrocyte differentiation. 
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6.3.2 Neuronal differentiation 
Exposure of fetal MSC to other agents known to influence adult and rodent- 
derived MSC provided further original data. Exposure to BHA led to dramatic 
morphological and phenotypic change similar that that described in other MSC 
by Woodbury et al. (Woodbury et al, 2000), suggesting neuronal differentiation. 
The experiments did not however demonstrate the coordinated development of 
neural progenitors prior to mature neurons and the derived cells did not appear 
to any different from naive cells in their electrophysiological properties. This, of 
course, does not mean that neurons cannot be derived from MSC but adds 
weight to published work suggesting the dramatic and rapid changes in cell 
architecture and antigenic phenotype in response to potent reducing agents are 
stress responses, and not true differentiation (Neuhuber et al, 2004; Lu et al, 
2004; Croft & Przyborski, 2006). 
6.3.3 Apoptotic signalling in fetal MSC 
Fetal MSC are highly proliferative stem cells that have the capacity to 
differentiate along multiple lineages and are a promising cell source for stem 
cell therapy. This is the first study demonstrating functional mitochondrial and 
death receptor apoptotic pathways in primary human MSC. A thorough 
understanding of apoptotic signalling in these cells will be helpful in designing 
strategies for the protection of stem cell grafts from apoptosis (for example with 
trophic/growth factor support, caspase inhibition or transduction with anti- 
apoptotic genes). In addition, the apoptotic pathways may well be 
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developmentally regulated, and further work will examine the effects of 
differentiation on the sensitivity of fetal MSC. 
6.4 Directions for future research 
6.4.1 Fetal MSC isolation and basic biology 
Although fetal blood-derived MSC share many characteristics of adult-derived cells, 
there remains a need to continue exploring their basic characteristics and properties. 
Also, at present these cells cannot be obtained from ongoing pregnancies, but our 
ambition is to develop sampling and isolation strategies that allow this. This would 
open an avenue to use fetal MSC in autologous cell therapy. 
It appears from early studies that fetal cells may have advantages over adult-derived 
MSC in terms of their proliferation and plasticity, but this needs to be confirmed on 
further isolates. In addition there is a need to evaluate critically the properties of fetal 
MSC obtained from a range of gestations and to document cell characteristics and 
phenotype though development. Already, for example, it is known that there are 
dramatic changes in integrin expression on fetal MSC derived from different tissues 
(blood, bone marrow and liver) and gestations which may relate to their potential to 
home from one haemopoietic site to another during ontogeny. Integrins are 
essential for stem cell homing and engraftment and direct MSC homing during 
fetal ontogeny. MSC from fetal liver, bone marrow blood express a2ß1, a4ßl 
and a5ßl molecules (de la Fuente et al, 2002; de la Fuente et al, 2003). Whilst 
fetal blood MSC express a4ß1, most adult bone marrow-derived MSC do not. 
Also, the expression of a4ßl by fetal blood MSC is biphasic with peak 
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expression at 9 and 11 weeks corresponding to establishment of haemopoiesis 
in fetal liver and fetal bone marrow respectively (de la Fuente et al, 2003). 
Only after such developmental changes are described and understood can the 
optimal gestation for cell harvest be determined. As well as studying the influence of 
the gestation at cell sampling, we need to carefully determine the effect of increasing 
time in cell culture on proliferation and plasticity, and the need to develop serum-free 
media, similar to that recently described for adult MSC (Meuleman et al, 2006), 
which can sustain proliferation in the undifferentiated state. Although human fetal 
MSC proliferate at a higher rate than adult-derived cells, they do not have the 
proliferation potential of rodent MSC. It will be interesting to study telomere length 
and telomerase activity and relate it to the loss of proliferation potential after long 
periods in cell culture. Additionally, in studies of other stem cell systems, prolonged 
time in culture has been associated with cell transformation (Wang et al, 2005c) or 
the acquisition of genetic abnormalities in the cells (Imreh et al, 2006) and therefore 
detailed karyotypic analysis is required if these cells are to be considered for cell 
replacement therapy. 
There remains a critical need to identify specific markers of fetal MSC, as for adult- 
derived MSC, to allow homogeneous populations of cells to be studied and 
compared. The isolation of MSC by their adherence to plastic is adequate for initial 
studies, but the heterogeneous nature of resulting cell populations is far from ideal, 
and the need to perform experiments on carefully characterised clonal populations 
cannot be over-emphasised. 
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6.4.2 Oligodendrocyte differentiation in vitro 
The in vitro data point to fetal MSC being able to differentiate into oligodendrocyte 
precursors that mature in culture to multi-processed complex cells. The 
demonstration of the acquisition of nestin, the upregulation of Olig 1, Olig 2 and 
NKx2.2 followed by the presence of early and then late oligodendrocyte markers 
suggested appropriate maturation in culture. The findings were confirmed in a clonal 
population of fetal MSC. This differentiation process at present involves the use of 
B104 conditioned medium. Before investigating the active components of the 
conditioned medium, it would be preferable to define the signalling mechanisms of 
the morphological and phenotypic changes more precisely. As well as the 
acquisition of oligodendrocyte markers, it is important to document the loss of 
mesenchymal phenotype, and look more closely at differentiated cell function. 
The effects of the gliogenic transcription factors Olig 1, Olig 2 and Nkx2.2 could be 
investigated in conditional over-expression systems and their necessity for 
differentiation studied in knock-down experiments using, for example, RNA 
interference. Again, the effect of passage number and gestation of the donor would 
be important in order to determine the optimal timing for deriving oligodendrocytes. 
The maturation of differentiated cells in cultures, and different stages of development 
will be studied. The purification of fetal MSC derived oligodendrocyte precursors 
could be performed by selecting for A2B5+ cells by immunopanning (Wright et al, 
1997). It would be ideal to determine culture conditions that could maintain this 
population of precursor cells in a dividing state without further differentiation. This 
would enable a large pool of oligodendrocyte precursors to be derived for future 
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study of therapy. With a homogeneous population of oligodendrocyte precursors, the 
signalling involved in cell proliferation and maturation can be evaluated and the 
effect of factors known to be important in this process (ie PDGF, FGF, IGF, thyroid 
hormones (Miller, 2002)) can be studied in a systematic way. Ultimately, however, it 
will be important to demonstrate function (myelination) of oligodendrocytes derived 
from fetal MSC. This remains problematic and, to my knowledge, there is no reliable 
in vitro model of human oligodendrocyte myelination. There are research groups that 
have developed in vitro myelination with neuronal coculture from rodent cells (Yan & 
Wood, 2000) and, of course, it would be gratifying if a similar system could be 
developed for human cells to allow the study of myelination by immunocytochemistry 
with confocal microscopy and electron microscopy. 
My interest in brain injury in preterm infants focussed my study on oligodendrocyte 
development, and indeed little evidence of other neural cell types being created was 
observed after exposure to medium containing B104 conditioned medium. It would 
be interesting, however, to examine progenitor cells that are nestin+ after 48-72 
hours in more detail in order to evaluate their potential to derive neuronal cells and 
astrocytes. 
6.4.3 In vivo differentiation 
The fate of injected fetal MSC was followed after injection into the E15 developing 
murine brain. This is a time in murine brain development prior to oligodendrocyte 
development and maturation, and our hypothesis was that extrinsic factors involved 
in normal oligodendrocyte development may influence differentiation of fetal MSC. 
Both survival and integration of fetal MSC occurred, although a disappointingly low 
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level acquisition of oligodendrocyte markers was seen. Perhaps not surprisingly, a 
host response to injected cells was eventually mounted leading to loss of grafts by 
33 days. The low levels of oligodendrocyte differentiation may be explained by using 
an animal model of normal brain development. The proportion of oligodendrocytes 
may well be enhanced by using an oligodendrocyte injury model (ie EAE model of 
MS) or a dysmyelinated strain of mouse where the contribution of donor cells to 
oligodendrocyte numbers could be readily evaluated. There are now several 
examples of donor cell differentiation being increased in injury compared with the 
normal developmental state. As well as the detailed phenotypic evaluation by 
confocal microscopy, longer-term functional studies could be undertaken on the 
animals. Indeed we demonstrated the increased acquisition of oligodendrocyte 
markers with pre-differentiation in vitro for 48 hours in ODM, future studies will 
attempt to purify oligodendrocyte precursors as described earlier (by A2B5 
immunopanning) and ascertain their fate in the same model. This would be 
comparable in approach to published work where oligodendrocyte precursors 
(derived from ES cells) mature and remyelinate neurons in the Shiverer mouse 
model (Nistor et al, 2005). In my experiments, cell fate was largely determined by 
double labelling of GFP+ cells with fluorescence microscopy, ideally future 
experiments should utilise confocal microscopy to precisely define the colocalisation 
of GFP and lineage-specific markers. In addition, experiments used a single cell 
source of fetal MSC and future experiments should evaluate a number of sources 
(e. g. fetal blood, bone marrow, liver) and study the effects of passage number (time 
in cell culture) and gestational age at sampling. 
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While the loss of cell grafts was disappointing, the timing of the host response was 
not. In the future, it may be interesting to look at which mononuclear cells infiltrate 
and whether the late graft loss is related to the evolving murine immune system, loss 
of tolerance or increased immunogenicity of differentiated cells compared with naive 
MSC (perhaps due to upregulation of class I and II molecules). The pragmatic 
addition of immunosuppressive therapy to the same immunocompetent model would 
be possible, with the aim of prolonging graft survival enough to see enhanced 
differentiation, or the development of a similar model with immunocompromised 
(nude or SCI D) mice strains. 
6.4.4 Apoptotic signalling 
The data demonstrate active and functional mitochondrial and death receptor 
apoptotic pathways in undifferentiated fetal MSC. Future experiments will be 
designed to study the sensitivity to apoptotic stimuli of fetal MSC from different 
gestations to evaluate any developmental regulation, and also compare the 
sensitivity of differentiated fetal MSC to apoptotic stimuli at varying stages of 
oligodendrocyte development. It is known, for example, that developmental changes 
occur in apoptotic signalling during oligodendrocyte maturation from oligodendrocyte 
precursors, that impact on sensitivity to apoptosis (Pirianov et al, 2006). It would be 
of interest to undertake similar studies comparing apoptotic signalling at stages of 
oligodendrocyte differentiation from fetal MSC. 
There were some other interesting data that warrant further investigation. For 
example, during SSP exposure, a coincidental finding of the immunostaining 
experiments was the apparent localisation of cleaved caspase-9 in or around 
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the nucleus. There is very little published literature describing its transport to 
the nucleus and its role there has yet to be precisely defined (Krajewski et al, 
1999). The highly fluorescent, crescent-shaped staining in the nuclear region 
may suggest that active caspase-9 translocates into the nucleus or the nuclear 
membrane or that it is activated there. It may be that caspase-9 has an 
executioner role in cleaving nuclear substrates during apoptosis, but at present 
this is speculation and remains to be proven (Alnemri, 1999). Confocal 
scanning fluorescence microscopy, which was not available during the course 
of this project, may be used for further investigation to confirm the precise 
location of the staining. Subcellular fractionation of proteins would be another 
possible method to verify these findings. 
The serum withdrawal experiments demonstrated the possible involvement of 
the PI3K/Akt pathway in MSC apoptosis. It will be important to study this 
further. In particular it would be interesting to study the cellular localisation of 
Akt and the sites of phosphorylation. For example in nerve growth factor- 
dependent survival of PC12 cells, Akt is phosphorylated at Thr308, before 
translocation to the nucleus where it impacts on specific gene expression 
(Borgatti et al, 2003). The specific site of phosphorylation of Akt can be studied 
by immunocytochemistry and western blot analysis (including sub-cellular 
fractions) using phosphorylation site-specific antibodies. Kinases, such as Akt, 
phosphorylate downstream targets like the transcription factor FKHR within the 
nucleus leading to their transport to the cytosol and thereby inhibiting 
transcription (Brunet et al, 2001; Woods & Rena, 2002). Nuclear and cytosolic 
cell extracts will be obtained from serum-starved cells and the phosphorylation 
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state of Akt and FKHR determined at different time-points. It would be of 
particular interest to investigate the involvement of other Akt substrates; Akt 
has also been shown to phosphorylate Bad (Datta et al, 1997; Datta et al, 
2000) and caspase 9 (Cardone et al, 1998), both important components of the 
apoptotic machinery. Finally it would be interesting to investigate the potential 
involvement of the death receptor pathway in serum starved fetal MSC. The 
promoter of the FasL gene contains a Forkhead binding site (Brunet et al, 
1999), and our data demonstrates that fetal MSC express the Fas receptor on 
their surface (Kennea et al, 2005). It is therefore possible that upon serum 
withdrawal FKHR upregulates the transcription of FasL leading to further 
apoptosis though death receptor signalling. This could be studied by testing the 
ability of Fas blocking antibodies to inhibit serum withdrawal-induced apoptosis. 
In parallel experiments, the upregulation of FasL could be studied by RT-PCR, 
immunocytochemistry and western blotting in time-course experiments of 
serum withdrawal. Ultimately, it would be interesting to over-express anti- 
apoptotic proteins such as Akt (Mangi et al, 2003) and compare the response of 
transfected and non-transfected cells to a variety of apoptotic stimuli in vitro, 
and compare graft survival and differentiation in vivo. 
6.5 Conclusion 
Fetal MSC are a highly proliferative cell type that can be readily isolated from 
first trimester fetal blood. With the prospect that such cells could be isolated 
from ongoing pregnancies in the near future, they represent an exciting 
potential source of multipotent cells for study and therapy. I have demonstrated 
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ordered oligodendrocyte differentiation from populations of these cells, with the 
acquisition of early followed by later markers of oligodendrocyte development. 
The mechanisms underlying the in vitro and in vivo morphological and 
phenotypic change of fetal MSC remain unknown. The experiments on clonal 
populations show that this apparent differentiation is not due to contamination 
by rare multipotent cells, while my in vivo work suggests differentiation is not 
due to cell fusion. Whether these oligodendrocytes are a product of de- 
differentiation, or transdifferentiation of fetal MSC, or whether these cells in the 
fetal circulation are more multipotent per se warrants further investigation. Fetal 
MSC are clearly a promising source of multipotent cell for study and potential 
therapy. 
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APPENDIX 1. 
Consent form for fetal blood sampling. 
REC 2001/6234 
Information Sheet for Research Participants 
You will be given a copy of this Information Sheet 
Study title: Biology of fetal stem cells 
We would like to invite you to participate in a research study. If you decide to 
take part, please let us know beforehand if you have been involved in any 
study during the last year. Ask us if there is anything that is not dear or if you 
would like more information. Take time to decide whether or not you wish to 
take part. Thank you for reading this. 
What is the purpose of the study? 
Stem cells are underdeveloped cells that have the potential to repair damaged 
tissues or treat inherited diseases. Fetal blood or tissues appear to have high 
concentrations of stem cells. We are trying to see what type of stem cells are 
present, and how they compare with other sources of stem cells. 
Why have I been chosen? 
We are asking you because you are due to have a termination of pregnancy 
under general anaesthetic. You may also have agreed to undergo a training 
procedure. We would like permission to use any fetal blood or tissue collected 
at that time. 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive. 
What will happen to me if I take part? 
Unless you request otherwise, tissues from the operation would normally be 
disposed of after it is over. We ask your permission instead to allow fetal 
blood or tissue taken at the time of termination to be used for research. The 
use of this tissue will be strictly controlled according to official guidelines and 
restricted to uses for which fetal tissue is necessary for medical benefit. 
The stem cells we derive will then be thoroughly tested and evaluated in the 
laboratory. Occasionally some cells will be introduced into experimental 
animal models to test their stem cell properties. If you are unhappy out 
this, please tell us and your cells would then be used only for test tube studies 
in the laboratory. Some cells may be stored or banked for future research. 
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What are the possible disadvantages and risks of taking part? 
There is no risk to you or your baby. 
What are the possible benefits of taking part? 
There is no benefit to you from taking part The information we get from this 
study will help develop better treatment methods in future for babies before 
and after birth. These include treating brain damage from oxygen shortage, 
and developing cures for serious blood disorders, and handicapping 
hereditary conditions. 
What if something goes wrong? 
This is highly unlikely. However, in the event of your suffering any adverse 
effects as a consequence of your participation in this study, you will be 
compensated through the Imperial College School of Medicine's "No Fault' 
Compensation Scheme 
Will my taking part in this study be kept confidential? 
Yes. The samples collected will be anonymised and cannot be traced back to 
you. 
What will happen to the results of the research study? 
The work using your sample may be published in the medical and scientific 
literature. 
Who is organising and funding the research? 
The work is funded by a variety of bodies, including Wellcome and the 
Medical Research Council. No member of staff is being paid for including you 
in this study. 
Who has reviewed the study? 
The research has been approved by the joint Queen/Queen Charlotte's & 
Chelsea and Acton Hospitals' Research Ethics Committee. It complies with 
government guidelines on the use of Fetal Tissue for Research Purposes. A 
research ethics committee would also approve any future research on stored 
tissues or cells. 
Contact for Further Information 
Further information can be obtained from Dr O'Donoghue (0207-594 2121) or 
Dr Kumar (0208-383 3998) 
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Participant Consent Form 
Title of project 
Biology of fetal stem cells 
The participant should complete the whole of this sheet him or herself. (please tick each statement if it applies to you) 
I have read the Information Sheet for Patients and Healthy Volunteers. 
I have been given-the opportunity to ask questions and discuss this study. 
I have received satisfactory answers to all my questions. 
I have received enough information about the study. 
The study has been explained to me by: 
Prof/Dr/Mr/Mrs/Ms 
I understand that I am free to withdraw from the study at any time, without 
having to give a reason for withdrawing and without affecting my future 
medical care. 
I agree to take part in this study. 
Signed ........................................................................ 
Date................................. 
(NAME IN BLOCK CAPITALS) .......................................................................... 
Investigator's signature .............................................. 
Date:.............................. 
(NAME IN BLOCK CAPITALS) ........................................................... 
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